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Abstract	  
 
Breast cancer is the most common cancer in women and in 2008 accounted for 
8% of UK cancer related deaths. A poor prognosis is particularly conferred upon 
individuals with evidence of metastatic breast cancer. With some studies noting 
that at least 70% of patients dying with breast cancer have evidence of 
metastatic disease. In order to develop novel therapeutic strategies a greater 
understanding of breast cancer tumourigenesis and metastasis is required. 
Metalloproteinases were implicated as key drivers of metastasis through their 
ability to degrade the components of the extracellular matrix. This perspective is 
now superseded with evidence highlighting the involvement of 
metalloproteinases in an array of biological roles, from maintaining tissue 
homeostasis to angiogenesis, and importantly these roles can have tumour 
suppressive effects. Several metalloproteinases from the A Disintegrin and 
Metalloproteinase with thrombospondin motifs (ADAMTS) family are candidate 
tumour suppressors, including ADAMTS-15. In the context of breast cancer 
relatively high levels of ADAMTS-15 expression had previously been associated 
with increased relapse free survival. However the functional consequences of 
ADAMTS-15 expression in breast cancer are unknown and are the focus of this 
thesis. 
ADAMTS-15 reduced the migration of MDA-MB-231 and MCF-7 cells, in a 
metalloproteinase-independent manner. This anti-migratory effect likely involves 
syndecan-4, since modulation of syndecan-4 expression and signalling 
attenuated this effect. In contrast to its effects on cell migration, only wildtype 
ADAMTS-15 exhibited an anti-angiogenic effect in in vitro and ex vivo models of 
angiogenesis. In experimental metastasis assays, both ADAMTS-15 and E362A 
(metalloproteinase inactive form of ADAMTS-15) reduced metastasis of MDA-
MB-231 cells to the liver, though paradoxically, ADAMTS-15 but not E362A 
enhanced lung colonisation.  Taken together these studies demonstrate for the 
first time that extracellular ADAMTS-15 has multiple tissue context-dependent 
actions on breast tumour pathophysiology, some of which require its proteolytic 
activity whereas others do not. 
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Chapter	  One:	  Introduction	  
 
1.1	  Cancer	  
Cancer is a group of diseases associated with uncontrolled cellular proliferation 
that occurs when cells lose key regulatory mechanisms associated with the 
control of cell growth, genome stability and cell survival  (Figure 1.1; Brown et 
al. 2009; Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). 
Cancer aetiology and progression are the result of complex processes. It was 
originally thought that a single, as of yet undiscovered event was at the heart of 
cancer initiation (Foulds, 1958; Klein, 1998). In 1958 Leslie Foulds changed the 
carcinogenesis paradigm when his research proposed that cancer development 
was a progressive process in which tissue abnormalities associated with cancer 
were acquired over time (Foulds, 1958; Klein, 1998). Ideas emerged which 
complemented Fould’s concept with somatic mutation theory, whereby it was 
the acquisition of genetic mutations and epigenetic alterations which over time 
equipped cancer cells with the capacity for uncontrolled proliferation and 
survival (Klein, 2009; Sonnenschein and Soto, 2008). 
Cancer cells that are able to escape the local tumour microenvironment and 
establish distant secondary tumours (metastasis) are of the greatest clinical 
concern, with some indications that metastasis may account for up to 90% of 
cancer deaths (Croft and Olson, 2008; Klein, 2009; Nguyen et al. 2009 Pagani 
et al. 2010). For metastasis, cancer cells must invade into the surrounding 
tissues, intravasate into the circulatory or lymphatic system, extravasate into 
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distant tissues and then proliferate to form a novel tumour (Kopfstein and 
Christofori, 2006; Nguyen et al. 2009).  
 
Figure 1.1: A summary of the fundamental characteristics that tumour 
cells acquire. Figure based upon figures 1 and 3 in Hanahan and Weinberg, 
2011. 
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1.2	  Breast	  Cancer	  
Breast cancer is the most common cancer in women and in 2008 accounted for 
8% of UK cancer related deaths (Cancer Res. UK, 2009; Quinn et al. 2008) 
Although screening and therapeutic strategies have contributed to a 35% 
decline in UK mortality since 1989 levels, the annual incidence of breast cancer 
continues to rise (Autier et al. 2010; Quinn et al. 2008). In recent years the 
lifetime risk for women developing breast cancer in the UK has risen from 1in9 
to 1in8 (Cancer Research UK, 2013). A poor prognosis is particularly conferred 
upon individuals with evidence of metastatic breast cancer, with some studies 
noting that at least 70% of patients dying with breast cancer have evidence of 
metastatic disease (Buijs and van der Pluijm, 2009; Rubens, 1998).  
Breast cancer progression from healthy tissue towards an invasive carcinoma is 
complex and was originally classified through the emergence of histo-
morphological changes in which normal breast architecture is aberrantly 
disrupted (Wellings and Jensen, 1973). Mammary glands in healthy breast 
tissue form into a layered structure consisting of luminal epithelial cells, which 
are responsible for the secretion of milk into the adjacent lumen (Figure 1.2; 
Adriance et al. 2005). Underneath luminal epithelia, myoepithelial cells form a 
continuous layer interfacing between the luminal epithelial cells and the 
basement membrane (Figure 1.2; Adriance et al. 2005). A highly fibrous 
connective stroma and adipose tissue surrounds the glandular structures of the 
mammary ductal tree (Adriance et al. 2005). 
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Figure 1.2: Schematic of human breast tissue architecture. The diagram is 
a representation of the general features of human breast tissue architecture. A 
cross section of a breast duct is shown as are two important cell types that are 
responsible for breast tissue homeostasis and function. The luminal epithelial 
cells, which line the lumen of the duct, are responsible for the generation of milk 
proteins. The myopepithelial cells are phenotypically a combination of muscle 
and epithelial like features. Myoepithelial cells are involved in the generation of 
the contractile forces needed to secrete the milk proteins into the lumen during 
lactation. This figure is based upon information that was adapted from Butcher 
et al. 2009 and Gordon et al. 2003. 
 
During lactation these glandular structures, termed terminal duct lobular units 
(TDLUs), are under mechanical pressure, due to the stresses exerted with the 
build-up of milk (Adriance et al. 2005; Butcher et al. 2009; Cichon et al. 2010). 
Myoepithelial cells, a combination of muscle (myo) and epithelial-like character, 
must contract to secrete luminal milk to alleviate these pressures and restore 
tissue homeostasis (Adriance et al. 2005; Butcher et al. 2009). Myoepithelial 
and luminal epithelial cells seek clues about the environmental tensile forces 
from cell-cell (e.g. E-Cadherin), desmosomal (e.g. DSg3) and hemidesmosomal 
(e.g. integrin α6β4) signalling interactions (Butcher et al. 2009; Gordon et al. 
2003). In vitro studies demonstrate that signalling interactions between the 
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epithelial cell layer and the basement membrane are essential for apical-basal 
polarity and differentiation for the generation of milk proteins (Barcellos-Hoff et 
al. 1989; Butcher et al. 2009). Desensitisation of these signalling elements 
through constant exposure to tensile stress can lead to a loss of tissue integrity 
invoking extensive tissue remodelling (Butcher et al. 2009). Luminal epithelial-
like cells and in rarer cases myoepithelial-like cells, which have acquired the 
capacity for unrestrained proliferation, gain a selective advantage during this 
remodelling process and potentially initiate tumourigenesis (Adriance et al. 
2005; Gordon et al. 2003; Polyak and Hu, 2005).  
Unrestrained proliferation of malignant cells in the TDLUs results in the 
emergence of tissue abnormalities (Figure 1.3; Allred et al. 2001; Wellings and 
Jensen, 1973). The most common tissue abnormalities that develop during 
disease progression have been extensively characterised and histologically 
modelled (Allred et al. 2001; Cichon et al. 2010; Wellings and Jensen, 1973). 
According to histological models of breast cancer, hyper-proliferation of the 
TDLU epithelium leads to the development of extended tissue structures, such 
as cysts and unfolded lobules at the proliferative disease without atypia (PDWA) 
and hyperplastic enlarged lobular units (HELU) stage (Figure 1.3; Cichon et al. 
2010; Lee et al. 2006). Over time alterations in cell adhesion, polarity and other 
cellular abnormalities develop resulting in the distension of acini (Allred et al. 
2008; Cichon et al. 2010). These changes are characteristic of the transition 
into the atypical hyperplasia stage, which can manifest itself in ductal (atypical 
ductal hyperplasia, ADH) or lobular (atypical lobular hyperplasia, ALH) forms 
(Allred et al. 2008; Cichon et al. 2010). Differences between ductal and lobular 
Chapter 1 | Page 19 
 
forms are largely descriptive and not necessarily representative of the lesions’ 
site of origin (Cichon et al. 2010).  
Figure 1.3: Schematic of the histological model of breast cancer 
progression. Abbreviations: TDLU, terminal duct lobular units; HELU, 
hyperplastic enlarged lobular units; ADH, atypical ductal hyperplasia; 
ALH, atypical lobular hyperplasia; DCIS, ductal carcinoma in situ; 
LCIS, lobular carcinoma in situ; IBC, invasive breast cancers; RR, 
relative risk of invasive breast cancer. This figure is based upon data 
that was adapted from Allred et al. 2001; Cichon et al. 2010; Wellings 
and Jensen, 1973. 
Hyperplasias can transition into either ductal or lobular forms of carcinoma in 
situ, DCIS or LCIS respectively (Allred et al. 2008; Bombonati and Sgroi, 2011). 
Carcinoma in situ is a descriptor for the last stage of benign breast neoplasia 
and DCIS in particular may account for up to 20% of all detected breast cancers 
(Ernster et al. 2000; Jones, 2006). DCIS is a broad descriptive term, which is 
frequently sub-divided into three groups, depending upon the appearance of 
cytonuclear features (Jones, 2006; NHSBSP Guidelines, 2005). At the in situ 
stage the myoepithelial and basement membrane interface is intact, essentially 
maintaining the rapidly proliferating neoplastic tissue within the ducts or lobules 
of the breast (Adriance et al. 2005; Cichon et al. 2010).  
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Invasive disease often follows DCIS, with up to 50% of DCIS lesions reported to 
progress to invasive disease (Jones, 2006; Sanders et al. 2005). Transition to 
invasive and/or metastatic disease typically requires the breakdown of the 
myoepithelial-basement membrane interface, an event that is likely to occur 
post-DCIS, in part due to the accumulation of myoepithelial cell genetic 
abnormalities (Adriance et al. 2005; Hsiao et al. 2011; Jones, 2006; Polyak and 
Hu, 2005). Once basement membrane integrity is compromised tumour cells 
are able to spread to distant tissues and organs. For breast tumours metastatic 
spread is typically to the lymph nodes, lungs, liver, bone and brain (Buijs and 
van der Pluijm, 2009; Nguyen, Bos, and Massagué, 2009) 
The descriptive histological characteristics of invasive disease are based upon 
observed growth patterns and diverging resemblance from healthy epithelial 
cells (differentiation) (Rakha et al. 2010). The Nottingham Grading System 
(NGS) describes the criteria for a semi-quantitative analysis and grading (I, II, 
III) of breast tumour patho-morphology which in combination with Lymph node 
(LN) status has prognostic value (Rakha et al. 2010). Despite the prognostic 
and therapeutic utility of histo-pathological models of breast cancer, they are 
arguably an over-simplistic representation of breast cancer disease 
progression.  
Critical appraisal of these models highlights several limitations, which 
refinements in descriptive histological terminology have not managed to 
overcome, but a molecular analysis may yet address (Bombonati and Sgroi, 
2011; Cichon et al. 2010; Griffith and Gray, 2013; Ma et al. 2003; Rakha et al. 
2010). Not all patients display clearly progressive histological features and even 
when they do the progression duration varies greatly, taking in some cases 
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decades (Allred et al. 2008; Jones, 2006; Sanders et al. 2005). Prediction of 
progression timescales from benign disease towards invasive disease is difficult 
from a purely histological analysis. For instance several DCIS studies have 
revealed that not all DCIS have invasive potential, or at least not in the patients’ 
lifetime (Emery et al. 2009; Jones, 2006; Sanders et al. 2005). This has an 
impact on therapeutic strategy. It is perhaps unfortunate for patients to undergo 
aggressive therapies with harmful side effects, when their form of cancer may 
not progress to a threatening stage within their lifetime (Jones, 2006). Perhaps 
more importantly these studies allude to the hidden diversity of breast cancer 
origins, progression and invasive potential, which can be masked in a purely 
histological analysis. 
It is argued that a molecular stratification of breast cancer is needed to fully 
understand the complexity of breast cancer progression and to usher in truly 
personalised therapeutic strategies (Bombonati and Sgroi, 2011; Curtis et al. 
2012; Prat et al. 2010; Rakha et al. 2010; Stephens et al. 2009; Swanton et al. 
2011). Breast cancer molecular subtypes are broadly categorised by the 
expression of Oestrogen Receptor (ER), Progesterone Receptor (PgR) and 
Human Epidermal Growth Factor Receptor 2 (HER2) respectively (Table 1.1). 
Luminal subtypes are the most frequently clinically presented of the breast 
tumour subtypes and since they are positive for ER, these cancers respond well 
to anti-endocrine therapies. However prolonged direct (Tamoxifen) or indirect 
(aromatase inhibitors, AIs) therapeutic modulation of ER signalling often leads 
to endocrine resistance and disease recurrence (Leary and Dowsett, 2006).  
Only 25% of breast tumours over-express the epithelial growth factor receptor 
(EGFR), Her-2 (Table 1.1; Dean-Colomb and Esteva, 2008). Yet for those 
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patients that have HER2+ tumours, treatment with the anti-HER2 monoclonal 
antibody Trastuzumab (Herceptin) has proven particularly effective (Dean-
Colomb and Esteva, 2008; Pero et al. 2007). Arguably the HER-2 subtype is 
currently the best example of how an examination of the molecular subtypes 
can inform a highly personalised and effective therapeutic strategy. In contrast 
to this, basal and claudin-low subtypes do not respond well to either anti-
endocrine or HER based therapies and are associated with a poor prognosis 
(Kennecke et al. 2010; Prat et al. 2010).  
 
 Normal-
like 
Luminal 
A 
Luminal 
B 
HER-2 Claudin
-Low 
Basal 
ER status + + + - - - 
PgR 
status 
+ + + - - - 
ErbB2 
(Her2/neu) 
status 
+ - + + - - 
% of triple 
negative 
tumours 
0% 3-4% 4-9% 14-22% 61-71% 73-80% 
Table 1.1: The hormone status of breast cancer subtypes. The percentage 
of these tumour subtypes which display a triple negative hormone status was 
derived from three patient data sets; UNC337, NKI295 and MDACC133 
respectively.  Table based upon Prat et al. 2010. 
 
Breast cancer subtypes also display differential capacities for metastatic 
spread, with basal tumours being particularly metastatic (Kennecke et al. 2010). 
These capacities are not just intrinsic to the tumour cells themselves but also 
involve co-operation with the tumour microenvironment. In other words only 
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tumour cells, which acquire the capacity to co-opt the tissue microenvironment 
are capable of successful metastatic spread (Klein, 2004; Klein, 2009; Langley 
and Fidler 2011; Mueller and Fusenig, 2004; Paget, 1889). 
1.3	  The	  tumour	  microenvironment	  
Tumour cells do not reside in isolation but are in fact surrounded by multiple cell 
types and an extracellular matrix (ECM), which in combination form the 
constituents of the tumour microenvironment (stroma) (Figure 1.4). The 
extracellular matrix includes the structural proteins such as collagens, laminins, 
fibronectin, as well as proteoglycans such as, hyaluronan, aggrecan and 
versican, (Butcher et al. 2009; Huxley-Jones et al. 2007; Mao and 
Schwarzbauer, 2005). The ECM influences tumour cell behaviour either directly 
through interaction with cellular receptors leading to cell signalling or mechano-
transduction of force, or indirectly via the proteolytic release of matricryptic 
fragments that in turn elicit cell signalling (Butcher et al. 2009; Hojilla, Wood and 
Khokha, 2008; Xu, Boudreau and Bissell, 2009). 
Within the context of breast tissues stromal cells include fibroblasts, adipocytes 
and the multiple cell types of the tumour-associated vasculature. The 
vasculature includes the pericytes and the endothelial cells that form the 
vessels themselves, as well as the natural killer cells, neutrophils, macrophages 
and other circulatory cells of the immune system. Tumour cells interact with and 
co-opt stromal cells to produce growth factors, cytokines and proteases that in 
combination create a pro-inflammatory environment which is conducive to 
tumourigenesis (Allen and Jones, 2011; Kessenbrock, Plaks, and Werb, 2010). 
Of these factors proteases are particularly important since they mediate several 
Chapter 1 | Page 24 
 
tumorigenic processes including an acceleration of tumour growth and the 
induction of the epithelial to mesenchymal transition (EMT), a process in which 
cancer cells become malignant (Edwards et al. 2009; Kempen, de Visserc and 
Coussens, 2006; Lopez-Otin and Matrisian, 2007; Ota et al. 2009). Originally, 
however, proteases were considered for their ability to degrade the ECM and as 
a result were thought to clear a pathway in which tumour cells could grow, 
invade and spread to distant tissues (Lopez-Otin and Matrisian, 2007). 
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Figure 1.4: Tumour-stroma signalling interactions during tumourigenesis and 
metastasis. (Upper) The assembly and collective contributions of the assorted cell 
types constituting the tumour microenvironment (stroma) are orchestrated and 
maintained by reciprocal heterotypic signalling interactions, of which only a few are 
illustrated. (Lower) The intercellular signalling depicted in the upper panel is 
reciprocal and highly dynamic. These signalling interactions drive the increasingly 
aggressive phenotypes that underlie growth, invasion, and metastatic 
dissemination. (Figure 5 from Hanahan and Weinberg, 2011. Permission granted 
via RightsLink Licence Number: 3167020799762). 	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1.4	  Proteases	  in	  tumour	  biology	  
Fisher (1946) proposed that the proteolytic activity of tumours actively facilitated 
the degradation of the ECM, permitting tumour growth, invasion and metastasis. 
This provided the basis for implicating proteases in cancer progression (Liotta et 
al. 1980; Lopez-Otin and Bond, 2008; Lopez-Otin and Matrisian, 2007; Overall 
and Kleifeld, 2006). Protease research continued and by the 1970s individual 
proteases were identified and later classified into five distinct classes: Cysteine-
, Serine-, Aspartic-, Threonine- and Metallo- proteases (Lopez-Otin and Bond, 
2008; Neurath and Walsh, 1976).  
The matrix metalloproteinases (MMPs) emerged from amongst the five classes 
of proteases as distinctly important in ECM turnover (Brinckerhoff and Matrisian, 
2002; Page-McCaw et al. 2007). A rationale evolved which placed the activities 
of MMPs as key drivers of tumour mediated ECM degradation and subsequent 
metastatic action (Egeblad and Werb, 2002). Evidence demonstrating the 
propensity for tumours in advanced disease stages to express high levels of 
MMPs strengthened arguments in favour of MMP inhibition (Baker et al. 2002; 
Brown, 1998; Greenwald, 1999; Sternlicht and Werb, 2001). An array of small-
drug MMP inhibitors (MMPIs) were developed in the 1980s and 1990s 
(McCullagh et al. 1984; Low et al. 1996; Zucker et al. 2000). However the 
proposed benefits associated with broad action MMP inhibition did not translate 
into the clinic. Phase III clinical trials with MMPIs did not increase the survival 
prospects of patients with advanced cancer (Coussens et al. 2002; Pavlaki and 
Zucker, 2003; Zucker et al. 2000).  
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Between 1962, which saw the discovery of the first MMP, and 1984, which 
marks the patenting of a first generation MMPI, only a handful of the 23 human 
MMPs had been discovered (Gross and Lapiere, 1962; Kessenbrock et al. 
2010; McCullagh et al. 1984). Perhaps then with hindsight it was not too 
surprising that first generation MMPIs, designed upon incomplete knowledge of 
the MMP family did not increase the survival prospects of patients with 
advanced cancer (Pavlaki and Zucker, 2003; Zucker et al. 2000). Critics have 
also argued that the design of early Phase III first generation MMPI clinical trials 
was also a major contributing factor to the failure of MMPIs. (Zucker et al. 
2000). The selection of advanced stage patients placed the focus on treating 
mature tumours and in doing so the roles of MMPs in earlier stages of tumour 
development were ignored. This focus also overlooked the major source of 
MMPs, the tumour stroma (Table 1.2), thus downplaying the importance of the 
interactions between the tumour and the tumour microenvironment. 
Breast architecture is frequently disturbed by the stresses of normal breast 
physiology (Butcher et al. 2008). In the healthy breast MMPs are major players 
in the tissue remodelling processes needed to maintain breast tissue 
homeostasis and to facilitate the architectural changes required for mammary 
gland growth, lactation and involution. To prevent aberrant remodelling 
processes the MMPs are tightly regulated at the level of transcription, activation 
of the pro-enzyme, and through the action of 4 endogenous MMP inhibitors, the 
tissue inhibitors of metalloproteinases (TIMPs) (Baker et al. 2002; Clark et al. 
2008). In tumourigenesis however, tumour cells are able to disrupt and 
aberrantly modulate the MMP:TIMP axis needed for the maintenance of breast 
tissue homeostasis. In doing so tumour cells are able to co-opt the surrounding 
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stroma into the production of yet more MMPs to aid an array of disease 
progression processes (Table 1.2; Kessenbrock et al. 2010; Page-McCaw et al. 
2007). These cancer disease progression processes of which MMPs are 
implicated include the epithelial-to-mesenchymal transition (EMT) of tumour 
cells to a more invasive phenotype (Ota et al. 2009), inflammatory responses 
(Hojilla et al. 2008), tumour angiogenesis (Handsley and Edwards, 2005) and 
mediation of the pre-metastatic niche (Kaplan et al. 2005).  
Stromal Cell MMPs / TIMPs 
Neutrophils MMP-8 and MMP-9. TIMP-1 
Macrophages MMP-1, -2, -7, -9, -12 and -14.  
TIMP -1, -2 and -3 
Mast Cells MMP-2 and MMP-9. TIMP-1 
Fibroblasts MMP-1, -2, -3, -9, -11, -13, -14 and -19.  
TIMP-1, -2 and -3 
Lymphocytes MMP-3 and MMP-9. TIMP-1 
Table 1.2: Stromal sources of MMPs and TIMPs. Table based upon 
Kessenbrock et al. 2010. 
 
In contrast to other matrix metalloproteinases, MMP-8 (Collagenase-2), an 
MMP that is involved with inflammatory and tissue remodelling processes may 
be tumour suppressive (Balbin et al. 2003; Gutiérrez-Fernández et al. 2007; 
Thirkettle et al. 2013). Male mice experimentally deficient of MMP-8 (MMP-8 -/-) 
demonstrated an increased susceptibility to skin cancer, marked by an increase 
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in skin tumour incidence (Balbin et al. 2003). In vitro studies where MMP-8 was 
over expressed in melanoma cell lines, showed reduced invasive capacity as 
expected for a tumour suppressor gene and breast cancer patients which show 
relatively high MMP-8 expression have a good prognosis (Gutiérrez-Fernández 
et al. 2008).  
In light of these studies the failure of first generation MMPIs can now be 
attributed in part to the broad-spectrum inhibition of MMPs, many of which had 
not yet been discovered and whose roles in cancer are still not fully understood. 
The unintentional inhibition of cancer anti-targets, such as the tumour 
suppressor MMP-8 was also a contributing factor and may even explain the 
poorer outcome of some MMPI treated patients (Devy et al. 2009; Gutierrez-
Fernandez et al. 2008; Overall and Kleifeld, 2006; Pavlaki and Zucker, 2003; 
Zucker et al. 2000). Additionally the failure of early generation MMPIs may also 
have been due to unforeseen off-target effects, most significantly that MMPIs 
demonstrate both direct and indirect inhibition of members of the related zinc 
moiety containing protease families, a disintegrin-like and metalloproteinase 
(ADAM) and a disintegrin-like and metalloproteinase with thrombospondin type 
1 motif (ADAMTS) (Figure 1.5; Figure1.6; Butler et al. 2008; Fridman et al. 
2007; Pavlaki and Zucker, 2003; Porter et al. 2005).  
The ADAMS and ADAMTSs have complex roles in health and disease. Atypical 
expression, regulation or function of these metalloproteinases can lead to 
inherited genetic disorders, or contribute to aberrant patho-physiological 
processes in arthritis, cardiovascular disease and cancer. Whilst the ADAMs 
are generally pro-tumourigenic, interestingly members of the ADAMTS family 
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exhibit tumour suppressor functions in some contexts and are therefore of great 
interest (Kelwick and Edwards, 2014). 
 
Figure 1.5: Historical overview of MMP cancer research. Proteases 
implicated in metastasis (Fisher, 1946; LopezOtin and Bond, 2008) through to 
the failure of MMPIs (Pavlaki and Zucker, 2003), the discovery of tumour 
suppressive MMPs (Gutierrez Fernandez 2008) and the related ADAMs 
(Edwards et al. 2008), ADAMTS (Kelwick and Edwards, 2014; Porter et al.  
2005; Wagstaff et al. 2011). 
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Figure 1.6: General domain organisation of several members of the 
metzincin superfamily. ECM associated MMPs and membrane type (MT-
MMPs) are depicted along with the ADAMs and ADAMTSs. The defining 
characteristics of these related families includes the HEXXH Zn-coordinating 
catalytic core and the presence of a Met residue downstream that sets up the 
topology of the active site cleft; a feature exploited by MMPIs. Figure adapted 
from Edwards et al. 2008.  
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1.5	  The	  ADAMTS	  Family	  
The human ADAMTSs (A Disintegrin and Metalloproteinase with 
Thrombospondin motifs) are a family of 19 secreted, matrix-associated zinc 
metallo-endopeptidases. The founding member of the family, ADAMTS-1 was 
discovered by Kuno et al. 1997. Subsequent research has identified a total of 
19 human ADAMTSs that can be sub-grouped based on phylogenetic analysis 
and according to their known substrate specificities (Figure 1.7; Table 1.3; 
Appendix A1; A3). 
The ADAMTSs have diverse roles in the regulation of tissue morphogenesis, 
patho-physiological tissue remodelling, inflammation, neural plasticity and 
angiogenesis (Kelwick and Edwards, 2014; Porter et al. 2005; Wagstaff et al. 
2011). Whilst the loss of individual ADAMTSs may in some cases be 
phenotypically mild, mutations or changes in ADAMTSs expression, localisation 
or function are associated with disease. Mutations in ADAMTS-2 lead to Ehler-
Danlos syndrome type VIIc, a connective tissue disorder and mutations in 
ADAMTS-13 drive an inherited form of thrombotic thrombocytopenic purpura 
(TTP), a disease associated with the accumulation of platelet thrombi that can 
obstruct the cardiovascular system (Li et al. 2001; Pimanda et al. 2004; Prockop 
et al. 1998). Broad changes in ADAMTS expression, function or localisation are 
also associated with an array of arthritis and cancer patho-physiological 
processes (Kelwick and Edwards, 2014; Kevorkian et al. 2004; Lin and Liu 
2010; Porter et al. 2004; Wagstaff et al. 2011). 
The basic structure of the ADAMTSs is broadly organised into a protease 
domain and an ancillary domain. The proteinase domain comprises of the 
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signal, pro, metalloproteinase and disintegrin-like domains. The ancillary 
domain varies greatly between different family members and is composed of 
one or more Thrombospondin type 1 Sequence Repeats (TSR), a Cysteine-rich 
domain and a spacer domain. Several ADAMTSs also contain one or more 
specialist domains as part of their ancillary domain, which regulate enzyme 
function in terms of substrate preferences, localisation, secretion and proteolytic 
activity (Figure 1.7). Beyond intrinsic structural features the ADAMTSs are also 
regulated at the level of transcription, via post-translational modifications and 
via endogenous inhibition (TIMPs). 
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Figure 1.7: The A Disintegrin And Metalloproteinase with 
ThromboSpondin motifs (ADAMTS) family. The figure illustrates the basic 
domain organisation of the 19 human ADAMTS family members and their major 
functional groups. Structurally the ADAMTS members are broadly organised 
into a proteinase domain and an ancillary domain. The diagram is drawn to 
scale. Adapted from Kelwick and Edwards, 2014. 
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1.6	  ADAMTS	  functional	  subgroups	  
The major functional ADAMTS sub-groups include, the pro-collagen N-pro-
peptidases (ADAMTS-2,-3 and -14), the cartilage oligomeric matrix protein 
(COMP) cleaving proteases (ADAMTS-7 and -20), von-Willebrand Factor 
proteinase (ADAMTS-13) and the largest sub group, the hyalectanases / 
aggrecanases (ADAMTS-1,-4,-5,-8,-9,-15 and -20). There are also several 
orphan proteases, with no known substrates (ADAMTS-6,-10,-16 to -19) 
(Table1.3). These subgroups will be examined in the coming sections. 
However it should also be noted that beyond the currently known sub-groups, 
proteomics based approaches are identifying novel ADAMTS substrates and by 
inference a greater understanding of the biological functions of the ADAMTS 
family (Canals et al. 2006; Esselens et al. 2010; Lopez-Otin and Overall, 2002). 
These types of degradomic approaches are highlighting that the ADAMTSs 
have functions beyond the current sub-group descriptors, which may be 
biologically relevant to breast cancer tumourigenesis and metastasis (Esselens 
et al. 2010; Rodríguez-Manzaneque et al. 2009).  
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Gene Substrates 
 Hyalectanases 
ADAMTS-1 Aggrecan, Versican, Dystroglycan, Syndecan-4, TFPI-2, 
Semaphorin 3C, Nidogen-1, -2, Desmocollin-3, Mac-2, Gelatin 
(Collagen type I). 
ADAMTS-4 Aggrecan, Versican, Neurocan, Biglycan, Brevican, Reelin, 
Matrilin-3, α2-Macroglobulin, COMP. 
ADAMTS-5 Aggrecan, Versican, Biglycan, Brevican, Reelin, Matrilin-4, α2-
Macroglobulin. 
ADAMTS-8 Aggrecan. 
ADAMTS-9 Aggrecan, Versican. 
ADAMTS-15 Aggrecan, Versican. 
ADAMTS-20 Versican. 
 Pro-collagen peptidases 
ADAMTS-2 Fibrillar pro-collagens type I-III and V. 
ADAMTS-3 Fibrillar pro-collagen type II, Biglycan. 
ADAMTS-14 Fibrillar pro-collagen type I (pNα1 and pNα2 chains). 
 Cartilage oligomeric matrix protein (COMP) proteinases 
ADAMTS-7 COMP. 
ADAMTS-12 COMP. 
 von Willebrand factor (vWF) proteinase 
ADAMTS-13 vWF. 
 Orphan ADAMTSs 
ADAMTS-6 - 
ADAMTS-10 Fibrillin-1. 
  
ADAMTS-16 - 
ADAMTS-18 - 
  
ADAMTS-17 - 
ADAMTS-19 - 
Table 1.3: Known ADAMTS substrates. Adapted from Kelwick and Edwards, 2014 
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1.6.1	  Pro-­‐collagen	  peptidases	  (ADAMTS-­‐2,	  -­‐3	  and	  -­‐14)	  
Ehler-Danlos syndrome (EDS) type VIIc is an autosomal recessive disorder 
caused by a reduction in the cleavage and maturation of pro-collagen N-pro-
peptides (Colige et al. 2004). Maturation of collagen fibrils is essential to ensure 
their tensile strength and to ensure that appropriate tissue morphologies are 
formed (Cabral et al. 2005; Colige et al. 2004). Patients with Ehler–Danlos 
syndrome (EDS) type VIIc present several phenotypes including severe skin 
fragility, depressed nasal bridges, micrognathia and short stature (Cabral et al. 
2005; Colige et al. 2004). The major proteases involved in collagen fibril 
maturation have been identified as ADAMTS-2, -3 and -14 (Cabral et al. 2005; 
Cal et al. 2002; Colige et al. 2002; Colige et al. 2004; Colige et al. 2005; 
Fernandes et al. 2001). ADAMTS-2 can process the removal of the N-terminal 
pro-peptides from pro-collagen types I, II and III, whereas ADAMTS-3 is only 
associated with the processing of type II and ADAMTS-14 can process type I 
(pNα1 and pNα2). (Table 1.5; Cal et al. 2002; Cabral et al. 2005; Colige et al. 
2002; Colige et al. 2004; Colige et al. 2005; Fernandes et al. 2001; Wang et al. 
2006). 
In the context of EDS type VIIc ADAMTS-2 is the most important pro-collagen 
peptidase. Several mutations in ADAMTS-2 have been described and are 
associated with EDS type VIIc (Colige et al. 2004). In addition to this ADAMTS-
2 null mice demonstrate that ADAMTS-3 and -14 are not sufficient to 
compensate for the loss of ADAMTS-2 within the skin, though ADAMTS-3 and -
14 may be physiologically important in other contexts such as cartilage (Colige 
et al. 2002; Fernandes et al. 2001; Li et al. 2001). 
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1.6.2	  COMP	  proteinases	  (ADAMTS	  -­‐7	  and	  -­‐12)	  
Cartilage oligomeric matrix protein (COMP) is a non-collagenous component of 
cartilage formed from five ~110 kDa subunits, held together by disulphide bonds 
(Liu 2006a,2006b; Oldberg et. al 1992). COMP only accounts for around 1% of 
the weight of articular tissue, though interest in this glycoprotein has increased 
since the discovery that COMP degradation is common in post-traumatic and 
arthritic joints (Di Cesare, 1996; Liu et al. 2006a, 2006b; Lohmander, 1994). 
COMP fragments can be found at higher levels in rheumatoid and osteoarthritic 
cartilage and may serve as a useful biomarker (Di Cesare, 1996; Liu et al. 
2006a, 2006b; Lohmander, 1994). 
ADAMTS-12 has been reported as the major protease responsible for COMP 
degradation. Increased ADAMTS-12 expression is common in osteoarthritic 
joints, with reports also showing that ADAMTS-12 is capable of binding to and 
proteolytically degrading COMP (Liu et al. 2006a, 2006b). ADAMTS-12 is not 
the only known protease that is able to degrade COMP. ADAMTS-7 which 
shares the same general structure as ADAMTS-12 is also able to degrade 
COMP (Figure 1.4; Liu et al. 2006a, 2006b). The binding of COMP to both 
ADAMTS-7 or-12 involves an interaction between their four C-terminal TSRs 
and the EGF-like repeat domain found in COMP (Figure 1.4; Liu et al. 2006a, 
2006b). COMP shares sequence homology with the Thrombospondins, which 
are known to reduce pathophysiological inflammatory and angiogenic 
processes in rheumatoid arthritis (Park et al. 2004). Therapeutic targeting of 
ADAMTS-7 and -12 may become of interest particularly if they are also shown 
to degrade the Thrombospondins. 
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1.6.3	  vWF	  cleaving	  protease	  (ADAMTS-­‐13)	  
The processing of Von-Willebrand Factor (vWF) proteins from large multimeric 
vWF precursor proteins into smaller cleaved vWF proteins is important to 
ensure proper blood coagulation (Dong et al. 2002; Fujikawa et al. 2001). This 
is apparent in thrombotic thrombocytopenic purpura (TTP), a thrombotic 
disorder in which ultra large (UL) vWF multimers coagulate with platelets that in 
combination ultimately occlude circulation (Dong et al. 2002; Fujikawa et al. 
2001; Metcalf et al. 2008). Several studies have associated mutations in 
ADAMTS-13 with the inherited form of TTP. An analysis of a patient with TTP 
revealed the presence of a frameshift mutation (4143-4144InsA) in the 
ADAMTS-13 gene (Pimanda, 2004). This mutation caused a truncated form of 
ADAMTS-13 to be expressed which lacked the final 49 amino acids in the 
second CUB domain (Pimanda, 2004).  
Whilst ADAMTS-13 has been confirmed to be capable of processing von-
Willebrand Factor (vWF) and ADAMTS-13 mutations are associated with TTP 
there are still some unanswered questions (Akiyama et al. 2009; Dong et al. 
2002; Pimanda et al. 2004). When a mutant form of ADAMTS-13 (4143-
4144InsA), which was discovered in a TTP patient, was expressed in COS-7 
cells, ADAMTS-13 displayed normal vWF protease activity (Pimanda, 2004). In 
another study ADAMTS-13 deficient mice did not display any apparent 
thrombocytopenia, however there was evidence of the presence of unusually 
large vWF multimers (Banno et al. 2006). Taken together it is clear that 
ADAMTS-13 is a physiologically important vWF cleaving protease, though more 
research is needed to fully understand TTP (Banno et al. 2006; Pimanda, 
2004). 
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1.6.4	  Hyalectanases	  (ADAMTS-­‐1,	  -­‐4,	  -­‐5,	  -­‐8,	  -­‐15,	  -­‐9	  and	  -­‐20)	  
The Hyalectanases were originally termed the aggrecanase sub-group largely 
due to efforts from researchers that were interested in understanding aggrecan 
cleavage during osteoarthritis (OA) (Troeberg and Nagase, 2012). The 
proteoglycan aggrecan is a member of the hyalectans and is a major 
component of the extracellular matrix (Troeberg and Nagase, 2012). Aggrecan 
structure is augmented with several keratin sulphate (KS) and CS GAG chains 
(Figure 1.8). The propensity for these structural features to attract water, 
enables aggrecan to provide a swelling pressure that contributes to the load 
bearing properties of tissues such cartilage and tendon (Chandran and Horkay, 
2012). In osteoarthritis (OA) aggrecan is progressively degraded and is lost 
from the cartilage (Echtermeyer et al. 2009; Fosang and Little, 2008; Jones and 
Riley, 2005; Kelwick and Edwards, 2014; Lin and Liu, 2010). For this reason the 
proteases responsible for aggrecanase activity became of interest to the 
arthritis field.   
ADAMTS-4 (AKA aggrecanase-1) and in particular ADAMTS-5 (AKA 
aggrecanase-2) were identified as the major physiologically relevant 
aggrecanases in OA (Abbaszade et al. 1999; Arner et al. 1999; Fosang and 
Little, 2008; Song et al. 2007; Troeberg and Hideaki Nagase 2012). ADAMTS -
1, -8 and -15 display negligible expression in osteoarthritic and normal cartilage 
(Kevorkian et al. 2004; Naito et al. 2007). Subsequent studies have identified at 
least limited aggrecanase activity amongst ADAMTS-1, -8, -9, and -15, though 
their physiological importance as aggrecanases is perhaps not related to 
cartilage (Collins-Racie et al. 2004; Kelwick and Edwards, 2014; Kuno et al. 
2000; Rodríguez-Manzaneque et al. 2002; Somerville et al. 2003; Yamaji et al. 
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2000).  For instance an ADAMTS-1 knock-out mouse model showed that 
ADAMTS-1 is an important aggrecanase in the developing kidney (Lee et al. 
2005).  
Because the aggrecanases can also cleave other hyalectans including versican, 
brevican and neurocan it has been argued that it is more appropriate for this 
sub-group to be termed the hyalectanases (Table 1.3; Figure 1.7; Kelwick and 
Edwards, 2014; Kuno et al. 2000; Stanton et al. 2011; Stupka et al. 2013; 
Tauchi et al. 2012; Zeng et al. 2006). Versican cleavage can be carried out by 
several hyalectanases including ADAMTS-1, -4, -5, -9, -15 and -20 (Figure 1.6; 
Table 1.5; Kintakas and McCulloch 2011; Russell et al. 2003; Sandy et al. 2001; 
Somerville et al. 2003; Stupka et al. 2013). Versican-null mice die during 
development primarily due to cardiac defects, though defects in versican 
expression or cleavage can affect limb morphogenesis, palate formation, 
melanoblast development and myogenesis (Dupuis et al. 2011; Kern et al. 
2010; McCulloch et al. 2009; Mjaatvedt et al. 1998; Silver et al. 2008; Stupka et 
al. 2013). The cleavage of versican is critical during developmental processes 
for several reasons. Versican rich matrices provide a temporary structural 
support which must be removed during morphogenesis and the cleavage of 
versican can release versican fragments that are bioactive (McCulloch et al. 
2009; Stupka et al. 2013). In combination these two mechanisms can influence 
tissue architecture, cell adhesion, migration and proliferation (Dupuis et al. 
2011; Kern et al. 2010; McCulloch et al. 2009; Mjaatvedt et al. 1998; Silver et al. 
2008; Stupka et al. 2013).  
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Figure 1.8: Aggrecan and Versican. The figure shows a schematic of the 
major structural features of Aggrecan and Versican. This figure is based upon 
Kelwick and Edwards, 2014; Stanton et al. 2011; Stupka et al. 2013; Wight, 
2002. 
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ADAMTS-15 along with ADAMTS-5 are emerging as important versicanases 
within the context of muscle development (Stupka et al. 2013). Several 
hyalectanases (ADAMTS-1, -4, -5 and -15) are expressed in developing 
embryonic muscle and in an in vitro myogenesis model which utilises 
differentiating C2C12 cells (Stupka et al. 2013). Knockdown of ADAMTS-5 in 
differentiating C2C12 myoblasts impaired their ability to fuse together to form 
multinucleated myotubes (Stupka et al. 2013). For myoblast fusion to occur 
versican must be cleared from the pericellular matrix to allow the myoblasts to 
make direct cell-cell contact and subsequent fusion (Stupka et al. 2013). This 
phenotype was rescued through the addition of catalytically active forms of 
ADAMTS-5 or ADAMTS-15, highlighting these hyalectanases as important 
versicanases within this process (Stupka et al. 2013). In other studies involving 
either the combinatorial knockout of ADAMTS-4 and -5 or a combinatorial 
deletion of ADAMTS-5, -9 and -20 there were no signs of significant skeletal 
muscle myopathy (Rogerson et al. 2008; Stupka et al. 2013). It has been 
suggested that the lack of any skeletal muscle myopathy in these knock-out 
mice was due to functional compensation from ADAMTS-15 (Rogerson et al. 
2008; Stupka et al. 2013). Ultimately it may be therapeutically useful to know 
the expression of ADAMTS-15 in patients which might be treated with 
ADAMTS-5 proteolytic inhibitors, such as those with arthritis. Whilst inhibition of 
ADAMTS-5 proteolytic activity might be therapeutically beneficial in terms of 
reducing aggrecan loss in OA, loss of ADAMTS-5 versicanase activity without 
compensation from ADAMTS-15 may lead to detrimental muscle wasting and/or 
impaired regeneration (Cudic et al. 2005; Rogerson et al. 2008; Stupka et al. 
2013; Vankemmelbeke et al. 2003).   
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The hyalectanases have also been noted for their ability to modulate angiogenic 
processes and are sometimes referred to as an angioinhibitory sub-group 
(Wagstaff et al. 2011). Several ADAMTSs, particularly the hyalectanases exert 
their pro and anti-tumorigenic effects through a regulation of angiogenesis. 
1.7	  ADAMTSs	  in	  cancer	  
The ADAMTSs influence an array of biological processes including tissue 
remodelling, cell migration, inflammation and angiogenesis (Esselens et al. 
2010; Kelwick and Edwards, 2014; Porter et al. 2005; Rodríguez-Manzaneque 
et al. 2009; Wagstaff et al. 2011). During tumourigenesis and metastasis many 
of these processes are aberrantly regulated and emerge as the hallmarks of 
cancer (Hanahan and Weinberg, 2011). Therefore it is unsurprising that the 
expression profiles of the ADAMTSs show significant alterations in cancer. In 
breast cancer ADAMTS-1, -3, -5, -8, -9, -10 and -18 are all downregulated 
compared to normal tissue, whereas ADAMTS-4, -6 and -14 are up-regulated 
(Porter et al. 2004). Interestingly ADAMTS-15 expression is not significantly 
different between normal tissues and cancerous mammary tumours. However 
ADAMTS-15 expression does inversely correlate with tumour grade, with 
expression significantly reduced in grade III breast tumours compared to grade I 
or II tumours (Porter et al. 2004). ADAMTS-15 expression has also been shown 
to inversely correlate with tumour grade in colorectal cancer (Viloria et al. 2009).  
The loss of expression of genes in a cancer context may be indicative of a 
tumour suppressive function (Hanahan and Weinberg, 2011). However 
determining whether an ADAMTS might be a tumour suppressor based upon 
expression level is complicated for several reasons. Firstly the pattern of 
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ADAMTS expression (down or up-regulated) can differ between cancer type 
and stage. For instance ADAMTS-1 expression is down-regulated in primary 
head and neck carcinomas, breast cancer and around 85% of colorectal cancer 
cell lines (Demircan et al. 2009; Lind et al. 2006; Porter et al. 2004). Yet in 
contrast to this ADAMTS-1 is up-regulated in metastatic head and neck 
carcinomas and also non-small cell lung cancer (NSCLC) (Demircan et al. 
2009; Rocks et al. 2006).  Secondly the mechanism underpinning the 
inactivation of the ADAMTS differs, where some ADAMTSs are epigenetically 
silenced and others are inactivated by mutation (Table 1.4). For example whilst 
ADAMTS-15 is inactivated by mutation in colorectal cancer, in breast cancer 
ADAMTS-15 is epigenetically silenced (Table 1.4; Porter et al. 2005; Porter et 
al. 2006; Viloria et al. 2009). 
 
Epigenetically 
Silenced 
Inactivated via Mutation Unknown 
ADAMTS-1(*) ADAMTS-15(*) ADAMTS-3 
ADAMTS-8(*)  ADAMTS-5(*) 
ADAMTS-9(*)  ADAMTS-10 
ADAMTS-12   
ADAMTS-15(*)   
ADAMTS-18   
Table 1.4: Members of the ADAMTS family that are down-regulated in 
cancer. (*) denotes that these genes have also been shown to be up-regulated 
in some cancers. Table adapted from Dunn et al. 2006; Jungers et al. 2005; 
Kelwick and Edwards, 2014; Koo et al. 2010; Kutz et al. 2008; Li et al. 2009; 
Llamazares et al. 2007; Lopez-Otin and Matrisian, 2007; Porter et al. 2005; 
Porter et al. 2006; Viloria et al. 2009; Stanton et al. 2004. 
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These seemingly ambiguous patterns of ADAMTS expression in cancer are 
further confounded by the activities of the ADAMTSs which can be anti- or pro- 
tumorigenic in a context dependent manner. These have been extensively 
covered in several reviews (Edwards et al. 2005; Kelwick and Edwards, 2014; 
Wagstaff et al. 2011), however an overview of ADAMTS-1 will be given since 
ADAMTS-1 is the archetype of these complexities (de Arao Tan, Ricciardelli, 
and Russell, 2013).  
The catalytic activities of ADAMTS-1 have been shown to be pro-tumourigenic 
in several cancers. Expression of catalytically active ADAMTS-1 enhances the 
metastatic propensity of TA3 mammary carcinoma and Lewis Lung Carcinoma 
cells in vivo (Liu et al. 2006). In other contexts, including breast cancer, 
ADAMTS-1 shedding of syndecan 4 or semaphorin 3C enhances the migratory 
behaviour of cancer cell lines (Esselens et al. 2010; Rodríguez-Manzaneque et 
al. 2009).  
Conversely ADAMTS-1 proteolytic activity can also be anti-metastatic. ADAMTS-
1 proteolytic cleavage of thrombospondins -1 and -2 releases anti-angiogenic 
fragments (Lee et al. 2006). ADAMTS-1 also displays auto-catalytic behaviour, 
at a cleavage site within its own spacer region (Liu et al. 2006). This 
autocatalytic event releases N-terminal and C-terminal anti-metastatic 
fragments, that primarily act as anti-angiogenic factors (Liu et al. 2006). 
ADAMTS-1 can also elicit anti-tumorigenic effects in a metalloproteinase 
independent manner, through the binding of VEGF. The binding of VEGF 
sequesters both pro-angiogenic and pro-migratory signalling (Freitas et al. 
2013; Luque et al. 2003). 
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1.8	  Cell	  Migration	  
Cell migration is a highly dynamic and tightly regulated process which is critical 
to the development and function of living systems. Perturbations of these 
processes contribute to pathological forms of migration such as tumour cell 
invasion and metastasis. To this end an understanding of the processes and 
factors, which influence cell migration, may elucidate druggable targets that will 
inhibit metastasis.  
Several migration types have been identified, and include mesenchymal and 
amoeboid forms (Ashby and Zijelstra, 2012; Even-Ram and Yamada, 2005; 
Germena and Hirsch, 2013; Holmes and Edelstein-Keshet, 2012; Petrie et al. 
2012). These forms of single cell migration are occasionally controversial since 
invading ‘mesenchymal-like’ tumour cells may not need to release proteases in 
order to clear a path for migration if they adopt an ameboid configuration to 
squeeze through the ECM (Ashby and Zijelstra, 2012; Even-Ram and Yamada; 
2005; Mierke et al. 2008). Cells can also collectively migrate as part of complex 
and highly dynamic multi-cellular structures (Friedl et al. 2012; Rørth, 2012). In 
the context of cancer, tumour cells may collectively invade and endothelial cells 
may collectively migrate to vascularise the tumour (Friedl and Wolf, 2003; 
Nguyen-Ngoc et al. 2012). 
The factors which influence cell migration are varied and include those which 
are intrinsic (e.g. regulation of cytoskeleton, adhesion receptors, proteases), 
extrinsic (e.g. cell-cell interactions, soluble signalling factors) and matrix 
associated (e.g. composition, structure, stiffness) (Ashby and Zijelstra, 2012; 
Even-Ram and Yamada, 2005; Holmes and Edelstein-Keshet, 2012; Schiller et 
Chapter 1 | Page 48 
 
al. 2013). Whilst the full complexities of cell migration processes have not yet 
been fully characterised a general model of the migration cycle is fairly well 
established.  
1.8.1	  Migration	  cycle	  
Cell migration is often conceptualised as a cyclical model in which four general 
stages occur, as summarised in Figure 1.9. Initially cells become polarised, in 
which a migration direction is determined. Cellular polarisation is primarily 
regulated by the Rho GTPase, Cdc42, which is active at the leading edge of a 
migrating cell (Mullins and Hansen, 2013; Petrie, Doyle and Yamada, 2009; 
Reymond et al. 2012). Cdc42 acts to localise and reorient the microtubule-
organising centre and the Golgi apparatus towards the leading edge (Hehnly et 
al. 2010; Raftopoulou and Hall, 2004; Ridley et al. 2003). The leading edge is 
visibly defined through the extension of the cell membrane either as ‘finger like’ 
filopodia or as ‘broad ruffle like’ lamellipodia projections (Mullins and Hansen, 
2013; Raftopoulou and Hall, 2004; Ridley et al. 2003). These transient 
extensions are broadly driven by the forces elicited by the dynamic assembly 
and disassembly of actin bundles (actin polymerisation) (Carlsson, 2010; 
Mullins and Hansen, 2013). Actin polymerisation dynamics are themselves 
regulated by Cdc42 acting in co-operation with the Rho-GTPase, Rac1 (Bass et 
al. 2007; Choi et al. 2011; Keum et al. 2004; Riddley et al. 1992). However 
Cdc42 and Rac1 do not directly bind to actin bundles, instead they act via 
members of the WASp/SCAR/WAVE family of scaffold proteins (Mullins and 
Hansen, 2013; Raftopoulou and Hall, 2004; Ridley et al. 2003). Cdc42 acts via 
the direct activation of WASp (Lamalice, Le Boeuf and Huot, 2007; Raftopoulou 
and Hall, 2004; Rohatgi, Ho and Kirschner, 2000; Ridley et al. 2003). Rac1 on 
Chapter 1 | Page 49 
 
the other hand acts via an indirect pathway in that it activates members of the 
Scar/WAVE family of scaffold proteins via the Nck-adapter complex 
(Raftopoulou and Hall, 2004; Ridley et al. 2003; Rohatgi et al. 2001). Activated 
WASp/SCAR/WAVE proteins subsequently go on to activate the Arp2/3 
complex, which initiate de novo actin polymerisation (Mullins and Hansen, 
2013). Cdc42 regulated actin polymerisation tends to favour filopodia 
membrane protrusions, though Rac1 regulated actin polymerisation leads to the 
formation of lamellipodia (Mullins and Hansen, 2013; Ridley et al. 1992; Ridley 
et al. 2003).  
Cdc42 and in particular Rac1 also signal to recruit transient adhesion 
complexes (Mullins and Hansen, 2013; Reymond et al. 2012; Ridley et al. 
2003).  Transient adhesion complexes include integrins and co-receptors such 
as syndecans (Beauvais and Rapraeger, 2004; Reymond et al. 2012; Schiller et 
al. 2013). These complexes maintain localised Rac1 and Cdc42 signalling at 
the leading edge and as a result assist in the stabilisation of the lamellipodia 
(Beauvais and Rapraeger, 2004; Petrie, Doyle and Yamada, 2009; Schiller et 
al. 2013). It is thought that these adhesion complexes also serve as regions in 
which cells can dynamically ‘sample’ the rigidity and composition of the 
extracellular matrix in order to seek out an optimal migration pathway (Beauvais 
and Rapraeger, 2004; Petrie, Doyle and Yamada, 2009; Schiller et al. 2013). 
However in order to migrate, cells require a secure attachment site from which 
enough force can be generated to facilitate cell migration (Lui, Lee and Nelson, 
2012; Lai, Hsieh and Chang, 2003). The GTPase RhoA induces the formation 
of stress fibres and stable focal adhesions that provide the cytoskeletal tension 
required for cell contractility (Brew et al. 2009; Mullins and Hansen, 2013; 
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Tilghman et al. 2010). RhoA acts via several downstream effectors including the 
Rho-associated kinases, ROCK (Bhadriraju et al. 2007; Brew et al. 2009; 
Tilghman et al. 2010). Rock activated myosin II promotes the stabilisation of 
actin-myosin filament bundles which provide the cellular tension needed for cell 
contractility (Bhadriraju et al. 2007; Brew et al. 2009; Mullins and Hansen, 2013; 
Tilghman et al. 2010). Tension is transduced via mechanosensitive integrins 
which elicits further activation of RhoA (Ross et al. 2013; Schiller et al. 2013; 
Streuli and Akhtar, 2009). This positive feedback network increases focal 
adhesion size and induces the formation of stress fibres via increased RhoA 
activation of mDia (Doherty and McMahon, 2008; Ridley et al. 2003; Schiller et 
al. 2013; Spiering and Hodgson, 2011). Thus RhoA signalling acts 
synergistically to alter cytoskeletal dynamics in order to generate the contractile 
forces needed for cell migration. 
The force of cell migration is largely transmitted to the leading and trailing edges 
of the cell (Beningo et al. 2001; Holmes and Edelstein, 2012; Mierke et al. 2008; 
Ridley et al. 2003). In response, adhesion complexes must be temporally co-
ordinated to disassemble at both edges of the cell. At the leading edge cell 
adhesion complexes must disassemble and then reform as the cell membrane 
rolls forward (tread milling effect) (Carlsson, 2010; Friedl and Wolf, 2003 
Germena and Hirsch, 2013; Ridley et al. 2003). These newly formed adhesion 
complexes reinforce Cdc42 and Rac1 signalling at the leading edge (Friedl and 
Wolf, 2003; Ridley et al. 2003). Rac1 and RhoA are mutual inhibitors of their 
activities (Caswell, Vadrevu and Norman, 2009; Germena and Hirsch, 2013; 
Ridley et al. 2003). As a consequence Rac1 activity is restricted to the leading 
edge and RhoA activity is highest at the periphery and trailing edges (Bass et 
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al. 2007; Friedl and Wolf, 2003; Ridley et al. 2003). This maintains migration 
polarity whilst also serving to co-ordinate the detachment of adhesion 
complexes at the trailing edge, which is a RhoA and myosin-dependent process 
(Schiller et al. 2013; Terry et al. 2012). However it should be noted that multiple 
signalling pathways are also implicated in focal adhesion turnover such as focal 
adhesion kinase (FAK), ERK and Src (Bass et al. 2007; Beningo et al. 2001; 
Ross et al. 2012; Streuli and Akhtar, 2009).  
RhoA also stabilises microtubules at the trailing edge (Fonseca et al. 2010; 
Fonseca and Corbeil, 2011; Heck et al. 2012). As noted earlier Cdc42 and Rac1 
also regulate microtubule dynamics, such that Cdc42 orientates microtubules 
towards the direction of migration and Rac1 enables the elongation of 
microtubules into the newly forming lamellipodia (Hehnly et al. 2010). In co-
ordination these GTPases provide a platform from which adhesion receptor 
complexes can be recycled and transported along the microtubules towards the 
leading edge (Caswell, Vadrevu and Norman, 2009). Thus the migration cycle 
comes full circle.   
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Figure 1.9: Cell migration cycle. The 4 main stages of the cell migration cycle 
are depicted alongside several key signalling pathways. Cells may become 
polarised in response to a pro-migratory stimulus such as a chemo-attractant 
gradient or matrix topology (stiffness etc.) (1) Polarisation of the cell and the 
formation of lamellipodia from which a migration direction is established. (2) The 
formation of more stable focal adhesion sites and stress fibres that enable the 
cell to generate enough force to (3) contract. (4) The rear of the cell is released 
and migration signalling complexes are reorganised around the newly formed 
leading edge. This figure is based upon information from Lamalice, Le Boeuf 
and Huot, 2007. 
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1.8.2	  Integrins	  and	  cell	  migration	  
Integrins are the principal family of cell adhesion receptors in vertebrates 
(Humphries et al. 2006; Hynes, 2002; Hynes, 1987). Integrins form into one of 
24 known mammalian heterodimers that consist of an α and a β subunit (Figure 
1.10; Humphries et al. 2006; Hynes, 2002). Integrin heterodimers, span the cell 
membrane such that their ectodomains directly bind to the matrix and their 
intracellular domains directly interact with the cytoskeleton and the cell 
signalling machinery, including: Rac1, RhoA and Cdc42 (Figure 1.10, 1.11; 
Beauvais and Rapraeger, 2004; Beningo et al. 2001; Schiller et al. 2013; 
Wertheimer et al. 2012). Ligand binding is thought to cause a conformational 
change in integrin structure, which subsequently alters the propensity for 
membrane receptors and intracellular signalling proteins to form signalling 
clusters around activated integrins (Campbell and Humphries, 2011).  Thus 
integrins are able to modify cellular behaviour through direct ‘outside-in’ 
signalling pathways.  
Within the context of cell migration, integrins play several important roles that 
have been extensively reviewed, but are not yet fully understood (Huttenlocher 
and Horwitz, 2011; Hynes, 2002; Plotnikov and Waterman, 2013). Principally, 
integrins enable cells to adhere to the extracellular matrix and thus are a major 
component of the adhesive structures required to generate the traction needed 
for cell migration (Huttenlocher and Horwitz, 2011; Plotnikov and Waterman, 
2013). Additionally, integrin heterodimers are matrix-ligand specific, thus a layer 
of specificity is added to these interactions, which provide context to the 
regulation of downstream signalling (Table 1.5; Caswell et al. 2009; Humphries 
et al. 2006; Hynes, 2002; Streuli and Akhtar, 2009). 
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Matrix 
component 
Integrin heterodimers 
Collagen α10β1, α2β1, α1β1, α11β1 
Laminin α3β1, α6β1, α6β4, α7β1, α1β1, 
α2β1, α10β1 
Fibronectin αVβ3, αVβ6, αVβ1, α5β1, α8β1 
Table 1.5: Integrin heterodimers that bind to major components of the 
extracellular matrix. This table is based upon Humphries, Byron and 
Humphries, 2006. 
 
Due to the specificity of integrin-ligand binding, changes in the expression of 
integrins can drastically alter the adhesive, migratory and/or invasive capacity of 
a cell. For instance, an increase in the expression of integrin α6β4 is generally 
associated with an increase in the invasive capacity of breast tumour cells 
(Chen et al. 2008; Gabarra et al. 2010; Gordon et al. 2003). Yet interestingly, it 
is generally understood that overexpression of integrins may ultimately inhibit 
cell migration, since cells may become ‘anchored’ to the matrix (Huttenlocher 
and Horwitz, 2011). Therefore, a balance in the expression and turnover of 
integrins is required to ensure persistent cell migration (Huttenlocher and 
Horwitz, 2011). Indeed, integrin-containing adhesion complexes, of which focal 
adhesions are the most characterized, are largely transient (Beauvais and 
Rapraeger, 2004; Petrie, Doyle and Yamada, 2009; Schiller et al. 2013). The 
transient nature of focal adhesion complexes is also of paramount importance 
because they are sites at which cells can dynamically enact integrin-mediated 
sampling of the rigidity and composition of the ECM (Beauvais and Rapraeger, 
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2004; Petrie, Doyle and Yamada, 2009; Schiller et al. 2013). Integrin signalling 
is co-ordinated with an array of signaling and adhesion receptors, such as the 
syndecans, that together influence cell adhesion and migration pathways 
(Beauvais and Rapraeger, 2004; Huttenlocher and Horwitz, 2011; Plotnikov and 
Waterman, 2013). 
 
Figure 1.10: Typical integrin structure. (A) The schematic displays a typical 
integrin heterodimer. (B) The schematic displays the structure of a typical 
integrin as it sits within the membrane. Adated from Barczyk et al. 2010. 
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1.8.3	  Syndecans	  and	  cell	  migration	  
The syndecans are a family of four heparan sulfate proteoglycans that sit within 
the cell membrane as type I transmembrane receptors (Choi et al. 2011). 
Syndecans are functionally diverse and have been shown to partake in the 
regulation of cell adhesion and migration signalling (Choi et al. 2011; Couchman 
and Woods, 1999; Morgan et al., 2007). There seems to be an intimate 
connection between the syndecans and the ADAMTSs, which co-ordinate with 
other metalloproteinases to regulate cell-ECM interactions. In transfected 
human chondrosarcoma cells, the MMP-17 processed form of ADAMTS-4, 
termed p53, directly associates with syndecan-1 (Gao et al. 2004). Since 
ADAMTS-4 does not undergo autolytic processing within this context it is 
possible that the association of ADAMTS-4 within the MMP:ADAMTS:syndecan 
complex favours proteolytic processing, rather than autolytic processing. (Gao 
et al. 2004). This is functionally important since proteolytic and autolytic 
processing can alter ADAMTS localisation, substrate preferences and 
proteolytic activity.  
In the case of ADAMTS-5, its association with syndecan-4 within an 
osteoarthritic context enhances ADAMTS-5 aggrecanase activity (Echtermeyer, 
et al. 2009). Syndecan-4 enhances ADAMTS-5 aggrecanase activity in part 
through their direct interaction and also through the syndecan-4 enhanced 
expression of matrix metalloproteinase-3 (MMP-3) (Echtermeyer, et al. 2009). 
Thus these complexes may serve as a regulatory mechanism from which to 
modulate the activities of secreted ADAMTSs.  
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Metalloproteinases can also feedback into these complexes since it has been 
demonstrated that TIMP-3 responsive metalloproteinases are responsible for 
the shedding of syndecan-1 and -4 (Fitzgerald et al. 2000). More specifically 
ADAMTS-1, and -4 are major syndecan-4 ectodomain sheddases and MMP-7, 
and MT1-MMP are major syndecan-1 sheddases (Rodríguez-Manzaneque et 
al. 2009). MMP-9 and ADAM-17 may also shed syndecan -1 and -4 in some 
contexts (Brule et al. 2006; Pruessmeyer et al. 2010). Critically these shedding 
activities have functional consequences, particularly with regards to the 
regulation of cell adhesion and migration (Rodríguez-Manzaneque et al. 2009).  
Syndecan-4 can mediate cell adhesion to fibronectin either directly or as a co-
receptor with Integrin α5β1 as part of a focal adhesion complex (Figure 1.11; 
Choi et al. 2011; Rodríguez-Manzaneque et al. 2009). Upon engagement with 
fibronectin, the cytoplasmic domain of syndecan-4 recruits, stabilises and 
activates PKCα at the plasma membrane (Keum et al. 2004; Woods and 
Couchman, 1997). Subsequent downstream Rac1 signalling is thus localised in 
a PKCα-dependent manner to a region of the cell in which syndecan-4 and 
other co-receptors are engaged with the extracellular matrix (Bass et al. 2007; 
Bass, Morgan and Humphries, 2007). Rac1 activity promotes the spreading and 
ruffling of the cell membrane into actin-rich lamellipodia (Riddley et al. 1992). 
PKCα also activates RhoA signalling which is required to generate stable focal 
adhesion complexes (Avalos et al. 2009; Brew et al. 2009; Car et al. 2013) In 
combination these structures provide a leading edge from which cell polarity 
and a stable migration direction can be established (Bass et al. 2007; Choi et al. 
2011; Keum et al. 2004; Riddley et al. 1992). Thus syndecan-4 promotes 
persistent migration (directionality) by maintaining Rac1 localisation at the 
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leading edge (Bass et al. 2007). ADAMTS-1 shedding of syndecan-4 from the 
cell surface results in a functional loss of cell adhesion and promotes a pro-
migratory phenotype with a concomitant loss of directionality (Bass et al. 2007; 
Choi et al. 2011; Rodríguez-Manzaneque et al. 2009). Shedding of syndecan-4 
also results in a functional loss of cell adhesion and an altered cytoskeletal 
topology, such that actin stress fibres are redistributed to the periphery 
(Rodríguez-Manzaneque et al. 2009). Therefore it is likely that the ADAMTSs 
are functionally linked with the syndecans within the context of regulating the 
ability of a cell to adhere and migrate in response to a highly dynamic ECM. 
 
Figure 1.11: Syndecan-4 in co-operation with α5β1 provides a mechanical 
link between the extracellular matrix and the actin cytoskeleton. An 
adapted version of the figure from Beauvais and Rapraeger, 2004. © 2004 
Beauvais and Rapraeger; licensee BioMed Central Ltd. This is an Open Access 
article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's 
original URL: http://www.rbej.com/content/2/1/3   
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1.9	  Project	  hypothesis	  and	  thesis	  aims	  
Hypothesis: ADAMTS-15 is a tumour suppressor gene within the context 
of breast cancer. 
An array of in vitro and in vivo approaches will be utilised to determine the 
functional consequences of the expression of ADAMTS-15 within the context of 
breast cancer disease progression. 
1. Characterisation of appropriate myoepithelial and epithelial breast 
cancer cell lines to establish in vitro models for the investigation of 
ADAMTS-15 in breast cancer. 
2. Investigate the effects of ADAMTS-15 expression on breast cancer 
cell behaviour in an array of in vitro cell assays, including: 
aggrecanase, proliferation, adhesion and migration assays. 
a. Determine the mechanism(s) underpinning any observed 
ADAMTS-15 tumour suppressive effects. 
b. Discern whether ADAMTS-15 metalloproteinase activity is 
required for the tumour suppressive actions of ADAMTS-15 in 
breast cancer. 
3. Determine if ADAMTS-15 modulates angiogenic processes. 
4. Investigate the consequences of ADAMTS-15 expression on in vivo 
tumour development and metastasis. 
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Chapter	  Two:	  Materials	  and	  Methods	  
2.1	  Buffers	  
Buffer Contents 
Aggrecanase Assay Buffer 50mM Tris-HCl (pH 7.5), 150 mM 
NaCl; 10mM CaCl2; 0.05% (v/v) Brij-35 
Blocking / Antibody Buffer 5% (w/v) half-fat milk or 5% (w/v) BSA 
in PBS (or TBS) with or without 0.02% 
(v/v) Tween-20 
Coating Buffer 0.1M NaCO3, (pH 9.6) 
Coomassie Blue 45% (v/v) methanol, 10% (v/v) glacial 
acetic acid, 0.25% (w/v) Coomassie 
Brilliant Blue G-250 (Fluka), dH2O 
Coomassie Blue (De-stain) 20% (v/v) methanol, 5% (v/v) glacial 
acetic acid, 75% (v/v) dH2O. 
Lysis Buffer 50mM Tris-HEPES pH 7.8, 150mM 
NaCl and 1% (v/v) Triton X-100 
detergent supplemented with protease 
inhibitor (Roche, Hertfordshire, UK; 
#11836170001) 
Methylene Blue 1% (w/v) Methylene Blue, 10mM 
borate buffer (pH8.5), 50% (v/v) 
Methanol. 
Methylene Blue (De-stain) 50% Ethanol, 50% 0.1M HCl 
PBS (1x) Dissolve in 1 litre of dH2O: 8g of NaCl, 
0.2g of KCl, 1.15g of Na2HPO4, 0.2g of 
KH2PO4, (pH 7.4) 
Ponceau S Stain 5% (w/v) Acetic acid, 0.1% (w/v) 
Ponceau S in dH20 
TAE (Tris/Acetate/EDTA) 50x Stock: 2M Tris-HCl, 1M glacial 
acetic acid, 100ml 0.5M EDTA, made 
up to 1L with dH2O.  
TAE (1x): 1:50 dilution of stock in 
dH2O. 
Tris-buffered saline (TBS) (1x) 50mM Tris-Cl (pH 7.5), 150mM NaCl 
trypsin-EDTA (TE) 10mM Tris-HCl, 1mM EDTA, (pH 8.0) 
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Washing Buffer 1x PBS, 0.1% (v/v) Tween-20 
Western Blotting Sample Buffer 125mM TRIS-HCl, 5% SDS, 15% 
Glycerol, Bromophenol Blue, (pH 6.8) 
Table 2.1: List of buffers and their contents 
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2.2	  Reagents	  
Reagent Description Catalogue No. 
ADAMTS-15 siRNA ON-TARGET plus 
SMART pool 
Thermo scientific  
#L-005766-00-0005 
BCA BCA protein assay kit Thermo scientific 
#PN23227 
Collagen Type I Rat tail type I, sterile 
solution 100ml for gels. 
First Link UK Ltd.  
#60-30-810 
Collagen Type I Collagen, Type I solution 
from rat tail. 
Sigma #C3867 
Control siRNA ON-TARGET plus Non-
targeting siRNA 
Thermo scientific  
#D-001810-01-05 
ECL Pierce ECL WB 
Substrate 
Thermo scientific #32106 
EGF epidermal growth factor 
1mg 
Sigma #E4127 
FGF-2 Basic fibroblast growth 
factor 
PeproTech 
Fibronectin Fibronectin from bovine 
plasma 
Sigma #F1141 
HyClone Water HyPure Cell Culture 
Grade Water 
Thermo Scientific 
#SH30529.02 
Insulin insulin 10mg Sigma #10516 
Laminin Laminin from human 
placenta sterile filtered 
Sigma Aldrich  
#L6274-.5MG 
LipoD293 DNA In Vitro 
Transfection Reagent 
SignaGen Laboratories 
#SL100668 
Lipofectamine RNAiMAX Reagent Life technologies  
#13778-100 
Matrigel BD Matrigel Basement 
membrane Matrix 
BD Biosciences #356234 
Milk Blotting grade milk Bio Rad #170-6404 
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MM TaqMan master mix 
universal 5x5ml 
Applied Biosystems 
#4440048 
NEAA Non-essential amino 
acids 
Sigma #M7145 
Oligofectamine Transfection reagent Life technologies  
#12252-011 
OPTIMEM with Glutamax Life technologies  
#51985 
ProtoGel Acrylamide 30% w/v 
stock solution 37.5:1 
National Diagnostics 
#EC-890 
RNAzol RNAzol B Amsbio #CS105B 
ROCK inhibitor Y-27632 Sigma #Y0503-1MG 
Sodium Pyruvate TC supplement Sigma #S8636 
SuperScript II Reverse Transcription Life technologies 
#18064-022 
Syndecan-4 siRNA ON-TARGET plus 
SMART pool 
Thermo scientific 
#L-003706-00-0005 
Tween-20 Tween 20 sigma ultra Sigma #P7949-500ML 
VEGF vascular endothelial 
growth factor 
PeproTech 
Phalloidin Alexa Fluor 568 
Phalloidin 
Life technologies 
#A12380 
SV Total RNA Isolation 
Kit 
RNA extraction kit. Promega #Z3105 
Table 2.2: List of experimental reagents 
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2.3	  Cell	  culture	  
Cells were generally cultured at 37oC and 5% CO2 in T75 tissue culture flasks 
(Nunc) containing 12ml of culture media as described below. Cells were 
passaged upon reaching 80% confluency and were routinely tested for 
mycoplasma.  Cell lines were also validated via ‘SNP barcodes’ (Demichelis et 
al. 2008) to confirm that the correct cell types were being used. 
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Cell Line Description Culture Media 
MDA-MB-231 Epithelial (more 
mesenchymal-like) human 
breast adenocarcinoma 
with an invasive 
phenotype  
(Lacroix and Leclercq, 
2004). 
DMEM (Invitrogen, 
Paisley, UK, #21885) 
supplemented with 10% 
FCS and non-essential 
amino acids. 
MDA-MB-231  
EV / TS15 / E362A 
MDA-MB-231 cells 
constitutively expressing 
empty vector (EV), wild 
type ADAMTS-15 (TS15) 
or metalloproteinase 
inactive ADAMTS-15 
(E362A). 
As above plus selection 
antibiotic G418 (500µg/ml 
of culture media). 
MCF7 Epithelial-like human 
breast adenocarcinoma  
(Lacroix and Leclercq, 
2004) 
DMEM (Invitrogen 
#21885) supplemented 
with 10% FCS and non-
essential amino acids. 
MCF7  
EV / TS15 / E362A 
MCF7 cells constitutively 
expressing empty vector 
(EV), wild type ADAMTS-
15 (TS15) or 
metalloproteinase inactive 
ADAMTS-15 (E362A). 
As above plus selection 
antibiotic G418 (400µg/ml 
of culture media). 
HCT-116 Epithelial -like human 
colorectal carcinoma  
(Viloria et al. 2009). 
McCoy’s 5A (Invitrogen 
#36600-021) + 10% FCS 
1089-β4 / 1089-β6 Myoepithelial –like  
(Jones et al. 2009) 
Ham’s F12 Plus media 
(Sigma #N4888) with 10% 
FCS, L-Glutamine (2mM), 
Hydrocortisone (1µg/ml), 
insulin (1µg/ml) and EGF 
(100µg/ml). 
HUVEC (Primary Cells) Primary human umbilical 
vein endothelial cells 
(HUVECs)  
(Cooley et al. 2010). 
Large Vessel Endothelial 
Cell Basal Medium (TCS 
Cell Works #ZHM-2951) 
+2% FCS  
Table 2.3: Cells and culture conditions. 
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2.4	  ADAMTS-­‐15	  constructs	  
To investigate the role of ADAMTS-15 in in vitro models of breast cancer 
several ADAMTS-15 constructs were generated by Dr. Laura Wagstaff. In 
addition to full length ADAMTS-15, a metalloproteinase inactive form of 
ADAMTS-15 (E362A) and several truncated ADAMTS-15 constructs (ΔA, ΔB, 
and ΔC) which lack C-terminal domains were also generated. These constructs 
were PCR cloned into pcDNA 3.2 plasmid (Invitrogen #K2440-20). A FLAG tag 
was also cloned in-frame into the C-terminal sequence of all ADAMTS-15 
constructs to enable purification and detection of ADAMTS-15 protein. 
 
Figure 2.1: ADAMTS-15 constructs and pcDNA3.2 plasmid map. In total six 
constructs were generated: wildtype ADAMTS-15 (TS15), a metalloproteinase 
inactive form of ADAMTS-15 (E362A) and three truncation constructs (ΔA, B, C) 
that lack the c-terminal domains to the right of the indicated blue line. A FLAG 
tag was cloned in frame into the C-terminal sequence of all ADAMTS-15 
constructs to enable purification and detection of ADAMTS-15 protein.  
Chapter 2 | Page 67 
 
2.4.1	  Constitutive	  expression	  
ADAMTS-15 constructs were established in several breast cancer cell lines; 
MDA-MB-231 cells and MCF-7 cells. The constructs were cloned into the 
pcDNA3.2 backbone and were transfected according to manufacturer’s 
guidelines (Invitrogen #12489-019) into the cell lines for stable constitutive 
expression by Dr. Laura Wagstaff. Polyclonal pools were used in all 
experiments and antibiotic selection (G418) was utilised to select for 
overexpressing cells. 
2.5	  Cell	  growth	  assay	  
MDA-MB-231 EV / TS15 / E362A cells were seeded into 24 well plates at a 
density of 10,000 cells / well in 1ml of serum containing media. Cells were left 
overnight at 37oC / 5% CO2 to adhere. The next day the wells were washed with 
DPBS and changed to either 1ml of serum containing media (10% FCS) or 1ml 
of serum free media (0% FCS). At days 2, 3 and 4 post seeding cells were 
trypsinised, suspended and counted using a haemocytometer to determine total 
cell number. Four wells were counted for each cell line at each time point. The 
data was averaged to determine cell growth curves. 
2.6	  Cell	  viability:	  MTT	  assay	  
The MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
was utilised to determine cell viability (van Meerloo et al. 2011). Cells were 
seeded into 96 well plates and cultured for three days. MTT treated cells 
(0.5mg/ml final concentration) were cultured for 4 hours at 37oC before 
Absorbance of the DMSO solubilised formazan product was measured at 
550nm with a plate reader (ThermoMAX, Molecular Device). Cell number was 
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optimised for each cell line used and wells containing MTT substrate only were 
used as a negative (background signal) control. 
2.7	  Aggrecanase	  assay	  
ADAMTS-15 and E362A were partially purified from serum-free conditioned 
media of heparan-treated (100 µg/ml) MDA-MB-231 TS15 and E362A cultures 
by affinity chromatography on anti-FLAG Sepharose. Bovine Aggrecan (0.5 
mg/ml) was incubated with either purified ADAMTS-5 (2nM; domain deletion 
mutant consisting of catalytic, disintegrin and thrombospondin 1 domains), 
ADAMTS-15 (~0.6 nM) or E362A mutant ADAMTS-15 (~0.6 nM) in 700µl of 
aggrecanase assay buffer (Table 2.1) with or without N-TIMP-3 (200 nM) for the 
indicated time at 37 °C. Assay samples were de-glycosylated using 
chondroitinase ABC and keratanase (each 0.01 U / 10 µg of aggrecan) at 37°C 
overnight as previously described (Kashiwagi et al. 2004). De-glycosylated 
samples were analysed by SDS PAGE and western blotted using aggrecan 
neo-epitope antibody (anti-AGEG), which recognizes the N-terminal AGEG 
generated by aggrecanase cleavage of bovine aggrecan at Glu1771-Ala1772 
(Troeberg et al. 2008). 
2.8	  Plasmid	  DNA	  transient	  transfection	  
Cells were seeded into tissue culture treated 6 well plates and grown to 90% 
confluency. LipoD293 transfection reagent was utilised in all plasmid DNA 
transient transfection experiments. Transfection mixes containing 50µl serum 
free media and 3µl LipoD293 and DNA mixes containing 50µl serum free 
DMEM and 1µg plasmid DNA for each well were prepared. Transfection and 
DNA mixes were pipetted into the same tube and then mixed by tapping the 
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tube. The transfection/DNA mix was incubated for 15 minutes at room 
temperature. During the incubation steps cells were washed twice with DPBS 
and 900µl serum free media. 100µl transfection/DNA mix was added to each 
well. Media was replaced 6 hours post transfection with either 1ml serum free 
media or 1ml serum containing media.   
2.9	  siRNA	  transfection	  
MDA-MB-231 cells were seeded into 6 well plates at a density of 200,000 cells / 
well in 1ml of serum containing media. Cells were left overnight to adhere at 
37oC / 5% CO2. The next day media was removed from each well and then 
washed with OPTIMEM. 800µl of OPTIMEM was then added to each well. 
Transfection master mixes were then created containing 5µl Oligofectamine, 
194µl OPTIMEM and 1µl ADAMTS-15 siRNA (10nM final concentration) per 
well. 200µl of transfection master mix was added to relevant wells. At 4 hours 
post siRNA transfection 500µl / well of serum containing media was added. 
2.10	  Adhesion	  assay	  
Tissue culture treated 96 well plates were coated with either Collagen type I, 
Laminin or Fibronectin at a final concentration of 5µg/ml. Matrix components 
were diluted to the final concentration in coating buffer (Table 2.1) and left 
overnight at 4ºC.   
Matrix coated wells were then washed twice with DPBS (1x) and blocked in 1% 
bovine serum albumin/DPBS (w/v) for 30 min at 37ºC. MDA-MB-231 cells were 
seeded at a density of 60,000 cells / well and MCF7 cells were seeded at a 
density of 100,000 cells / well in 100µl of serum free DMEM.  
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Seeded plates were spun at 193 x g for 1 min and then incubated for 30 min at 
37ºC and 5% CO2. Media was aspirated off and wells were carefully washed 
with 100µl DPBS to remove any non-adherent cells. Adhered cells were fixed 
and stained for 30 minutes at room temperature with a Methanol/Methylene 
Blue solution (Table 2.1). Plates were rinsed with dH2O and then 100µl 
Methylene Blue de-stain (Table 2.1) was added to each well. 10 minutes post-
addition of de-stain, plates were read in a micro-plate reader (ThermoMAX, 
Molecular Device). The absorbance of stained adhered cells was determined at 
630 nm. These assays are based upon Oliver et al. 1989.  
2.11	  2D	  Cell	  migration	  assays	  
MDA-MB-231 or MCF7 cells were seeded into 24 well plates at a density of 
10,000 cells/well with serum containing media and left overnight to adhere at 
37oC / 5% CO2. Then each well was washed with DPBS and replaced with 1ml 
serum free media. For some assays cells were treated with EGF (0-100 ng/ml), 
Phorbol myristate acetate (PMA) (0-100nM) or bis-indolylmaleimide I (BIM I) (0-
1µM). 2D cell migration was analysed as described in section 2.11.4. 2D cell 
migration assay methods reviewed by Ashby and Zijlstra, 2012.  
2.11.1	  Matrix	  migration	  assay	  
Tissue culture treated 24 well plates were coated with either Collagen type I, 
Laminin or Fibronectin at a final concentration of 5µg/ml. Matrix components 
were diluted to the final concentration in coating buffer (Table 2.1) and left 
overnight at 4ºC. Matrix coated wells were then washed with DPBS (1x) and 
blocked in 1% bovine serum albumin/DPBS (w/v) for 30 min at 37ºC. 
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Wells were washed again with DPBS and 10,000 MDA-MB-231 cells were 
seeded in1ml of serum free media per well. Seeded plates were spun down in a 
centrifuge at 193 x g for 1 minute. Time-lapse microscopy 2D Migration was 
tracked as described in section 2.11.4.  
Time-lapse images, taken at 4 hours post seeding were also utilised to 
determine cell spreading on each matrix. The polygon tool in Image J 
(http://rsbweb.nih.gov/ij/) was utilised to determine the spreading area (pixel 
area) of individual cells. 
2.11.2	  Conditioned	  matrix	  assay	  
100,000 MDA-MB-231 EV / TS15 / E362A cells were seeded into 12 well plates 
with serum containing media and were cultured for 3 days to reach 100% 
confluency. Wells were washed with DPBS and cells were removed with 
EDTA/EGTA (5mM) to preserve the underlying conditioned matrices. 20,000 
MDA-MB-231 naïve EV cells were then seeded onto each conditioned matrix 
and migration was tracked via time-lapse microscopy for 24 hours. 
2.11.3	  siRNA	  treated	  migration	  assay	  
MDA-MB-231 cells were seeded into 6 well plates at a density of 25,000 cells / 
well in 1ml of serum containing media. Cells were left overnight to adhere at 
37oC / 5% CO2. The next day media was removed from each well and then 
washed with OPTIMEM. 800µl of OPTIMEM was then added to each well. 
Transfection master mixes were then created containing 5µl Oligofectamine 
(Invitrogen #12252-011), 194µl OPTIMEM and 1µl siRNA (10nM final 
concentration) per well. 200µl of transfection master mix was added to relevant 
wells. At 4 hours post siRNA transfection 500µl / well of serum containing media 
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was added immediately prior to the start of time-lapse microscopy. 2D Migration 
was tracked as described below. 
2.11.4	  Time-­‐lapse	  microscopy	  and	  analysis	  
2D and 3D migration was tracked with a Zeiss Inverted CCD microscope at 10x 
magnification and phase contrast illumination. Images were automatically taken 
every 10min for 24 hours to create time-lapse microscopy videos. Image J and 
two plugins (Manual Tracking and Chemotaxis Migration Tool) were utilised to 
manually track individual cells in order to determine average cell velocity 
(µm/min) and cell directionality. 
2.12	  3D	  migration	  assay	  
MDA-MB-231EV / TS15 / E362A cells were seeded into 12 well plates at a 
density of 87,500 cells / well. The cells were seeded within 150µl / well of 
Matrigel or Collagen I. Gels were set for 30 min at 37oC. Once gels were set 
250µl serum free media was added per well. The plates were incubated for an 
additional 60 min at 37oC / 5% CO2 to allow cells to adhere. Migration was 
tracked as described above, except multiple Z planes for each XY position were 
also tracked. 
2.13	  Scratch	  assay	  
MDA-MB-231 cells were seeded at high density (450,000 cells / well) into 12 
well plates with 1ml serum containing media and left overnight to adhere. The 
next day scratches were generated with a pipette tip. Wells were then washed 
with 1ml DPBS before the addition of 1ml / well of serum containing media. 
Scratch recovery was tracked via time-lapse microscopy, with images 
automatically taken every 10min for 24 hours on a Zeiss Inverted CCD 
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microscope. Image J software was utilised to determine scratch wound closure 
(% of initial wound area that has recovered) at 12h and 24h post scratch. Assay 
reviewed in Ashby and Zijlstra, 2012. 
	  2.14	  RNA	  extraction	  
Cells were cultured to 80%-90% confluency in a T75 Flask. Media was 
removed; cells were washed twice with DPBS and then scrapped into 5ml 
DPBS using a cell scrapper (Fisher #FB55199). Cells were suspended into 
DPBS and then centrifuged in a 15ml tube (193 x g, 5min). PBS was removed 
and then the cell pellet washed in PBS. Cells were then centrifuged (193 x g, 
5min); PBS removed and re-suspended in 1ml RNA BEE (Amsbio #CS105B). 
RNA was extracted using SV Total RNA Isolation Kit. A Nano-drop (NR-1000, 
Labtech) was utilised to determine sample RNA concentration. RNA 
absorbance was measured at 260nm and the absorbance ratios of 
260nm/280nm (typically used to identify contaminants that absorb at 280nm, 
such as proteins or phenols) and 260nm/230nm (typically utilised to identify 
contaminants that absorb at 230nm, such as carbohydrates and phenols) were 
utilised to determine the purity of the RNA samples. RNA samples were stored 
at -80oC. 
2.15	  Reverse	  transcription	  
RNA samples were reverse transcribed to cDNA according to the Invitrogen 
superscript II protocol. Typically 1µg of RNA was reverse transcribed per 
reaction. RNase OUT Inhibitor (40 U/ µl) was added into the reaction mix. 
Transcribed samples were stored at -20oC.  
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2.16	  Quantitative	  real	  time	  PCR	  
To determine relative gene expression using mRNA, Quantitative Real Time 
PCR (qRT-PCR) was utilised. Primers and probes were designed to be specific 
for each gene. Reaction volumes were 20µl and contained 1-5ng of sample 
cDNA, 50% 2 x Fast master mix (v/v), 200 nM of primer and 100 nM of 
Universal Probe. Reaction cycles were programmed to follow: 2 minutes at 
50oC, 10 minutes at 95oC then 40 cycles of 95oC for 15 seconds / 60oC for 1 
minute. Data was analysed using 7500 SDS Software (Applied Biosystems). 
The Comparative CT method (Schmittgen and Livak, 2008) of relative 
quantitation was utilised to determine the results. All samples were normalised 
to 18S.  
2.17	  Collection	  of	  cell	  lysates	  
Cells were washed and scrapped into 5ml DPBS before being centrifuged at 
2000 x g for five minutes. Cell pellets were lysed with lysis buffer (Table 2.1). 
2.18	  Collection	  of	  cell	  derived	  matrix	  
MDA-MB-231 EV / TS15 / E362A cells were seeded into 6-well tissue culture 
plates. Cells were cultured in 1ml serum free media/well until cell confluency 
reached 80%. The cell media was removed and then the cell layer was washed 
and detached with 1ml/well of 5mM EDTA / 5mM EGTA in DPBS. Matrices 
were scrapped into sample buffer and analysed via SDS-PAGE gel 
electrophoresis and western blotting to detect ADAMTS-15.  
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2.19	  TCA	  precipitation	  of	  conditioned	  media	  samples	  
MDA-MB-231 EV / TS15 / E362A cells cultured in 6-well tissue culture plates 
were grown to 80% confluency in 1ml of serum free media to generate 
conditioned media. Samples were stored at -20oC. To concentrate protein 
content, samples were precipitated with 10% (trichloroacetic acid) TCA/dH2O 
(v/v) at a ratio of 1:3 (sample: 10%TCA) on ice for 4 minutes. Samples were 
then centrifuged at 10 000 g, for 4 minutes at 40C. Pellets were washed twice 
with ice-cold acetone and centrifuged again at 10 000 g, for 4 minutes at 40C. 
Supernatant was removed, pellets were then air dried and re-suspended in 
sample buffer (Table 2.1). Samples were then used for SDS-PAGE gel 
electrophoresis and western blotting to detect ADAMTS-15.  
2.20	  Determination	  of	  total	  protein	  
The bicinchoninic acid (BCA) assay was utilised to determine the total protein 
concentration of cell lysates. The assay was carried out according to 
manufacturers’ guidelines. Protein samples were then analysed via SDS PAGE 
and Western Blot analysis.   
2.21	  SDS	  PAGE	  gel	  electrophoresis	  
Typically protein samples (30µg) in loading buffer were reduced with ß-
mercaptoethanol (β-ME) and loaded into 10% Sodium dodecyl sulfate 
polyacrylamide (SDS) gels as described according to Cleveland et al. 1977. 
Protein samples were separated for one hour at 200v, alongside a protein 
molecular mass marker (dual colour).  
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2.22	  Antibodies	  
Target / 
Description 
Species / 
Application 
Company Dilution / 
Dilution Buffers 
Primary Antibodies 
Anti-FLAG M2 Mouse / WB Stratagene 
200472-21 
1:500 / PBST-
Milk 
Anti-MMP-14, 
catalytic domain, 
clone LEM-2/15.8 
Mouse / FC Millipore MAB3328 1µg / PBS-BSA 
Cytokeratin 14 Mouse / WB Abcam ab9220 1:1000 / PBST-
Milk 
Cytokeratin 18 Mouse / WB Cell Signaling 
4548 
1:2000 / PBST-
Milk 
DYKDDDDK 
Anti-Flag 
Rabbit / IF Cell Signaling 
2368P 
1:800 / PBST-
BSA 
E-Cadherin Rabbit / WB Cell Signalling 
4065 
1:1000 / PBST-
Milk 
GAPDH – HRP 
Conjugated 
Rabbit / WB Cell Signalling 
3683 
1:2000 / PBST-
Milk 
Integrin α6 Rabbit / WB (Clone U21) Gift 
from Professor Uli 
Mayer 
1:1000 / PBST-
BSA 
Integrin αV Rabbit / WB Millipore AB1930 1:5000 / PBST-
Milk 
Integrin β1 Mouse / WB AbD Serotec 
MCA1189 
1:1000 / PBST-
Milk 
Integrin β1 
(12G10) 
Mouse / IF Ab cam ab30394 1:500 / PBST-
BSA 
Integrin β1 (APC 
Conjugated) 
Mouse / FC BD 559883 20ul / / PBS-BSA 
Integrin β4 Rabbit / WB Cell Signaling 
4707 
1:1000 / TBST-
BSA 
Integrin β4 Mouse / FC Millipore MAB1964 1:500 / PBS-BSA 
p44/42 MAPK 
(Erk1/2) 
Rabbit / WB Cell Signaling 
9102 
1:1000 / TBST-
BSA 
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Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
Rabbit / WB Cell Signaling 
9101 
1:1000 / TBST-
BSA 
Syndecan-4 
(5G9) 
Mouse / FC Santa Cruz sc-
12766 
1µg / PBS-BSA 
Vimentin Rabbit / WB Cell Signalling 
3932 
1:1000 / PBST-
Milk 
β-Catenin 
 
 
Rabbit / WB Cell Signalling 
9587 
1:1000 / PBST-
Milk 
Secondary Antibodies 
Donkey Anti- 
Mouse Alexa 488 
/ FC Invitrogen A21202 1µg / PBS-BSA 
Allophycocyanin 
Goat Anti-Mouse 
/ FC Invitrogen A-865 1µg / PBS-BSA 
Mouse IgG1 / FC Invitrogen MG100 1µg / PBS-BSA 
Mouse IgG2a / FC Invitrogen MG200 1µg / PBS-BSA 
Goat anti-Rabbit 
(FITC) 
/ IF Sigma 1µg / ml PBS-
BSA 
Rabbit anti-
Mouse Alexa 
Fluor 488 
/ IF Invitrogen 2µg / ml PBS-
BSA 
Rabbit anti-
Mouse (HRP) 
/ WB Dako P0260 1:1000 / PBST or 
TBST-Milk 
Goat anti-rabbit 
(HRP) 
/ WB DAKO P0448 1:1000 / PBST or 
TBST-Milk 
Table 2.4: Antibodies used for Western Blot, Immunofluorescence and 
Flow Cytometry experiments. 
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2.23	  Western	  blot	  
Protein samples were transferred by the semi-dry method from the gels onto a 
nitrocellulose membrane at 100mA for one hour. Membranes were then 
Ponceau S stained (Table 2.1) to confirm that the protein samples had 
successfully transferred. Membranes were then blocked for one hour in the 
appropriate blocking buffer (Table 2.1). Application of the primary antibody 
(Table 2.4), typically diluted 1:1000 into antibody dilution buffer (Table 2.1) was 
either for one hour at room temperature or sixteen hours overnight at 4oC. 
Membranes were washed with washing buffer (Table 2.1) three times for ten 
minutes on a shaker before application of the secondary antibodies. Application 
of the secondary antibody (Table 2.4) typically diluted (1:1000) into antibody 
dilution buffer was for one hour at room temperature. Membranes were then 
washed with washing buffer three times for ten minutes on a shaker and ECL 
was applied according to manufactures instructions. Protein bands were imaged 
and detected using a Fuji Film (LAS-3000) system. Method reviewed by Bolt 
and Mahoney, 1997. 
2.24	  R&D	  phosphokinase	  array	  
MDA-MB-231 EV/ TS15 / E362A cells were grown to 80% confluency in a T75 
(nunc) tissue culture flask. Cells were washed and scrapped into 5ml DPBS 
before being centrifuged at 2000g for five minutes. Cell pellets were lysed with 
the lysis buffer supplied with the R&D kit (R&D Systems #ARY003) according to 
manufactures guidelines. Cell lysate samples were BCA analysed to determine 
the total protein concentration of each extract as described in methods section 
2.20. 
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100µg of cell lysate per sample was utilised in the R&D Phosphokinase array 
and the array was carried out according to manufacturers’ guidelines (R&D). 
Membranes were imaged with Fuji Film imager (LAS-3000) and images were 
analysed with Image J according to manufacturers’ guidelines. 
2.25	  Immunohistochemistry	  
300,000 cells were seeded onto coverslips, placed into tissue culture treated 6-
well plates. Cells were incubated overnight in 1ml of serum containing media at 
37oC and 5% CO2. The next day coverslips were washed twice in DPBS at 37ºC 
prior to fixation. Methods reviewed Odell and Cook, 2013. 
2.25.1	  Fixation	  and	  antibody	  staining	  
Cells on coverslips were fixed with 4% paraformaldehyde/DPBS (w/v) at room 
temperature for 10 min. Once fixed cells were washed twice with DPBS and 
then blocked with immunofluorescence blocking buffer (1% bovine serum 
albumin BSA in DPBS (w/v)) for 30 minutes at room temperature. Cells were 
then incubated with primary antibodies (Table 2.4) diluted in 1% BSA/DPBS 
(w/v) for 60 minutes at room temperature. Cells were then washed three times 
with blocking buffer before 60 minute incubation in the dark with secondary 
antibody (Table 2.4) diluted in 1% BSA/DPBS (w/v). Cells were then washed 
twice with blocking buffer (as described above). Coverslips were mounted onto 
slides with ProLong Gold-DAPI. 
2.25.2	  Phalloidin	  staining	  
Cells were seeded and fixed with 4% paraformaldehyde/DPBS (w/v) as 
described above. Once fixed cells were washed twice with DPBS and then 
blocked with blocking buffer (1% bovine serum albumin BSA in DPBS (w/v)) for 
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30 minutes at room temperature. Cells were washed twice with DPBS and 
stained in the dark with 0.2 U Phalloidin in DPBS for 20 minutes at room 
temperature. Cells were then washed twice with blocking buffer and Coverslips 
were mounted onto slides with ProLong Gold-DAPI. 
2.25.3	  Imaging	  	  
Images were taken using either a charge-coupled device (CCD) upright 
microscope or a LSM Confocal Microscope (Carl Zeiss). Images were analysed 
and fluorescence intensity determined with Axiovision 4.7.1 software or Zeiss 
LSM Examiner 4.0 software.  
2.26	  Flow	  Cytometry	  
All flow cytometry experiments were carried out using an Acruri C6 (BD 
Biosciences) and analysed with BD Acuri C6 Software or FlowJo. A gating 
strategy was utilised to identify events which correspond to single live cells 
(doublet discrimination, FL2A:FL2W; Wersto et al. 2001). 
2.26.1	  Cell	  cycle	  analysis	  
50,000 MDA-MB-231 EV / TS15 / E362A cells were seeded into tissue culture 
treated 6 well plates and cultured for three days in serum containing media at 
37oC and 5% CO2. Media was removed and wells were washed with DPBS. 
Cells were trypsinised and suspended in 600µl of serum containing media. Cells 
were then spun down at 2000g for 5 minutes and the cell pellet was washed 
with DPBS. Cells were then fixed with 70% ethanol in DPBS (v/v) and incubated 
for 2 hours at 4oC. Cells were washed with DPBS and spun down at 2000g for 5 
minutes. Cell pellets were re-suspended and stained with propidium iodide 
solution (5µg PI, 10µg RNAase A in 1ml DPBS). Samples were analysed with a 
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flow cytometer. Events were gated as described above and readings were 
taken with FL2-A. Cell cycle analysis was performed using FlowJo and the 
Watson Pragmatic Model (Watson et al. 1987).       
2.26.2	  Cell	  surface	  protein	  detection	  	  
MDA-MB-231 EV / TS15 / E362A cells were scrapped into ice cold DPBS. Cells 
were centrifuged at 2000g for five minutes and then cell pellets were re-
suspended and fixed in 4% PFA for 10 minutes at room temperature. Cells were 
then washed twice via centrifugation and re-suspended with 100µl antibody 
blocking buffer and incubated for ten minutes at room temperature. Primary or 
isotype control antibodies (Table 2.4) were added at the appropriate dilution and 
incubated for one hour. Cells were washed twice as described before and re-
suspended in 100µl antibody blocking buffer (Table 2.1). Secondary antibody 
(Table 2.4) was applied at the appropriate dilution and incubated for 30 minutes. 
Cells were washed via centrifugation as described before and re-suspended in 
DPBS. Samples were analysed with a flow cytometer. Events were gated as 
described above and the appropriate filter for each fluorochrome-conjugated 
secondary antibody was used. Assay based upon protocols described by 
Beauvais et al. 2004. 
2.27	  Angiogenesis	  Assays	  
2.27.1	  Generation	  of	  ADAMTS-­‐15	  conditioned	  media	  
300,000 MDA-MB-231 cells constitutively expressing either empty vector (EV), 
wild type ADAMTS-15 (TS15) or metalloproteinase inactive ADAMTS-15 
(E362A) were seeded into T75 tissue culture treated flasks (nunc) with serum 
containing media. The next day cells were washed and HUVEC media with 2% 
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FCS was applied. HUVEC media was conditioned for 48 hours before being 
used in HUVEC 3D tube formation assays.  
2.27.2	  HUVEC	  3D	  tube	  formation	  assay	  
Primary human umbilical vein endothelial cells (HUVECs) when cultured in 3D 
Collagen Type I gels spontaneously form tube like structures (Cooley et al. 
2010). This and similar assays are used as in vitro models of angiogenesis. 
HUVECs were routinely grown on flasks coated with 60µg/ml Collagen type I 
and were used before reaching the sixth passage for all experiments. For the 
3D tube formation assay HUVECs (1.25x106 cells/ml) were suspended into 
Collagen gels (1.6 mg/ml) and seeded into 24-well plates. Collagen gels were 
prepared using rat-tail Collagen Type I solution (BD Biosciences) mixed with 
10× 199 medium (Sigma), VEGF (25ng/ml) and FGF-2 (25ng/ml). Collagen gels 
were then polymerised by adjusting the pH to 7.5 using sodium hydroxide (1N). 
The process of polymerisation was carried out at 37°C and 5% (v/v) CO2 for 30 
minutes. ADAMTS-15 conditioned media (MDA-MB-231 EV / TS15/ E362A) 
was added to appropriate wells. Positive control wells were cultured with serum 
containing HUVEC media supplemented with VEGF (25ng/ml) and FGF-2 
(25ng/ml). At 24 hours post seeding into collagen gels, wells were washed with 
DPBS and fixed with 4% PFA. Gels were then stained with Phalloidin and DAPI. 
Images were taken using a charge-coupled device (CCD) upright microscope 
(Zeiss). Images were focused at multiple Z-axis focal plane using DAPI staining 
as a guide. Phalloidin staining of HUVEC F-actin cytoskeleton was used to 
identify HUVEC tube like structures. Fluorescence from background signals and 
non-tube like structures (e.g. cell debris) was removed from the analysis.   
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2.27.3	  Aortic	  ring	  assay	  	  
Thoracic aortae were isolated from 6 to 8 week-old mice and prepared for 
embedding in collagen type I matrix as described in Baker et al. 2012. Aortic 
rings were treated with MDA-MB-231 EV, TS15 or E362A conditioned media as 
described in 2.27.1 and VEGF (30ng/ml). Six days later, rings were fixed and 
the number of micro vessels were quantified under phase contrast. 
2.28	  Experimental	  Metastasis:	  Tail	  Vein	  Assay	  
To determine the effect of ADAMTS-15 expression on the metastatic potential 
on human breast cancer cells an experimental model of metastasis was utilised. 
The tail vein assay as described by Elkin and Vlodavsky, 2001 involves the 
intravenous injection of tumour cells into immune-compromised mice (e.g. CD1 
nu/nu mice), enabling circulating tumour cells to spread to the lungs, liver and 
other organs or tissues. 
Prior to the experiment all cell lines were tagged by retroviral transduction with a 
β-galactosidase marker (lacZ tagged) as previously described in (Krüger et al. 
1994). 1x106 MDA-MB-231 (EV, TS15 or E362A) cells were suspended into 
200µl of DPBS and injected intravenously into the tail vein of CD1 nu/nu mice. 
Mice were culled 35 days post injection. Lungs, Liver, Bone and Spleen were 
excised and stained for analysis of micro-metastasis. 
2.29	  Statistical	  analysis	  
In all experiments ADAMTS-15 and E362A transfected breast cancer cell lines 
were compared with EV (control cells containing empty pcDNA3.2 plasmid). 
Experimental procedures were repeated independently at least three times and 
statistical analysis was performed using two-tailed, unpaired t-test. Aortic ring 
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assay statistics were based upon Mann-Whitney non-parametric µ test. Data 
bars represent the mean value with error bars indicating s.e.m. Values of 
*p≤0.05 were considered to be statistically significant. 
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Chapter	   Three:	   Characterisation	   of	   ADAMTS-­‐15	  
Expression	  Systems	  
 
3.1	  Introduction	  
Previous studies have demonstrated that ADAMTS-15 expression inversely 
correlates with tumour grade in breast cancer, with expression significantly 
reduced in grade III breast tumours compared to grade I or II tumours (Porter et 
al. 2004). ADAMTS-15 expression also inversely correlates with tumour grade 
in colorectal cancer (Viloria et al. 2009). Another study involving a cohort of 229 
Dutch patients showed that relatively high levels of ADAMTS-15 expression 
were associated with a good prognosis in breast cancer (Porter et al. 2006).  
Taken together these studies indicate that ADAMTS-15 is protective in breast 
and colorectal cancer and that an examination of ADAMTS-15 expression may 
be a clinically useful independent predictor of survival (Porter et al. 2004; Porter 
et al. 2006; Viloria et al. 2009). However the functional consequences of 
ADAMTS-15 expression in breast cancer are unknown. To this end, this thesis 
set out to explore the effects of ADAMTS-15 on human mammary cell 
behaviour. This chapter outlines the characterisation of human mammary cell 
lines, and the ADAMTS-15 expression systems that were used in this study.  
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3.2	  Characterisation	  of	  human	  mammary	  cell	  culture	  models	  	  
3.2.1	  Myoepithelial	  cells	  
In healthy adult breast tissue ADAMTS-15 is expressed in myoepithelial cells, 
which sit in a continuous layer between the luminal epithelial cells and the 
basement membrane of the ductal lumen (Figure 1.8; Table 2.3; Porter et al. 
2004). Myoepithelial cells are a combination of muscle (myo) and epithelial-like 
character that function to secrete luminal milk and to maintain breast tissue 
architecture (Adriance et al. 2005; Butcher et al. 2009; Gordon et al. 2003). To 
counteract the tensile forces that breast tissues experience during lactation, 
myoepithelial cells mediate ECM remodelling processes (Butcher et al. 2009; 
Gordon et al. 2003). As part of these remodelling processes myoepithelial cells 
express an array of factors that also help to maintain luminal epithelial cell 
apical-basal polarity (Barcellos-Hoff et al. 1989; Butcher et al. 2009). Several of 
these factors are potentially tumour suppressive, including MMP-8 and 
ADAMTS-15 (Decock et al. 2008; Gordon et al. 2003; Hsiao et al. 2011; Jones 
et al. 2003; Polyak and Hu, 2005; Thirkettle et al. 2013; Xiao et al. 1999). 
The role of myoepithelial cells in maintaining breast tissue architecture is 
particularly important to understand as a subset of aggressive breast cancer 
tumours express myoepithelial markers such as (α6β4 integrin) and therefore 
may be of myoepithelial cell-like origin (Gordon et al. 2003; Jones et al. 2004; 
Polyak and Hu, 2005; Tan and Ellis, 2013). Even in the majority of breast 
cancers which are thought to originate from luminal epithelial cells, an absence 
of a myoepithelial cell population is observed during the progression to invasive 
disease (Gordon et al. 2003; Hsiao et al. 2011; Porter et al. 2004). Thus the 
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loss of wildtype myoepithelial cells and/or the loss of the protective factors 
expressed by these cells contribute to the transformation of in situ tumour cells 
into invasive disease (Gordon et al. 2003; Hsiao et al. 2011; Porter et al. 2004). 
To investigate the functional consequences of ADAMTS-15 expression within a 
myoepithelial cell population, two cell lines 1089 β4 and 1089 β6 were acquired. 
These cell lines were kindly gifted to our lab from Professor Louise Jones, 
Queen Mary University of London. 1089 β4 and β6 cells are immortalised 
myoepithelial cell lines and both express integrin β4. However the 1089 β6 cell 
line has been engineered to over express integrin β6. Integrin β6 is up-
regulated in myoepithelial cells in high grade DCIS (Jones et al. 2009). Thus the 
original myoepithelial cell line (1089) is an in vitro model of wildtype cells and 
the 1089 β6 is more DCIS-like.  
Myoepithelial cells and luminal epithelial cells both express several markers 
including E-cadherin, integrin β1, α2, α3, and α6, though α6 is expressed at 
lower levels in luminal epithelial cells compared to myoepithelial cells (Gordon 
et al. 2003). However there are some differences, which enable luminal cell 
populations to be distinguished from myoepithelial cells and vice versa. Integrin 
β4, Vimentin, CK14, tenascin, and α-smooth muscle actin are all expressed in 
myoepithelial cells and are not expressed in luminal epithelial cells (Gordon et 
al. 2003). Likewise in contrast to myoepithelial cells, luminal epithelial cells 
express CK18 (Gordon et al. 2003). 
To characterise 1089 β4 and 1089 β6 cell lines several cell markers were 
selected and analysed via western blot (Figure 3.1; Methods 2.17; 2.20-2.23). 
However these cell lines were prone to phenotypic drift with changes in marker 
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profiles and cell morphology occurring soon after entering culture (Figure 3.1). 
Both 1089 β4 and 1089 β6 cell lines displayed altered morphology from a 
‘cobble stone’ like appearance to a more elongated fibroblastic like appearance 
(Figure 3.1). In concurrent to these morphological changes the cell lines lost E-
cadherin and CK14 expression and occasionally gained CK18 expression 
(Figure 3.1). 
The dynamic phenotype of the myoepithelial cell lines were determined to be 
inappropriate for experiments designed to investigate the long term 
consequences of ADAMTS-15 expression. It would have been difficult to 
determine and distinguish the effects of ADAMTS-15 expression from those that 
were due to phenotypic drift. Therefore alternative in vitro models of breast 
cancer were utilised.   
Chapter 3 | Page 89 
 
 
Figure 3.1: Myoepithelial cells display a dynamic phenotype in culture. 
Myoepithelial cell lines 1089 β4 and 1089 β6 undergo a phenotypic drift in 
culture. Images (a, b) show evidence that the cells display altered morphology 
and western blot analysis from cell lysates of the expression of cell markers (c) 
E-Cadherin (135kDa), bands at the bottom are GAPDH loading control. (d) 
Cytokeratin 18 (45kDa). (f) A summary table compares our results with those 
from Prof. Louise Jones lab. + = expressed, - = not expressed, +/- = weak 
expression, LJ = Louise Jones lab result and DE = Dylan Edwards lab result. 
Numbers in brackets represent the predicted molecular weights of the 
respective proteins. Cell lysates from MDA-MB-231, MCF-7 and G361 cells 
were used as controls.	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3.2.2	  Breast	  cancer	  cells	  
The luminal epithelial cells lie in close proximity to the surrounding layer of 
myoepithelial cells within the ductal structures of the breast (Figure 1.8; Gordon 
et al. 2003; Hsiao et al. 2011; Porter et al. 2004). Therefore it is likely that the 
luminal epithelial cells come into contact with ADAMTS-15, expressed by 
neighbouring  myoepithelial cells (Figure 1.8; Gordon et al. 2003; Hsiao et al. 
2011; Porter et al. 2004). And since the majority of breast cancers are thought 
to originate from an epithelial-like cell it is appropriate to investigate the 
functional consequences of ADAMTS-15 expression on luminal epithelial cell 
types. Several well established in vitro models of epithelial-like breast cancers 
exist (Lacroix and Leclercq, 2004). From amongst them, MCF-7 cells and MDA-
MB-231 cells, both of which endogenously express ADAMTS-15 were chosen 
as appropriate models (Figure 3.3; Table 2.3; Table 3.1; Lacroix and Leclercq, 
2004).  
MCF-7 cells are a luminal epithelial-like, metastatic ductal carcinoma cell line. 
MCF-7 cells express an array of luminal epithelial markers (e.g. CK18, and 
progesterone receptor) and in vivo tumours derived from these cells display 
histological features that are representative of those found in patients (Figure 
3.1; Table 3.1; Lacroix and Leclercq, 2004). The molecular profiles of MCF-7 
cells (ER+/PgR+/ErbB2-) also correlate well with epithelial-like tumours found in 
patients, though there are some functional differences. MCF-7 derived tumours 
do not readily grow in vivo unless supplemented with oestrogen (Table 3.1; 
Lacroix and Leclercq, 2004). Though this has proved to be useful as a model for 
understanding oestrogen dependent tumour growth, and the development of 
tumour resistance to anti-oestrogen therapies e.g. Tamoxifen (Table 3.1; 
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Lacroix and Leclercq, 2004). Also whilst cancer cells from patients with a similar 
molecular profile to that of MCF-7 cells are able to metastasise, in animal 
models MCF-7 cells are poorly invasive and rarely metastasise (Table 3.1; 
Lacroix and Leclercq, 2004). However the relatively low invasive potential of 
MCF-7 cells is useful, particularly as a comparator model against more invasive 
breast cancer cell lines, such as MDA-MB-231 cells.  
MDA-MB-231 cells are an invasive mesenchymal-like, metastatic ductal 
carcinoma cell line. The morphology and behaviour of MDA-MB-231 cells is 
overtly different to that of MCF-7 cells (Figure 3.2; Table 3.1). MDA-MB-231 
cells appear more elongated and fibroblastic than the more epithelial-like MCF-
7 cells (Figure 3.2).  Also in contrast to MCF-7 cells, MDA-MB-231 cells are 
highly invasive and metastatic in vivo (Table 3.1; Lacroix and Leclercq, 2004). 
MDA-MB-231 cells may have originally derived from a luminal epithelial cell 
type, though it is difficult to determine since these cells have ‘turned off’ several 
epithelial markers (e.g. E-Cadherin) and have ‘turned on’ expression of a variety 
of mesenchymal markers including Vimentin (Figure 3.1; Table 3.1; Lacroix and 
Leclercq, 2004). This ‘epithelial to mesenchymal transition’ (EMT) is thought to 
be a tumorigenic process in which epithelial cells acquire the morphological and 
molecular phenotypes associated with invasiveness (Figure 3.2; Table 3.1; 
Lacroix and Leclercq, 2004). MDA-MB-231 cells are therefore likely to be a de-
differentiated cell type and in concordance with their molecular profile (ER-
/PgR-/ErbB2-, triple negative) are representative of the basal breast cancer 
subtype which frequently form poorly differentiated tumours (Grade III) (Table 
1.1; Table 3.1; Lacroix and Leclercq, 2004). Indeed MDA-MB-231 cells were 
originally derived from a patient with a poorly differentiated tumour (Lacroix and 
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Leclercq, 2004). In order to provide additional characterisation data an 
expression profile via qRT-PCR was carried out to determine the baseline 
expression (mRNA) levels of several hyalectanases, syndecans and integrins 
(figure 3.3; Appendix A7). 
 MDA-MB-231 MCF-7 
Description Invasive mesenchymal-like, 
metastatic ductal carcinoma 
cell line 
Luminal epithelial-like, metastatic 
ductal carcinoma cell line 
Original Tissue metastasis; pleural effusion metastasis; pleural effusion 
Modal 
Chromosome 
number(s) 
64, 69–70 88,86,79,65 
ER status - + 
PgR status - + 
ErbB2 
(Her2/neu) 
status 
- -/+ (low) 
Tumourigenicity 
of cell line in 
mouse models 
Aggressive, highly invasive 
and high incidence of 
metastatic spread particularly 
to the Lungs of nude and 
SCID mice. 
Cells are viable but require 
estrogenic supplementation for 
tumourigenesis in nude mice. 
Cells are also poorly invasive and 
rarely metastatic in mice. 
Table 3.1 Comparison of MDA-MB-231 and MCF-7 human mammary 
cancer cell lines. Adapted from Lacroix and Leclercq, 2004. 
Figure 3.2: Images of MCF-7 cells and MDA-MB-231 cells. 
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Figure 3.3: Expression profile of MDA-MB-231 and MCF-7 cells. qRT-PCR 
analysis of gene expression in MDA-MB-231 and MCF-7 cells. Relative 
expression levels are shown as a Ct value heat-map. The displayed Ct values 
are averaged from three independently collected RNA samples. See appendix 
A7 to see an expanded version of this data set.  
MDA-­‐MB-­‐231 MCF7	  
ADAMTS1 26 34 Ct 15-25 Very high expression
ADAMTS4 21 40 Ct 26-30 High expression
ADAMTS5 36 40 Ct 31-35 Moderate expression
ADAMTS8 40 40 Ct 36-39 Low expression
ADAMTS9 26 40 Ct <40 Very low / undetectable expression
ADAMTS15 29 30
ADAMTS20 37 36
TIMP3 26 29
Syndecan 1 28 26
Syndecan 4 25 26
Integrin β1 25 27
Integrin α5 24 27
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3.3	   Generation	   of	   ADAMTS-­‐15	   expressing	   mammary	   cancer	   cell	  
lines	  
3.3.1	  Validation	  of	  ADAMTS-­‐15	  constructs	  
To investigate the functional consequences of ADAMTS-15 expression in in 
vitro models (MCF-7 and MDA-MB-231 cells) of breast cancer several 
ADAMTS-15 constructs were generated by Dr. Laura Wagstaff (Figure 2.1). In 
addition to full length ADAMTS-15, a metalloproteinase inactive form of 
ADAMTS-15 (E362A) and several truncated ADAMTS-15 constructs (ΔA, ΔB, 
and ΔC) which lack C-terminal domains were also generated. These constructs 
were PCR cloned into pcDNA 3.2 plasmid (Invitrogen #K2440-20). A FLAG tag 
was also cloned in-frame into the C-terminal sequence of all ADAMTS-15 
constructs to enable purification and detection of ADAMTS-15 protein. 
These constructs were validated through sequencing, which confirmed that 
these constructs had been cloned as expected, and via restriction digest. Empty 
vector (EV) pcDNA 3.2 contains a unique BamHI recognition sequence, which 
results in a linearized plasmid (Figure 3.4). During the construction of constructs 
TS15, E362A and ΔA, ΔB, ΔC the BamHI site was removed from the vector 
backbone. However ADAMTS-15 contains a unique BamHI site, therefore when 
digested with BamHI a single linearised product was formed as expected 
(Figure 3.4). ΔC did not linearise because the BamHI site is positioned 
immediately prior to the first TSR, a region which is lost in the ΔC truncated 
form of ADAMTS-15 (Figure 3.4; Figure 3.11a). 
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Figure 3.4: Validation of ADAMTS-15 pcDNA 3.2 constructs. 200ng of DNA 
loaded into each lane except for lane 1 which contained 10kb DNA ladder to 
approximate restriction digest product sizes. Even numbered lanes contained 
uncut circularised plasmid DNA and odd numbered lanes contained plasmid 
DNA that were linearised with BamHI restriction enzyme. Predicted sizes 
pcDNA 3.2 (EV) 7.7kb, TS15 and E362A 10.6kb, ΔA 10.2kb,	   ΔB 9.7kb and	   ΔC 
9.21kb. 
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3.3.2	  Transient	   expression	  of	  ADAMTS-­‐15	   in	  human	  breast	  
cancer	  cell	  lines	  
ADAMTS-15 constructs were validated through transient transfection into MCF-
7 and MDA-MB-231 cell lines. Western blot analysis (Methods 2.17; 2.20-2.23) 
of cell lysate samples collected 72 hours post transfection confirmed expression 
of ADAMTS-15 and E362A constructs (Figure 3.5). Transient expression of 
ADAMTS-15 was tolerated by both cell types. However since ADAMTS-15 is 
potentially protective in breast cancer it is possible that these cell types might 
reject and/or mutate the ADAMTS-15 plasmid over time. Also on a technical 
note transient transfection of plasmids into MDA-MB-231 cells are generally 
inefficient. Therefore systems that facilitate the stable expression of ADAMTS-
15 were deemed more appropriate for longer-term assays.  
 
 
Figure 3.5: Characterisation of ADAMTS-15 transient expression in human 
breast cancer cell lines. Western blot analysis of human breast cancer cells 
transfected with pcDNA3.2 empty vector control (EV), wildtype ADAMTS-15 
(TS15) or a metalloproteinase inactive form of ADAMTS-15 (E362A). Anti-Flag 
antibodies were utilised to detect ADAMTS-15 from cell lysate samples. These 
data are representative of several experiments. 
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3.3.3	   Constitutive	   expression	   of	   ADAMTS-­‐15	   in	   human	  
breast	  cancer	  cell	  lines	  
ADAMTS-15 constructs empty vector (EV) control, wildtype ADAMTS-15 (TS15) 
and a metalloproteinase inactive form of ADAMTS-15 (E362A) were stably 
transfected as described in materials and methods (Methods 2.4.1) into MDA-
MB-231 and MCF-7 cells. Polyclonal pools were used in all experiments and 
antibiotic selection (G418) was utilised to select for ADAMTS-15 or E362A 
overexpressing cells respectively. 
The expression of ADAMTS-15 was determined via western blot analysis 
(Methods 2.17; 2.20-2.23) of cell lysate samples (Figure 3.6) and qRT-PCR 
(Figure 3.8; Methods 2.14-2.16). Whilst several commercial ADAMTS-15 
antibodies were tested, none of them could reliably detect ADAMTS-15 protein 
(Appendix 5). Therefore detection of ADAMTS-15 protein was via an anti-FLAG 
antibody. A limitation of this approach was that endogenous ADAMTS-15 
protein could not be detected, however qRT-PCR primers and probes were 
designed to detect both endogenous and exogenous (over expression) 
ADAMTS-15 mRNA levels. Whilst mRNA levels may not always correlate with 
protein level, for several reasons (including protein stability, degradation etc.) 
the pattern of ADAMTS-15 expression and protein levels did match. In MDA-
MB-231 cells overexpression of TS15 and E362A were approximately 8x higher 
(3 Ct values lower) than endogenous ADAMTS-15 expression in EV cells 
(Figure 3.8). TS15 and E362A protein levels were also equal (Figure 3.6). In 
contrast to this the levels of stable overexpression of TS15 (Ct 20) and E362A 
(Ct 25) in MCF-7 cells were markedly different. This pattern could also be 
observed at the protein level (Figure 3.6; 3.8). Although MCF-7 EV, TS15 and 
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E362A cells were utilised, the expression levels of TS15 and E362A were more 
comparable in the MDA-MB-231 cells and were therefore chosen as the focus 
for the majority of the project.  
ADAMTS-15 overexpression was maintained throughout culture, suggesting 
that overexpression of ADAMTS-15 is not inherently toxic to the cells. Indeed 
both MDA-MB-231 and MCF-7 cells maintained their correct cell marker profile 
even when overexpressing ADAMTS-15 constructs (Figure 3.7). There were 
also few differences in the expression profiles of the hyalectanases and TIMPs 
examined via qRT-PCR in MDA-MB-231 EV, TS15 and E362A cells (Figure 
3.8). These expression profiles also remained comparable when comparing 
empty vector control cells with the appropriate parental cell lines (Figure 3.3).   
 
 
Figure 3.6: Characterisation of ADAMTS-15 expression in human breast 
cancer cell lines. Western blot analysis of human breast cancer cells 
engineered to constitutively express pcDNA3.2 empty vector control (EV), 
wildtype ADAMTS-15 (TS15) or a metalloproteinase inactive form of ADAMTS-
15 (E362A). Anti-Flag antibodies were utilised to detect ADAMTS-15 from cell 
lysate samples. These data are representative of multiple experiments. 
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Figure 3.7: Western blot analysis of MDA-MB-231 EV, TS15 and E362A 
cells. Western blot analysis of cell lysates from MDA-MB-231 cells engineered 
to constitutively express pcDNA3.2 empty vector control (EV), wildtype 
ADAMTS-15 (TS15) or a metalloproteinase inactive form of ADAMTS-15 
(E362A). Cell markers that are known to be involved with epithelial-
mesenchymal transition (EMT) were chosen; Cytokeratin 18 (45kDa), β-Catenin 
(92kDa), E-Cadherin (135kDa) and GAPDH loading control (37kDa). Numbers 
in brackets represent the predicted molecular weights of the respective proteins. 
Cell lysates from MDA-MB-231, MCF-7 and G361 cells were used as controls. 
 
Figure 3.8: Expression profile of MDA-MB-231 EV, TS15 and E362A cells. 
qRT-PCR analysis of gene expression in MDA-MB-231 EV, TS15 and E362A 
cells. Relative expression levels are shown as a Ct value heat-map. The 
displayed Ct values are averaged from three independently collected RNA 
samples. See appendix A7 to see an expanded version of this data set. 
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3.4	  Analysis	  of	  cell	  viability	  and	  proliferation	  
MTT assays and flow cytometry were utilised to evaluate the effects of 
ADAMTS-15 on breast cancer cell viability, proliferation and apoptosis. 
Overexpression of ADAMTS-15 did not affect MCF-7 or MDA-MB-231 cell 
viability (Figure 3.9a-b). MDA-MB-231 EV, TS15 and E362A cells did not show 
any differences in proliferation in either normal tissue culture conditions (10% 
FCS) or stress conditions (0% FCS) as determined by cell counts over a period 
of 4 days (Figure 3.9c; Methods 2.5). In corroboration with these results a flow 
cytometric analysis (Methods 2.26) of the cell cycle profiles of ADAMTS-15 
expressing cells did not identify any significant differences either (Figure 3.9d). 
An examination of the sub-G1 population also highlights that ADAMTS-15 does 
not appear to induce apoptosis (Figure 3.9d). From these data it can be 
concluded that ADAMTS-15 does not affect breast cancer cell viability or 
proliferation. A greater understanding of the context (localisation) in which 
ADAMTS-15 operates may shed some light into the tumour suppressive 
function(s) of this metalloproteinase. 
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Figure 3.9: ADAMTS-15 does not affect breast cancer cell viability or 
proliferation. MTT cell viability assay of MCF7 (a) and MDA-MB-231 (b) EV, 
TS15 or E362A human breast cancer cells. These data are based upon three 
independent experiments, error bars represent s.e.m. statistical tests revealed 
no significant differences. (c) Cell growth assay of MDA-MB-231 EV, TS15 and 
E362A expressing cells. Cells were grown with media containing either 0% or 
10% FCS. Total cell numbers were counted at the indicated time points post 
seeding, data were averaged across four wells per cell group, each day, error 
bars represent s.e.m. statistical tests revealed no significant differences. (d) 
Cell cycle analysis of MDA-MB-231 EV, TS15 and E362A cells was analysed 
via flow cytometry as described in materials and methods, data are represented 
by four independently collected cell samples, error bars represent s.e.m. 
statistical tests revealed no significant differences. 
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3.5	  ADAMTS-­‐15	  localisation	  
Association with the extracellular matrix is one of the defining characteristics of 
the ADAMTS family. The association of ADAMTSs with the ECM is largely 
mediated by the ADAMTS ancillary domains, whose broader functions also 
include the regulation of ADAMTS proteolytic activity and substrate preferences 
(Kelwick and Edwards, 2014). Thus ECM association is functionally important 
and also plays a role in determining the context in which the ADAMTSs operate. 
Since the localisation of ADAMTS-15 within the context of in vitro models of 
breast cancer is unknown, yet may be functionally important several 
experiments were designed to examine this.  
MDA-MB-231 EV, TS15 and E362A cells were seeded in serum containing 
media onto coverslips and allowed to adhere overnight. Immunofluorescence 
antibody staining (Methods 2.25) confirmed that ADAMTS-15 is an ECM 
associated metalloproteinase (Figure 3.10a). ADAMTS-15 E362A as expected 
also associates with the ECM (Figure 3.10a). Generally as can be seen in the 
images ADAMTS-15 sits in the pericellular space and may potentially interact 
with cell surface proteins (Figure 3.10a).   
To provide additional insight into ADAMTS-15 localisation ADAMTS-15 
constructs were transiently transfected. At 72 hours post transfection cell lysate, 
conditioned media and extracellular matrix samples were taken and the 
localisation of ADAMTS-15 was examined via western blot (Methods 2.17-2.23). 
Since the samples were proportionately loaded, absolute measurements of 
ADAMTS-15 localisation cannot be inferred however a qualitative view can be 
determined. In MCF-7 cells ADAMTS-15 was associated with the ECM, 
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however ADAMTS-15 was also detected in the conditioned media (Figure 
3.10b). It should also be noted that the association of ADAMTS-15 with the 
ECM via western blot was generally difficult to detect in both MDA-MB-231 and 
MCF-7 cells (Figure 3.10b). Though of course only exogenous, FLAG tagged 
ADAMTS-15 could be detected and so it is possible that a portion of ECM 
binding sites were already taken up by endogenously expressed ADAMTS-15. 
Thus an overexpression of ADAMTS-15 may have been unable to bind to a 
saturated ECM. Interestingly HEK293T cells, readily expressed high levels of 
ADAMTS-15 constructs though the greatest proportion of ADAMTS-15 
remained in the cell lysate (Figure 3.10b). ADAMTS-15 expressed in HEK293T 
cells did associate with the ECM (Figure 3.10b). However in comparison to the 
efficiency of the transfection, relatively little ADAMTS-15 associated with the 
ECM or the conditioned media (Figure 10b). It is possible therefore that 
ADAMTS-15 may localise differently in different cell types. 
Viloria et al. 2009 reported that the two C-terminal TSR’s in ADAMTS-15 are 
required for ECM binding, since transient transfection of truncated forms of 
ADAMTS-15 in HCT-116 (colorectal cancer cell lines) display reduced 
association with the ECM. In confirmation with reports in the literature these 
data also indicate that ADAMTS-15 associates with the ECM via its ancillary 
domain (Figure 3.11). Expression of truncated constructs, ΔA, ΔB or ΔC, which 
lack regions of the ancillary domain display a reduced level of association with 
the ECM in comparison to full-length ADAMTS-15 (Figure 3.11). Future studies 
may find it useful to further optimise and characterise these constructs, 
particularly within breast tumour cell lines to provide additional insight into 
ADAMTS-15 localisation. 
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It should also be noted that whilst ADAMTS-15 protein is shown to be ~103kDa 
(Figure 3.5, 3.6 and 3.10b) which is the predicted and reported molecular 
weight of ADAMTS-15 (Viloria et al. 2009). In several blots, different band sizes 
for ADAMTS-15 have been observed, which might correspond to pro and active 
(furin processed) forms of ADAMTS-15 (Figure 3.10c). However it is also 
possible that ADAMTS-15 may undergo post translational modification, though 
no conclusive evidence of this is provided in this thesis.  
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Figure 3.10: ADAMTS-15 associates with the ECM. (a) The expression and 
localisation of ADAMTS-15 (red) and active Integrin β1-12G10 (green) in MDA-
MB-231 cells was analysed by immunofluorescence. Cell nuclei are DAPI 
stained (blue), white scale bars represent 20µm in length data in collaboration 
with Dr. Christian Roghi. (b) Western blot analysis of ADAMTS-15 localisation. 
EV, TS15 and E362A were transiently transfected into MCF7 and HEK 293T 
cells. At 48h post transfection extracellular matrix (ECM), cell lysate and 
conditioned media samples were taken and proportionally loaded (40% of the 
respective sample). These data were generated in collaboration with Dr. Laura 
Wagstaff. (c) ADAMTS-15 and E362A protein was purified via flag tag from 
MDA-MB-231 TS15 and E362A cells and then analysed by western blot. Data 
provided by Dr. Kazu as part of collaborations with Professor Hideaki Nagase’s 
group. 
  
Chapter 3 | Page 106 
 
 
Figure 3.11: ADAMTS-15 associates with the ECM via it’s ancillary domain. 
(a) Schematic of ADAMTS-15. Ancillary domains to the right of the blue lines 
are missing in the three truncation constructs ΔA, ΔB and ΔC respectively (b 
and c) HCT-116 colorectal cancer cells were transiently transfected with either 
pcDNA 3.2 empty vector control (EV), TS15 or ΔA, ΔB or ΔC truncated 
constructs. Extracellular matrix (ECM) and conditioned media (CM) samples 
were taken and proportionally loaded (40% of the respective sample). 
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3.6	  Aggrecanase	  assay	  
ADAMTS-15 is reported as an aggrecanase in the literature, primarily due to 
phylogenetic similarities with the hyalectanases several of which have 
demonstrable aggrecanolytic activity. Whilst ADAMTS-15 is a proven 
versicanase, beyond a patent there is no evidence that clearly demonstrates 
ADAMTS-15 aggrecanolytic activity (Stupka et al. 2013; Yamaji et al. 2000). 
Therefore it seemed appropriate to examine ADAMTS-15 aggrecanolytic activity 
(Methods 2.7). 
ADAMTS-15 and E362A were purified using anti-FLAG M2 antibody-conjugated 
agarose beads from MDA-MB-231 TS15 and E362A conditioned media. 
Purified pro-forms of ADAMTS-15 and E362A were then activated with furin to 
ensure that only active ADAMTS-15 was used in each aggrecanase activity 
assay. Aggrecanolytic activity was detected via western blot using antibodies 
that can detect an aggrecan neo-epitope (anti-AGEG). Incubation of bovine 
aggrecan with wildtype ADAMTS-15 (TS15) but not the metalloproteinase 
inactive form (E362A) was able to cleave aggrecan (Figure 3.12). In comparison 
with ADAMTS-5, ADAMTS-15 displays weak activity. Incubation with N-TIMP3 
inhibited ADAMTS-15 aggrecanase activity, indicating that ADAMTS-15 is 
inhibited by TIMP3 (Figure 3.12). These data also indicate that ADAMTS-15 
E362A is catalytically inactive. Therefore in all future assays metalloproteinase 
independent effects can be discerned. 
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Figure 3.12: ADAMTS-15 aggrecanase activity is inhibited by N-TIMP-3. 
Aggrecanase activity of ADAMTS-15, as determined by western blot analysis of 
Aggrecan AGEG neo-epitope. Unconditioned media was used as a negative 
control and recombinant ADAMTS-5 (TS5) was used as a positive control. Data 
in collaboration with Dr. Kazuhiro Yamamoto from Professor Hideaki Nagase 
group. 
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3.7	  Discussion	  
The overall aim of this thesis is to investigate the role of ADAMTS-15 in breast 
cancer, since previous studies have shown that ADAMTS-15 is potentially 
protective (Porter et al. 2004; 2006). Yet the functional consequences of 
ADAMTS-15 expression in breast cancer are unknown. In vitro models, 
particularly immortalised cell lines are amenable to genetic manipulation and 
are suitable for long term functional studies. An array of mammary cell lines 
exist that represent several healthy and breast cancer tumour subtypes (Lacroix 
and Leclercq, 2004). Thus in vitro models can be utilised to gain an initial insight 
into the functional consequences of ADAMTS-15. Whilst in vivo studies are 
arguably more physiologically relevant, they are better designed if informed by 
in vitro studies. To this end several human mammary cell culture models were 
proposed as an appropriate starting point from which to explore the functional 
consequences of ADAMTS-15 in breast cancer. 
Within the ductal structures of the breast, the luminal epithelial cells and the 
myoepithelial cells are two physiologically and structurally important cell types. 
Of the two cell types the myoepithelial cells were determined to be the most 
appropriate for functional studies since it is the myoepithelial cells and not the 
luminal epithelial cells which express ADAMTS-15. Also a subset of aggressive 
breast cancer tumours express myoepithelial markers such as (α6β4 integrin) 
and therefore may be of myoepithelial cell-like origin (Gordon et al. 2003; Jones 
et al. 2004; Polyak and Hu, 2005; Tan and Ellis 2013). Even in the majority of 
breast cancers which are thought to originate from luminal epithelial cells, an 
absence of a myoepithelial cell population is observed during the progression to 
invasive disease (Gordon et al. 2003; Hsiao et al. 2011; Porter et al. 2004). 
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Thus the loss of wildtype myoepithelial cells and/or the loss of the protective 
factors expressed by these cells contribute to the transformation of in situ 
tumour cells into invasive disease (Gordon et al. 2003; Hsiao et al. 2011; Porter 
et al. 2004). Since ADAMTS-15 is potentially one of those myoepithelial 
protective factors, an investigation of the consequences of ADAMTS-15 
expression in myoepithelial cell populations would be informative. We acquired 
two immortalised cell lines 1089 β4 and 1089 β6 respectively. These cell lines 
were kindly gifted to our lab from Professor Louise Jones, Queen Mary 
University of London. However in our hands these cell lines were found to be 
prone to phenotypic drift with changes in marker profiles and cell morphology 
occurring soon after entering culture. Thus the dynamic phenotype of the 
myoepithelial cell lines were determined to be inappropriate for long term 
functional studies. 
Luminal epithelial cells were chosen as an appropriate alternative model for 
several reasons. Luminal epithelial cells are likely to come into contact with 
ADAMTS-15 expressed by neighbouring myoepithelial cells and the majority of 
breast cancers are thought to originate from a luminal epithelial-like cell. 
Several well established in vitro models of epithelial-like breast cancers exist, 
which have been extensively characterised in the literature. From amongst them 
MCF-7 cells and MDA-MB-231 cells were chosen as the most appropriate in 
vitro models since they retain the molecular characteristics of the tumours from 
which they were derived. However the majority of this thesis focused on MDA-
MB-231 cells, since these cells are representative of poorly differentiated (grade 
III) tumours. This is biologically important since ADAMTS-15 expression 
inversely correlates with tumour grade in breast cancer, with expression 
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significantly reduced in grade III breast tumours compared to grade I or II 
tumours (Porter et al. 2004). ADAMTS-15 expression also inversely correlates 
with tumour grade in colorectal cancer (Viloria et al. 2009).  
Several ADAMTS-15 constructs which were originally generated by Dr. Laura 
Wagstaff were validated as part of this thesis via sequencing and restriction 
digest. In addition to full length ADAMTS-15, a metalloproteinase inactive form 
of ADAMTS-15 (E362A) and several truncated ADAMTS-15 constructs (ΔA, ΔB, 
and ΔC) which lack C-terminal domains were validated for this project. Whilst 
these ADAMTS-15 constructs were successfully transiently transfected into 
several cell lines, since ADAMTS-15 is potentially tumour suppressive it is 
possible that these cell lines might reject and/or mutate the ADAMTS-15 
plasmid over time. Therefore systems that facilitate the stable expression of 
ADAMTS-15 were deemed more appropriate for longer term assays.  
MDA-MB-231 and MCF-7 cells, which stably constitutively express ADAMTS-15 
constructs, were used in preference to transient transfection experiments, since 
long term expression could be maintained via antibiotic selection. The 
generation of these stable cell lines utilised a transfection strategy that involved 
the random integration of constructs into the genome of these cells. To avoid 
clonal effects as a result of random integration, polyclonal pools were used in all 
functional assays. One caveat of the use of polyclonal pools is that the pools 
represent the average expression of the monoclonal populations. Thus those 
monoclonal pools which excessively overexpress the gene of interest, dominate 
the polyclonal population. Indeed the level of overexpression of ADAMTS-15 
constructs in MCF-7 cells was found to be excessive and lacked comparability. 
In contrast to this the overexpression of TS15 and E362A in the MDA-MB-231 
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stable polyclonal pools was comparable and only around 8x higher than 
endogenous ADAMTS-15 expression in EV control cells. Therefore the MDA-
MB-231 stable cells were deemed to be more appropriate since the 
overexpression is arguably more physiologically relevant and fairer 
comparisons between TS15 and E362A cells can be made.  
Despite earlier concerns about the potential for tumour cells to reject ADAMTS-
15, stable constitutive expression of ADAMTS-15 in MCF-7 and MDA-MB-231 
cells did not affect cell viability or proliferation. There were no observable 
toxicities associated with expression of ADAMTS-15 and expression was 
maintained throughout culture. Thus it can be concluded that ADAMTS-15 does 
not affect breast cancer cell growth or viability. 
Since ADAMTS-15 does not affect cell proliferation any insight into the 
localisation and by inference the functional context in which ADAMTS-15 
operates may be informative. To this end ADAMTS-15 localisation was 
examined in several cell lines, though particular attention was paid to 
localisation in human mammary cancer cell lines. As expected ADAMTS-15 
was secreted and localised to the extracellular matrix in both MDA-MB-231 and 
MCF-7 breast cancer cell lines. Unfortunately due to time constraints the 
localisation of ADAMTS-15 truncation constructs expressed in breast cancer 
cell lines was not examined. However an examination of ADAMTS-15 
localisation in other cell lines provided further insight including the importance of 
the ancillary domain for determining ADAMTS-15 localisation. The two C-
terminal ADAMTS-15 TSR’s are required for ECM binding, since transient 
transfection of truncated forms of ADAMTS-15, ΔA-C, or G849fs respectively in 
HCT-116 (colorectal cancer cells) display reduced ECM association. This is 
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functionally important as the loss of ECM association results in the mis-
localisation of ADAMTS-15 away from the pericellular space thus preventing 
interactions with cell surface proteins. Viloria et al. 2009 confirmed that ECM 
localisation was functionally important as expression of ADAMTS-15 G849fs did 
not reduce HCT-116 cell invasion to the same extent as wildtype ADAMTS-15. 
Though no ADAMTS-15 substrates or protein interaction partners were 
identified that could explain this observation (Viloria et al. 2009). However 
based on the reported sheddase activity of ADAMTS-1 it is possible to identify 
Syndecan-4, heparan-binding epidermal growth factor (HB-EGF) and 
amphiregulin (AR) as potential interaction candidates since ADAMTS-1 shares 
a 66% metalloproteinase domain identity with ADAMTS-15 (Liu et al. 2006; 
Rodríguez-Manzaneque et al. 2009). Also whilst there are no reports of an 
ADAMTS directly interacting with an integrin, it is possible that an ADAMTS 
may be able to interact with an integrin via it’s TSR domains. Whilst the 
identification of ADAMTS-15 interaction partners may be relevant, at the start of 
this project very little evidence about the hyalectanase activity of ADAMTS-15 
was known.  
It is only recently that reports have clearly shown that ADAMTS-15 is a 
proteolytically competent hyalectanase. Stupka et al. 2013 reports that 
ADAMTS-15 is an important versicanase within the context of muscle 
development. Whilst evidence of ADAMTS-15 versicanase activity is clear, with 
the exception of a Japanese patent there is no clear evidence of ADAMTS-15 
aggrecanolytic activity (Yamaji et al. 2000). In this thesis, these data 
demonstrate evidence of ADAMTS-15 aggrecanolytic activity (Figure 3.12). 
Though it should be noted that since absolute protein concentrations were not 
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utilised, this assay is qualitative. Therefore, whilst ADAMTS-15 aggrecanase 
activity appears to be weaker than ADAMTS-5, no absolute comparisons can 
be made. Several Aggrecan neo-epitopes were analysed, though only AGEG 
could be detected from ADAMTS-15 aggrecanase activity. Again this suggests 
that ADAMTS-15 is a relatively weak aggrecanase and therefore Aggrecan may 
not be the major substrate for ADAMTS-15. Additionally these data indicate that 
TIMP-3, the broadest inhibitor of the ADAMTSs is able to inhibit ADAMTS-15 
aggrecanolytic activity. However, this assay could be improved through the 
addition of a positive control, such as ADAMTS-5, which is known to be 
inhibited by TIMP-3. In contrast to wildtype ADAMTS-15, the catalytically 
inactive form of ADAMTS-15 (E362A), did not display aggrecanase activity 
(Figure 3.12). Therefore the metalloproteinase independent effects of ADAMTS-
15 can be discerned in all future functional assays. 
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3.8	  Chapter	  summary	  
In summary, whilst the myoepithelial cell lines displayed a dynamic phenotype 
in culture, several well-established in vitro models of breast cancer have been 
characterised. Transient or stable expression of ADAMTS-15 does not alter the 
fundamental characteristics of these models and therefore the functional 
consequences of ADAMTS-15 expression in these systems can be examined. 
Fundamental aspects about ADAMTS-15 localisation and activity have also 
been discerned:  
• ADAMTS-15 does not affect breast cancer cell growth or viability. 
• ADAMTS-15 associates with the ECM via it’s ancillary domain. 
• ADAMTS-15 has aggrecanase activity that is inhibited by N-TIMP-3. 
The following chapter investigates whether ADAMTS-15 modulates the 
migratory behaviour of human breast cancer cell lines.
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Chapter	   Four:	   ADAMTS-­‐15	   Modulates	   the	   Migratory	  
Behaviour	  of	  Human	  Breast	  Cancer	  Cell	  Lines	  
 
4.1	  Introduction	  
Functional in vitro studies have demonstrated that ADAMTS-15 reduces 
invasion in colorectal cancer cell lines (Viloria et al. 2009). However the 
functional consequences of ADAMTS-15 expression on breast cancer cell 
migration are unknown. 
4.2	  Analysis	  of	  migration	  in	  2D	  assays	  
4.2.1	  Scratch	  wound	  assay	  
The scratch wound assay is typically described as an in vitro wound healing 
model, since inflicted scratch wounds remove the underlying matrix along with a 
section of the cell layer (Ashby and Zijlstra, 2012; Hsu et al. 2012; Krampert et 
al. 2005). Whilst different parameters can be analysed, typically the closure 
(‘healing’) of the wound is tracked over time (Methods 2.13). The scratch wound 
assay is also an informative migration assay, as the directed movement of 
individual cells into the wound area can also be tracked. A potential limitation of 
this model is that wound healing can be the result of both cell migration and cell 
proliferation. Since ADAMTS-15 does not affect breast cancer cell proliferation 
(Figure 3.9) any observable effects are likely due to a modulation of cell 
migration. 
MDA-MB-231 EV, TS15 and E362A cells were seeded at high density onto 
tissue culture plastic in medium containing 10% (vol/vol) serum and allowed to 
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adhere overnight. The next day ‘scratch wounds’ were introduced and wound 
closure was monitored over a period of 24 hours via time-lapse video 
microscopy. Data are expressed as the percentage of wound closure at 12 and 
24 hours post wound. Expression of either wildtype (TS15) or catalytically 
inactive (E362A) ADAMTS-15 in MDA-MB-231 cells were associated with 
reduced scratch wound recovery in comparison to control (EV) (Figure 4.1). 
From these data it can be concluded that ADAMTS-15 inhibits breast cancer 
cell migration in a metalloproteinase independent manner.  
 
 
 
Figure 4.1: ADAMTS-15 reduces scratch wound recovery of human breast 
cancer cells in a metalloproteinase independent manner. Scratch wounds 
were introduced into monolayers of MDA-MB-231 EV, TS15 and E362A cells. 
Wound recovery was determined at the indicated time points, data represent 3-
5 individual wells analysed per cell group, error bars represent s.e.m. *p<0.05, 
**p<0.01, ***p<0.001. 
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4.2.2	  Analysis	  of	  random	  cell	  migration	  	  
To monitor the migration of individual cells a lower seeding density was utilised 
than that used during the scratch assays. Another notable difference between 
the scratch wound assay and a 2D cell migration assay is that random cell 
migration rather than directional migration is tracked (Methods 2.11; Ashby and 
Zijlstra, 2012).  
Individual cells were tracked over a period of 24 hours and Image J plugins 
(‘manual tracking’ and ‘chemotaxis’) were used to quantify migration velocity 
(µm/min). Expression of either wildtype (TS15) or catalytically inactive (E362A) 
ADAMTS-15 inhibited cell migration in MDA-MB-231 and MCF-7 cells (Figure 
4.3). To substantiate that these effects were attributable to ADAMTS-15 cells 
were transfected either with a smartpool of ADAMTS-15 or control non-targeting 
siRNAs (Methods 2.11.3). Migrating-siRNA transfected cells were tracked and 
analysed over a period of 24 hours. Knockdown of wildtype ADAMTS-15 (TS15) 
or E362A restored cell migration to control (EV) levels (Figure 4.3). Western blot 
analysis of ADAMTS-15 protein in siRNA transfected cells confirmed that 
ADAMTS-15 knockdown was successful. In concordance with the scratch 
wound assay these data confirm that ADAMTS-15 reduces breast cancer cell 
migration in a metalloproteinase independent manner. 
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Figure 4.2: ADAMTS-15 reduces 2D migration of human breast cancer 
cells in a metalloproteinase independent manner. 2D migration velocity of 
MDA-MB-231 (a) or MCF7 (b) human breast cancer cells that constitutively 
express empty vector control (EV), wildtype ADAMTS-15 (TS15) or 
metalloproteinase inactive ADAMTS-15 (E362A) was determined with time-
lapse microscopy over a period of 24 hours, data represent 60 individually 
tracked cells per group, error bars represent s.e.m. ***p<0.001. 
 
Figure 4.3: Knockdown of ADAMTS-15 abrogates the anti-migratory 
phenotype. MDA-MB-231 EV, TS15 or E362A cells were transfected with 
either non-targeting siRNA (scrambled) or ADAMTS-15 siRNA. Cell migration 
was tracked via time-lapse microscopy over a period of 24 hours, data 
represent 20-28 individually tracked cells per group, error bars represent s.e.m. 
*p<0.05, ***p<0.001. Accompanying western blot images confirm knockdown of 
ADAMTS-15. ADAMTS-15 and E362A were detected via anti-FLAG antibody 
using cell lysate samples of siRNA transfected cells.   
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4.3	  Analysis	  of	  matrix	  specific	  effects	  on	  cell	  migration	  
4.3.1	  Conditioned	  matrix	  migration	  assay	  
A conditioned matrix experiment was designed based upon several assays 
reported in the literature (Methods 2.11.2; Khalkhali-Ellis and Hendrix, 2007; 
Phillips et al. 2008). MDA-MB-231 EV, TS15 and E362A cells were seeded at 
high density and cultured for three days in serum conditions until 100% 
confluency. Cells were removed with EDTA/EGTA to preserve the underlying 
conditioned matrices. Visual conformation and methylene blue staining was 
utilised to confirm that EDTA/EGTA treatment successfully removed the cell 
monolayer (Figure 4.4b). Naïve MDA-MB-231 EV cells were then seeded at low 
density onto each of the conditioned matrices and 2D migration velocity was 
tracked. 
MDA-MB-231 (EV) cell migration was inhibited when seeded onto ADAMTS-15 
conditioned matrices. (Figure 4.4). E362A conditioned matrices also inhibited 
MDA-MB-231(EV) cell migration, however this was not statistically significant 
(p=0.06) (Figure 4.5). This may be due to differences in matrix deposition 
and/or the stability of ADAMTS-15 protein in comparison to E362A protein, 
however in these assays these parameters were not controlled for. Although 
matrices from MDA-MB-231 EV, TS15 and E362A were qualitatively analysed 
in a Coomassie blue-stained gel and no obvious differences were observed 
(data not shown). Based upon previous assays it is likely that these conditioned 
matrices inhibited cell migration due to ECM associated ADAMTS-15 deposited 
by the conditioning cells. To explore further how ADAMTS-15 might influence 
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cell-ECM interactions, MDA-MB-231 EV, TS15 and E362A cells were seeded 
onto physiologically relevant matrix components. 
 
 
Figure 4.4: ADAMTS-15 conditioned matrix reduces the migration of 
human breast cancer cells. MDA-MB-231 human breast cancer cells that 
constitutively express EV, TS15 or E362A were cultured for 72h to allow the 
formation of matrices. Cells were then removed with EDTA/EGTA (5mM) to 
preserve the underlying matrix. Naive MDA-MB-231 EV cells were then seeded 
onto the conditioned matrices. (a) 2D migration velocity of MDA-MB-231 (EV) 
cells was determined with time-lapse microscopy over a period of 24 hours, 
data represent 60 individually tracked cells per group, error bars represent 
s.e.m. **p<0.01. E362A was not statistically in comparison to EV, p0.06. (b) 
Methylene blue staining was utilised to demonstrate that the matrix conditioning 
cells had been successfully removed prior to the seeding of naïve EV cells. 
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4.3.2	   2D	   migration	   on	   fibronectin,	   collagen	   type	   I	   and	  
laminin	  
To understand how ADAMTS-15 might influence the migratory behaviour of 
breast tumour cells within a mammary matrix context MDA-MB-231 EV, TS15 
and E362A cells were seeded onto surfaces pre-coated with either collagen 
type I, fibronectin or laminin (Methods 2.11.1). These matrices were selected 
since they are important within the context of human mammary tissue 
architecture (Butcher, et al. 2009; Gusterson et al. 1982; Hancox et al. 2009; 
Mao and Schwarzbauer, 2005). 
MDA-MB-231 EV, TS15 and E362A expressing cells adhered to and migrated 
on collagen type I at comparable levels (Figure 4.5). However matrix-specific 
effects were observed on fibronectin and laminin. Expression of TS15 or E362A 
inhibited the migration of MDA-MB-231 cells on fibronectin and laminin 
compared to control EV cells (Figure 4.5; Figure 4.6c). The anti-migratory effect 
is explained in part by the adhesive behaviour of cells which express ADAMTS-
15. TS15 and E362A expressing cells displayed a relatively more spread out 
morphology and in adhesion assays more strongly adhered to laminin and 
fibronectin in comparison to control cells (Figure 4.5). Migration time lapse 
images revealed that TS5 and E362A expressing cells adhered strongly enough 
that cell detachment, particularly from laminin, required extensive cellular force 
(Figure 4.6a). In some cases adhesion was so strong that cells ruptured their 
cell membranes in order to de-adhere (Figure 4.6a).  
Migration directionality, expressed as a ratio between the Euclidian distance 
(distance between cell start and finish points) and the accumulated distance 
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(total migrated distance in a given time period) were also quantified in these 
assays (Figure 4.5). Cells which persistently migrate in a straight line will have a 
directionality of one, since the distance between the cell start and finish points 
and the total migrated distance will be equal (Figure 4.6d). Cells with more 
random migration patterns have a lower level of directionality and could 
potentially be zero since a cell could migrate back to its original starting point 
(Figure 4.6d).  
Within an in vivo context, cells which adhere and migrate along fibronectin fibrils 
are likely to exhibit more orderly or persistent migration patterns (Bass et al. 
2007; Mao and Schwarzbauer, 2005; Petrie, Doyle and Yamada, 2009). Since 
aberrant regulation of cell adhesion processes is likely to result in random 
migration patterns directionality can provide a qualitative indicator of the ability 
of cells to modulate behaviours in response to the ECM (Bass et al. 2007; 
Petrie et al. 2012; Petrie, Doyle and Yamada, 2009; Rodríguez-Manzaneque et 
al. 2009; Spiering and Hodgson, 2011). Expression of ADAMTS-15 and E362A 
enhanced directionality on fibronectin and laminin matrices (Figure 4.5). 
Therefore there may be differences in the level or activity of cell adhesion 
receptors in cells, which express ADAMTS-15. To this end the integrin profiles 
of these cells were examined.  
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Figure 4.5: ADAMTS-15 reduces 2D migration on Fibronectin and Laminin. 
(a) MDA-MB-231 EV, TS15 or E362A cells were seeded onto 24 well plates that 
were pre-coated with either Collagen type I, Laminin or Fibronectin. Cell 
migration was tracked via time-lapse microscopy over a period of 24 hours, data 
represent 20-39 individually tracked cells per group, error bars represent s.e.m.; 
***p<0.001. (b) The migration directionality (Euclidian distance / accumulated 
distance) of each individually tracked cell was also determined. Data represent 
20-39 individually tracked cells per group, error bars represent s.e.m. *p<0.05, 
**p<0.01. (c) MDA-MB-231 EV, TS15 or E362A cells were seeded onto 24 well 
plates that were pre-coated with either Collagen type I, Laminin or Fibronectin. 
At 4hours post seeding the cell spread area (pixel area) of individual cells was 
determined using ImageJ, data represent 57 individually analysed cells per 
group, error bars represent s.e.m.; **p<0.01, ***p<0.001 (d) Adhesion assay. 
MDA-MB-231 EV, TS15 or E362A cells were seeded onto 96 well plates that 
were pre-coated with either Collagen type I, Laminin or Fibronectin. Adhered 
cells were fixed and stained with Methanol/Methylene Blue. Absorbance 
(630nm) was measured and TS15, E362A values were normalised to the 
average EV absorbance value, six wells per cell group were analysed, error 
bars represent s.e.m.; *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4.6: MDA-MB-231 EV, TS15 and E362A cells on laminin and 
fibronectin. (a) Images of MDA-MB-231 EV, TS15 and E362A cells that have 
adhered to a laminin-coated surface. The white arrows highlight the adhesive 
behaviour of representative cells. TS15 and E362A cells adhered strongly to 
laminin in comparison to EV cells, to the extent that detachment from the matrix 
often resulted in a tearing of the cell membrane. (b) Images of MDA-MB-231 
EV, TS15 and E362A cells that have adhered to a fibronectin-coated surface. 
(c) Cell migration pathways of cells adhered to a fibronectin-coated surface as 
analysed by Image J plugins manual tracking and chemotaxis. All images are 
representative of the matrix migration assays in figure 4.5 (d) Schematic 
explanation of directionality. 
  
Chapter 4 | Page 126 
 
4.3.3	   ADAMTS-­‐15	   expression	   is	   associated	   with	   an	   altered	  
integrin	  profile	  
Adhesion to fibronectin and laminin was enhanced in TS15 and E362A 
expressing cells. Therefore there may be differences in the level of expression 
or activity of cell adhesion receptors in cells which express ADAMTS-15. To this 
end the integrin profiles of these cells were examined.  
Integrin α5 partners with integrin β1 to bind to fibronectin (Humphries et al. 
2006). Expression of integrin α5, as determined my qRT-PCR, was 
approximately 2-fold higher in TS15 and E362A expressing cells, which 
potentially explains why these cells adhered more strongly to fibronectin (Figure 
4.5; Figure 4.8). However due to time constraints integrin α5 was not examined 
at the protein level. 
Laminin is the ligand for several integrin heterodimers including, α6β1 and α6β4 
(Humphries et al. 2006). Expression of integrin β1, as determined my qRT-
PCR, was approximately 2-fold higher in TS15 and E362A expressing cells, 
which potentially explains why these cells adhered more strongly to laminin 
(Figure 4.5; Figure 4.6; Figure 4.8). However at the protein-level there were no 
overt differences in either integrin β1 or α6 (Figure 4.7a). Flow cytometric 
analysis did not detect any differences in the surface levels of integrin β1 either 
(Figure 4.7b). To examine whether integrin β1 was differentially activated, cells 
were stained with β1-12G10 antibody, which preferentially binds to active 
integrin β1 (Methods 2.25; Humphries et al. 2005). However no differences 
were observed in the level of active integrin β1 in these cells (Figure 3.10a). 
However differences in the laminin binding integrin β4 were detected. MDA-MB-
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231 TS15 and E362A expressing cells were associated with an increased level 
of total integrin β4 in comparison to control EV cells (Figure 4.7a). Whilst EV 
and indeed parental MDA-MB-231 cells do express integrin β4, the levels of 
total β4 were consistently higher in TS15 and E362A expressing cells in multiple 
independent western blots. As noted before the ligand for integrin α6β4 is 
laminin, thus increased levels of β4 may explain the adhesion and migration 
phenotype observed in TS15 and E362A cells. However, a caveat to this 
analysis is that based upon these flow Cytometry data there are no differences 
in the surface level of integrin β4 in either control (EV), TS15 or E362A 
expressing cells (Figure 4.7b; Methods 2.26).  
It should also be noted that not all laminin and fibronectin binding integrin 
heterodimers were examined in this study. An in depth examination of integrin 
signalling, localisation and trafficking may be required in future studies to fully 
characterise the matrix specific effects observed in TS15 and E362A expressing 
cells.  
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Figure 4.7: ADAMTS-15 expression is associated with an altered integrin 
profile. (a) Western blot analysis of the integrin profiles of MDA-MB-231 cells 
that constitutively express EV, ADAMTS-15 or E362A. Data are representative 
of three independently collected samples (b) Flow Cytometry analysis of the 
surface levels of Integrin β4 and Integrin β1 on MDA-MB-231 EV, TS15 and 
E362A cells. Data are representative of three independently collected cell 
samples. 
 
 
Figure 4.8: Expression profile of MDA-MB-231 EV, TS15 and E362A cells. 
qRT-PCR analysis of gene expression in MDA-MB-231 EV, TS15 and E362A 
cells. Relative expression levels are shown as a Ct value heat-map. The 
displayed Ct values are averaged from three independently collected RNA 
samples. These data are an extended set from that shown in figure 3.8. See 
appendix A7 to see an expanded version of this data set. 
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4.4	   Investigation	   of	   potential	   involvement	   of	   syndecan-­‐4	   in	  
ADAMTS-­‐15	  effect	  on	  cell	  migration	  
As discussed in the introduction chapter there seems to be an intimate 
connection between the syndecans and the ADAMTSs, which co-ordinate with 
other metalloproteinases to regulate cell-ECM interactions. This is particularly 
apparent since ADAMTS-1 shedding of syndecan-4 from the cell surface results 
in a functional loss of cell adhesion and promotes a pro-migratory phenotype 
with a concomitant loss of migration directionality (Bass et al. 2007; Choi et al. 
2011; Rodríguez-Manzaneque et al. 2009).  
In light of these studies and since both ADAMTS-15 and syndecan-4 are anti-
migratory there may be a functional link. Interestingly, expression of TS15 and 
E362A in MDA-MB-231 cells were associated with increased surface levels of 
syndecan-4 in comparison to control EV cells (Figure 4.9). Yet expression of the 
syndecan-4 sheddases ADAMTS-1 and -4 were approximately 2-fold higher in 
TS15 and E362A expressing cells (Figure 4.8). Thus it could be inferred that 
ADAMTS-15 may be protecting syndecan-4 from sheddase activity.  
In agreement with this hypothesis knockdown of syndecan-4 in MDA-MB-231 
TS15 and E362A expressing cells abrogated the anti-migratory phenotype 
(Figure 4.10). Directionality was also lost upon knockdown of syndecan-4 in 
TS15 and E362A expressing cells (Figure 4.10), whilst syndecan-4 knockdown 
in control cells elicited no effect (Figure 4.10). Based on these data it is possible 
that syndecan-4 and ADAMTS-15 are functionally linked within the context of 
regulating breast tumour cell migration. ADAMTS-15 may protect syndecan-4 
from sheddase action, thus promoting the anti-migratory effects of syndecan-4. 
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To explore this link further, the effects of modulation of PKCα signalling, which 
lies downstream of syndecan-4, were examined. 
  
 
Figure 4.9: ADAMTS-15 expression is associated with increased levels of 
syndecan-4 on the cell surface. Flow Cytometry analysis of the surface levels 
of Syndecan-4 (Black) on MDA-MB-231 EV, TS15 and E362A cells. Graphs are 
representative and median fluorescence intensity values were averaged from 
three independently collected cell samples. IgG isotype control (White) antibody 
was utilised as a negative control. 
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Figure 4.10: Knockdown of Syndecan-4 abrogates ADAMTS-15 anti-
migratory phenotype. (a) MDA-MB-231 EV, TS15 or E362A cells were 
transfected with either non-targeting siRNA (control) or Syndecan-4 siRNA and 
cell migration tracked via time-lapse microscopy over a period of 24 hours, data 
represent 50 individually tracked cells per group, error bars represent s.e.m.; 
***p<0.001. (b) The migration directionality (Euclidian distance / accumulated 
distance) of each individually tracked cell was also determined, data represent 
50 individually tracked cells, error bars represent s.e.m.; *p=0.05, ***p<0.001. 
(c) Flow cytometry analysis of surface levels of Syndecan-4 on MDA-MB-231 
EV, TS15 and E362A cells that were transfected with either non-targeting 
control siRNA (White) or syndecan-4 siRNA (Black). Isotype secondary 
antibody, IgG (Grey), was utilised as a staining control. Reduction in surface 
Syndecan-4 was determined as a percentage reduction of median fluorescence 
from cells transfected with syndecan-4 siRNA vs. control siRNA. Graphs are 
representative and median fluorescence intensity values were averaged from 
three independently collected cell samples. 
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4.5	  Analysis	  of	  the	  involvement	  of	  signalling	  pathways	  that	  might	  
be	   involved	   in	   mediating	   the	   ADAMTS-­‐15	   anti-­‐migratory	  
phenotype	  
4.5.1	  PKC	  signalling	  
PKCα signalling is intimately connected to syndecan-4 since none of the other 
syndecan family members contain a PKCα binding motif within their cytoplasmic 
domains (Keum et al. 2004; Oh, Woods and Couchman, 1997). Upon 
engagement with fibronectin, the cytoplasmic domain of syndecan-4 recruits, 
stabilises and activates PKCα at the plasma membrane (Keum et al. 2004; Oh, 
Woods and Couchman, 1997). PKCα signalling feeds into cell adhesion and 
migration pathways through the activation of Rac1 and RhoA (Avalos et al. 
2009; Carr et al. 2013). Since PKCα mediates syndecan-4 signalling, 
pharmacological activation or inhibition of PKCα may provide some insight into 
the role of syndecan-4 in the ADAMTS-15 anti-migratory phenotype. 
MDA-MB-231 EV, TS15 and E362A cells were treated with 0-100nM of phorbol 
12-myristate 13-acetate (PMA), a known activator of PKC signalling (Methods 
2.11; Keum et al. 2004; Oh, Woods and Couchman, 1997). Treatment of MDA-
MB-231 cells with either 50nM or 100nM PMA stimulated cell migration (Figure 
4.11a). Thus PMA-mediated activation of PKCα abrogated the anti-migratory 
phenotype.  
However, PMA is not a specific activator of PKCα, since it is known from 
previous studies that in addition to PKCα, PMA also stimulates PKCδ (Brodie et 
al. 2004; Murakami et al. 2004; Shanmugam et al. 1998). PKCδ serves as a 
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negative regulator of PKCα activity, since overexpression of PKCδ is associated 
with decreased PKCα activity, at least in endothelial cells (Murakami et al. 
2004). Whilst PKCα  establishes pro-adhesive and regulated migratory 
structures, PKCδ signalling on the other hand favours impaired cell migration 
(Brodie et al. 2004; Murakami et al. 2004). Therefore PMA stimulation of PKC 
signalling may have imposed an imbalance in these signalling pathways, 
towards the observed pro-migratory phenotype (Figure 4.11a).  
PMA also activates ERK1/2 signalling which is known to enhance tumour cell 
migration (Brodie et al. 2004; von Thun et al. 2012). Whilst this may suggest 
that PMA treatment may have stimulated migration independently of syndecan-
4 signalling, PKCδ has been shown to activate ERK1/2 (Brodie et al. 2004; 
Keshamouni, Mattingly and Reddy, 2002). 
Another interpretation of these data is that PMA may have accelerated the 
shedding of syndecan-4 through an induction of the expression of several 
metalloproteinases, including the syndecan-4 sheddase ADAMTS-1 (Brule et al. 
2006; Rodríguez-Manzaneque et al. 2009; Worley et al. 2009). Thus PMA 
stimulation may have accelerated the shedding of syndecan-4 such that any 
protective effects elicited by ADAMTS-15 were overcome (Rodríguez-
Manzaneque et al. 2009).  
Conversely treatment with the PKC inhibitor, bisindolylmaleimide I (BIM I) 
suppressed migration in control cells, yet had no effect on TS15 or E362A 
expressing cells (Figure 4.11a; Methods 2.11; Avalos et al. 2009; Bass et al. 
2007; Keum et al. 2004). Arguably PKC signalling in TS15 and E362A cells is 
already reduced such that the addition of an inhibitor has no effect. It can be 
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speculated that these data highlight that PKC signalling may be tightly regulated 
in ADAMTS-15 expressing cells such that PKC signalling is localised to 
syndecan-4 focal adhesion complexes. However until syndecan-4/PKC activity 
and localisation is examined in greater detail these data are supportive, but not 
conclusive of a functional link between ADAMTS-15 and syndecan-4. To this 
end several other signalling pathways were also examined. 
 
 
Figure 4.11: Modulation of signalling pathways down-stream of Syndecan-
4 abrogates ADAMTS-15 anti-migratory phenotype. (a) MDA-MB-231 EV, 
TS15 or E362A cells were treated with 0-100nM phorbol 12-myristate 13-
acetate (PMA) and cell migration tracked via time-lapse microscopy over a 
period of 24 hours. Data represent the mean of at least 15 individually tracked 
cells per group, error bars represent s.e.m.; **p<0.01, ***p<0.001. (b) MDA-MB-
231 EV, TS15 or E362A cells were treated with 0 µM or 1µM BIM I and cell 
migration tracked via time-lapse microscopy over a period of 24 hours, Data 
represent 30 individually tracked cells per group, error bars represent s.e.m. 
*p<0.05, ***p<0.001.  
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4.5.2	  EGF	  signalling	  
Following EGF stimulation MDA-MB-231 cells expressing either TS15 or E362A 
displayed reduced 2D migration at EGF concentrations up to 50ng/ml (Figure 
4.12; Methods 2.11). However, at 100ng/ml EGF, the migration levels of cells 
expressing TS15 or E362A were restored to control (EV) levels. The effect of 
ADAMTS-15 expression on pERK activation was investigated in greater detail 
via a pERK activation time course assay. MDA-MB-231 EV, TS15 and E362A 
cells were treated with EGF (50ng/ml) for the indicated times and then analysed 
via western blot (Figure 4.12). Whilst these western blots are not definitive it 
appears that EV cells show an increase in activation of pERK at 30 minutes 
post EGF stimulation, whereas TS15 and E362A expressing cells display a 
delayed activation of pERK at 60 minutes post EGF stimulation. This pattern 
was generally consistent across the two independent experiments shown; 
however there was some inter-experimental variability. 
Together these data indicate that independent of its catalytic activity, ADAMTS-
15 reduces the sensitivity of cells to the migration stimulatory effects of EGF. 
This is consistent with reports that ADAMTS-15 expression inhibits ERK 
activation in colorectal cancer cells (Viloria et al. 2009). 
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Figure 4.12: ADAMTS-15 reduces the sensitivity of breast cancer cells to 
the migration stimulatory effects of EGF. (Top) MDA-MB-231 EV, TS15 or 
E362A cells were treated with 0-100ng/ml EGF and cell migration tracked via 
time-lapse microscopy over a period of 24 hours, n=30-40, error bars represent 
s.e.m.; ** p≤0.01, *** p≤0.001. (Bottom) WB analysis of pERK activation post 
EGF stimulation (50ng/ml final concentration). Two independent experiments 
are shown. Protein sizes: ADAMTS-15 ~103kDa, ERK/pERK 42/44 kDa). 
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4.5.3	  ROCK	  signalling	  
MDA-MB-231 EV, TS15 and E362A cells were treated with an established and 
specific inhibitor of the Rho-associated kinases (ROCK) (Brew et al. 2009; 
Narumiya, Ishizaki and Uehata, 2000). Treatment with Y-27632 inhibited the 
migration of MDA-MB-231 control cells (EV), yet had no statistical effect on the 
migration of ADAMTS-15 expressing cells (Figure 4.13). Whilst not statistically 
significant, Y-27632 may have slightly enhanced the migration of E362A-
expressing cells (Figure 4.13). It is well established that inhibition of ROCK 
signalling has an anti-migratory effect, since ROCK-inhibited cells fail to form 
stable focal adhesion complexes from which cells can generate the forces 
needed to migrate (Brew et al. 2009; Narumiya, Ishizaki and Uehata, 2000). 
Therefore it is not surprising that Y-27632 inhibited the migration of MDA-MB-
231 control cells (EV). It is however interesting that inhibition of ROCK 
signalling did not completely abolish the migratory capacity of ADAMTS-15 
expressing cells. These data suggest that ROCK signalling is to some extent 
already inhibited in ADAMTS-15 expressing cells. Since RhoA (and Rac1) is 
frequently overexpressed in invasive breast tumours, lower levels of ROCK 
activation in ADAMTS-15 expressing cells may be a putative anti-migratory 
mechanism (Brew et al. 2009).  
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Figure 4.13: ROCK inhibitor Y27632 does not affect the ADAMTS-15 anti-
migratory phenotype. MDA-MB-231 EV, TS15 or E362A cells were treated 
with 0-10µM Y27632 and cell migration tracked via time-lapse microscopy over 
a period of 24 hours, data represent 27-37 individually tracked cells per group, 
error bars represent s.e.m. **p<0.01, ***p<0.001. 
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4.5.4	  Global	  effects	  on	  kinase	  phosphorylation	  
To examine global effects on cell signalling pathways that are associated with 
expression of ADAMTS-15 an R&D phosphokinase array was utilised (Methods 
2.24). Cell lysates from MDA-MB-231 EV, TS15 and E362A cells were 
incubated with membranes that were pre-printed with anti-phospho-kinase 
antibodies for 43 different kinases. The membranes were imaged using HRP 
and phosphokinase levels determined through an analysis of the pixel density of 
antibody detection spots. Pixel density is dependent upon the level of 
phosphokinases in cell lysate samples that bind to the anti-phospho-kinase 
antibodies. Raw data were plotted and analysed according to the observed 
patterns (Figure 4.14; Appendix 6).  
Kinases with increased (activity-independent activation) or decreased (activity-
independent inhibition) phosphorylation levels in both TS15 and E362A cells 
compared to EV, may indicate functional consequences that are independent of 
ADAMTS-15 metalloproteinase proteolytic activity. The phosphorylation levels 
of several kinases including Fyn, Lyn, Lck and Yes were all reduced in TS15 
and E362A cells compared to control. These kinases lie downstream of integrin 
β4 and are involved in regulating cell migration pathways (Figure 4.14b).  
Kinases with increased (TS15-dependent activation) or decreased (TS15-
dependent inhibition) phosphorylation levels specifically in TS15 cells may 
indicate functional consequences of ADAMTS-15 proteolytic activity. 
Interestingly ERK 1/2 phosphorylation levels were higher specifically in TS15 
overexpressing cells (TS15 dependent-activation). Yet ADAMTS-15 has been 
reported to reduce basal levels of pERK in ADAMTS-15 transfected HCT-116 
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cells (Viloria et al. 2009). Perhaps these differences indicate differences in 
breast and colorectal cancer cell lines or that ADAMTS-15 functions differently 
depending upon context. Conversely ERK signalling is involved in regulating 
cell proliferation, yet over expression of ADAMTS-15 does not affect breast 
cancer cell proliferation (Figure 3.4). Several pERK antibodies are reported to 
be sensitive enough to detect as little as 50pg of phosphorylated MAP kinase 
protein, therefore it is possible that these signal differences may only represent 
small differences in detectable protein levels. In addition to this only one cell 
lysate sample was used for each cell line and therefore this result may be an 
outlier. 
Several kinases showed no difference (c-Jun, MSK1/2 and JNK pan) or were 
ambiguous (p53-S392, Pyk2, Chk-2 and eNOS) in that the observed changes 
did not show a consistent pattern, and may simply be background ‘noise’. 
Kinases with increased (E362A-dependent activation) or decreased (E362A-
dependent inhibition) phosphorylation levels specifically in E362A cells were 
equally puzzling yet 21% of the kinases examined displayed an E362A-
dependent pattern. It is unclear how the metalloproteinase inactive form of 
ADAMTS-15 (E362A) could have a ‘gain-of-function’, though it is possible that 
E362A could act as a dominant-negative against endogenous ADAMTS-15. 
However no E362A specific effects have been observed in any functional assay 
and therefore it is possible that these patterns are also random ‘noise’. 
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Figure 4.14: Global effects on kinase phosphorylation in ADAMTS-15 
expressing cells. Cell lysates from MDA-MB-231 EV, TS15 and E362A were 
incubated with membranes that were pre-treated with anti-phosphokinase 
antibodies as part of the R&D Human phosphokinase array kit. (a) An analysis 
of HRP signal pixel density was utilised to determine the levels of kinase 
activation compared to control spots on the membrane. (b) Genomatix cloud 
based software was utilised to highlight kinases (yellow) that were less active in 
TS15 and E362A cells compared to control EV cells. Genes shown in grey are 
there to demonstrate several cell migration/integrin signalling pathways that the 
highlighted kinases are a part of. Data represent one cell lysate sample per cell 
group. 
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4.6	  Analysis	  of	  migration	  in	  3D	  matrices	  
The ADAMTS-15 anti-migratory phenotype has largely been characterised 
within a 2D context, yet cells exist within a 3D environment in vivo. Whilst 2D 
assays are informative cells may exhibit behaviours that are more 
physiologically relevant when seeded within 3D matrices. For instance cells 
exhibit different modes of migration when seeded into a 3D context in 
comparison to 2D tissue culture environments (Ashby et al. 2012; Blobel et al. 
2010; Even-Ram and Yamada, 2005; Friedl et al. 2012; Petrie et al. 2012). To 
address this, ADAMTS-15 expressing breast tumour cells were seeded within 
either collagen type I gels or matrigel (Methods 2.12). Because cells could 
migrate up or down through these 3D gels, multiple planes on the Z-axis were 
captured. This was an appropriate precaution since cells did migrate into and 
out of the ideal focal plane. However cells could still be tracked and analysed in 
a similar manner to the method established for 2D assays.  
Another notable difference between 2D and 3D assays is that cells may need to 
proteolytically degrade the 3D matrix in order to clear a migration pathway. 
Therefore the surface levels of the collagenase MT1-MMP were analysed since 
this membrane bound metalloproteinase has been shown to enhance the 
invasive potential of tumour cells, in part through the degradation and clearing 
of collagen (Eisenach et al. 2012; Ota et al. 2009; Sabeh et al. 2004). Surface 
levels of MT1-MMP were equivalent in MDA-MB-231 EV, TS15 and E362A 
expressing cells and in agreement with 2D migration data ADAMTS-15 
expression does not affect cell migration either on or through collagen type I 
(Figure 4.5; 4.15b-c). 
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Interestingly expression of TS15 or E362A did reduce 3D migration of MDA-MB-
231 cells, through matrigel in comparison to empty vector (EV control) cells 
(Figure 4.15). Since Matrigel is a mix of several basement membrane matrix 
components including laminin these data are in agreement with the matrix 
specific effects of ADAMTS-15 observed in 2D migration assays (Figure 4.5). 
 
 
 
Figure 4.15: ADAMTS-15 reduces 3D migration through matrigel but not 
collagen type I in a metalloproteinase independent manner. MDA-MB-231 
EV, TS15 and E362A cells were seeded into Matrigel (a) or Collagen type I gels 
(b). 3D cell migration tracked via time-lapse microscopy over a period of 24 
hours, data represent 43 individually tracked cells per group, error bars 
represent s.e.m. *p<0.05, ***p<0.001 (c) Flow cytometry analysis of surface 
levels of MT1-MMP on MDA-MB-231 EV, TS15 and E362A cells. Data are 
representative of three independently collected cell samples per group. 
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4.7	  Discussion	  
4.7.1	   ADAMTS-­‐15	   inhibits	   cell	   migration	   in	   a	  
metalloproteinase	  independent	  manner	  
ADAMTS-15 is emerging as an anti-migratory metalloproteinase, which so far 
has been shown to reduce the invasive potential of colorectal cancer cell lines 
in vitro and in vivo (Viloria et al. 2009). Thus an inhibition of the invasive 
potential of tumour cells may be the putative protective mechanism that 
underpins the increased survival prospects for breast and colorectal cancer 
patients that express ADAMTS-15 (Porter et al. 2006; Viloria et al. 2009). In 
light of these studies the aim of this chapter was to investigate the functional 
consequences of ADAMTS-15 expression on human breast cancer cell 
migration. To this end several migration assays were utilised, including the 
scratch wound assay. 
The scratch wound assay is typically described as an in vitro wound healing 
model, since inflicted scratch wounds remove the underlying matrix along with a 
section of the cell layer (Ashby and Zijlstra, 2012; Hsu et al. 2012; Krampert et 
al. 2005). Wounding is typically a manual process, which adds a level of 
variability to these assays since scratches may not always be perfectly uniform 
and cells along the wound edges may be inadvertently damaged. To ensure 
consistency, cell density and wounding strategies were optimised prior to the 
experiments and non-uniform scratches were excluded from the analysis.   
These data show for the first time, that expression of ADAMTS-15 reduces the 
scratch wound recovery of human breast cancer cells (Figure 4.1). Wound 
closure can also be a consequence of cell proliferation, though based upon data 
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presented earlier, ADAMTS-15 does not affect breast cancer cell proliferation 
(Figure 3.9), and thus it is likely that ADAMTS-15 inhibited scratch wound 
closure through an inhibition of cell migration (Figure 4.1). In addition to this the 
expression of the metalloproteinase-inactive form of ADAMTS-15 (E362A) also 
reduced scratch wound recovery (Figure 4.1). Therefore, ADAMTS-15 inhibition 
of cell migration is independent of its catalytic activity.  
The scratch wound assay can be adapted to examine individual or collective 
migration. For collective migration assays, the cell monolayers at either side of 
the scratch have the potential to collectively migrate into the wound 
(Bindschadler and McGrath, 2007; Riahi et al. 2012). However, close 
examination of the time-lapse images reveals that in these assays, the cells 
tended to migrate individually into the scratch wound (Figure 4.1). In light of this, 
these data are not sufficient to examine any influence ADAMTS-15 might have 
on collective cell migration. Nevertheless, future studies should examine this, 
since collective migration during embryonic development and tumour cell 
invasion may be mediated by several metalloproteinases (Ismat, Cheshire and 
Andrew, 2013). It is therefore possible that ADAMTS-15 might have a role in the 
regulation of collective cell migration. To investigate this Matrigel spheroid 
assays could be utilised as previously described (Dang, Prechtl, and Pearson, 
2011; Serres et al., 2013). 
Whilst collective cell migration could not be examined, cell density is still an 
important factor to consider since cell-cell interactions are known to influence 
cell behaviour. However, in this case, expression of ADAMTS-15 inhibited 
breast cancer cell migration even when cells were seeded at a low density 
(Figure 4.2). These 2D migration assays were also adapted such that siRNA 
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knockdown of TS15 or E362A restored migration to control, EV levels (Figure 
4.3). In combination these data demonstrate a robust and reproducible 
association between ADAMTS-15 expression and a metalloproteinase 
independent inhibition of breast cancer cell migration.  
4.7.2	  ADAMTS-­‐15	  modulates	  cell-­‐ECM	  interactions	  
Previously, ECM associated ADAMTS-15 has been shown to reduce the 
invasive potential of colorectal cancer cell lines (Viloria et al. 2009). Whilst the 
mechanism was not identified, these data suggest that ADAMTS-15 might 
modulate cell-ECM interactions and influence cell migration.  To determine 
whether ECM associated ADAMTS-15 is functionally capable of modulating 
breast cancer cell migration, several matrix assays were established, including 
an adapted conditioned matrix assay (Khalkhali-Ellis and Hendrix, 2007; Phillips 
et al. 2008). To summarise these conditioned matrix data, ADAMTS-15 and to a 
lesser extent, E362A conditioned matrices inhibited the migration of naïve EV 
control cells (Figure 4.4). Therefore these data provide additional evidence that 
ECM-deposited ADAMTS-15 inhibits breast cancer cell migration and by 
extension ADAMTS-15 modulates cell-ECM interactions.  
A potential limitation of the conditioned matrix assay is that the absolute amount 
of deposited matrix was not quantified. Instead conditioned matrix samples 
were visualised in Coomassie blue-stained gels (data not shown). Whilst there 
were no qualitative differences in matrix deposition, a quantitative analysis of 
matrix deposition may be required for future studies. Thus matrix variability 
could potentially explain why E362A conditioned matrices did not inhibit cell 
migration to the same extent as TS15 conditioned matrices. Differences in 
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protein stability between wildtype and E362A forms of ADAMTS-15 may have 
also contributed to these disparities. Nevertheless, as previously discussed, 
attempts were made to control for these factors. For instance conditioned cells 
were seeded at a density that was informed through the optimisation of the 
scratch wound assay and as discussed in chapter 3, the mRNA and protein 
levels of TS15 and E362A were comparable between the appropriate cell lines 
(Figure 3.6; Figure 3.8). In summary, reasonable controls were enacted to 
ensure that MDA-MB-231 EV, TS15 and E362A cells would lay down 
comparable levels of matrices.  
In addition to the conditioned matrix assays, MDA-MB-231 EV, TS15 and 
E362A cells were seeded onto surfaces pre-coated with either collagen type I, 
fibronectin or laminin. These matrices were selected since they are ECM 
components that are found within human mammary tissue architecture 
(Butcher, et al. 2009; Gusterson et al. 1982; Hancox et al. 2009; Mao and 
Schwarzbauer, 2005). As expected ADAMTS-15 inhibited cell migration in a 
metalloproteinase-independent manner, however in these assays the effects 
were matrix specific. Expression of TS15 or E362A inhibited cell migration on 
fibronectin and laminin but not collagen type I (Figure 4.5). In all other assays 
(e.g. scratch wound) cells were seeded with serum-supplemented media. Since 
serum contains fibronectin, essentially ADAMTS-15 was inhibiting cell migration 
on a fibronectin-enriched matrix.  
These matrix specific effects can be explained in part by the adhesive 
behaviour of ADAMTS-15 expressing cells. TS15 and E362A expressing cells 
display a relatively more spread out morphology and in adhesion assays more 
strongly adhered to laminin and fibronectin in comparison to EV control cells 
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(Figure 4.5). There were no differences in cell adhesion on collagen type I 
(Figure 4.5). Migration time-lapse images also revealed that TS15 and E362A 
expressing cells adhered to the extent that cell detachment, particularly from 
laminin, required extensive cellular force (Figure 4.6a). In some cases cell 
adhesion was so strong that cells ruptured their cell membranes in order to de-
adhere (Figure 4.6a). 
These matrix specific effects were also recapitulated within 3D migration 
models that are more representative of the 3D in vivo tissue environment 
(Ashby et al. 2012; Blobel et al. 2010; Even-Ram and Yamada, 2005; Friedl et 
al. 2012; Petrie et al. 2012). MDA-MB-231 EV, TS15 and E362A cells were 
seeded within either collagen type I gels or Matrigel, a basement membrane 
matrix solution, that includes laminins, collagen type IV and fibronectin. In 
agreement with the 2D migration assays, the inhibition of 3D cell migration was 
also matrix specific: ADAMTS-15 inhibited breast cancer cell migration in a 
metalloproteinase-independent manner through Matrigel but not collagen type I 
gels (Figure 4.15). Thus ADAMTS-15 modulates interactions between breast 
tumour cells and specific components of the surrounding extracellular matrix. As 
an extension of this, it can be argued that these matrix specific effects provide 
insight into the broader significance of ADAMTS-15 during breast 
tumourigenesis.  
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4.7.3	   Importance	   of	   ADAMTS-­‐15	   during	   breast	  
tumourigenesis	  	  
Within the ductal structures of the breast, it is the ADAMTS-15 expressing 
myoepithelial cells that maintain breast tissue architecture (Adriance et al. 2005; 
Butcher et al. 2009; Gordon et al. 2003). Since ADAMTS-15 enhances cell 
adhesion to basement membrane proteins, it is possible that expression of 
ADAMTS-15 is one of the mechanisms through which myoepithethial cells 
maintain breast tissue integrity (Figure 4.5; Figure 4.15; Adriance et al. 2005; 
Butcher et al. 2009; Gordon et al. 2003). In other words, during breast 
tumourigenesis ADAMTS-15 may be protective since it may function to restrain 
tumour cells within the basement membrane. Tumour cells might tolerate the 
presence of myoepithelial derived ADAMTS-15 during the earlier stages of 
tumourigenesis, due to ADAMTS-15 having no observable influence on breast 
tumour cell proliferation (Figure 3.9). Indeed there are no differences in 
ADAMTS-15 expression between cancer and normal tissues (Porter et al. 2004; 
2006). During the transition to invasive disease however, breast architecture 
becomes increasingly aberrant (poorly differentiated), the myoepithelial-
basement membrane interface is lost and tumour cells are more freely able to 
invade into the surrounding tissue (Adriance et al. 2005; Butcher et al. 2009; 
Gordon et al. 2003; Hsiao et al. 2011; Porter et al. 2004; 2006; Jones, 2006; 
Polyak and Hu, 2005). Within this context, ADAMTS-15 expression is lost and 
as a consequence the invasive potential of luminal epithelial cells is enhanced 
(Porter et al. 2004; Porter et al. 2006; Viloria et al. 2009).  
As well as the loss of the basement membrane, additional changes in the ECM 
also occur during breast tumourigenesis. The extracellular matrix ‘stiffens’ due 
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to the increased deposition of collagen type I and other matrix components. 
These changes enhance the invasive and metastatic potential of tumour cells 
(Gusterson et al. 1982; Hojilla et al. 2008; Kakkad et al. 2012; Mueller and 
Fusenig, 2004; Spivey et al. 2012; Svetlanaet al. 2007). As a side note, the 
MDA-MB-231 cells used in this study were also chosen since they are 
intrinsically capable of proliferating, adhering and migrating within stiff matrix 
environments (Tilghman et al. 2010). Therefore, the poorly differentiated MDA-
MB-231 cells, within the 3D collagen type I gels are an appropriate model of the 
‘stiff-matrix’ environment that occurs post-DCIS. Within this ‘stiff-matrix’ 
environment ADAMTS-15 expression did not alter the intrinsic capabilities of 
MDA-MB-231 cells to adhere and migrate on or through collagen type I (Figure 
4.5; Figure 4.15). However, like other ADAMTSs, ADAMTS-15 may have 
additional tumour suppressor functions, beyond the ability to restrain tumour 
cells within the breast ductal structure, which will be covered in the subsequent 
chapter. Before moving onto these additional tumour suppressor functions , 
these matrix specific effects were examined further. To provide a greater 
mechanistic insight, the integrin profiles of MDA-MB-231 EV, TS15 and E362A 
cells were examined, since differences in the expression of fibronectin and 
laminin binding integrins could explain why ADAMTS-15 expressing cells 
adhered more strongly to these matrices.  
Several integrins were profiled that are known to bind to either fibronectin 
and/or laminin. Integrin β1 was examined since it is capable of forming into 6 
laminin and 3 fibronectin adhesion complexes, depending upon which α subunit 
forms the heterodimer pair (Table 1.5). Expression of integrin β1, as determined 
by qRT-PCR, was approximately 2x higher in MDA-MB-231 TS15 and E362A 
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cells in comparison to control EV cells (Figure 4.8). These data are suggestive 
that ADAMTS-15 expressing cells may express higher levels of integrin β1 
containing adhesion complexes. Yet at the protein level there were no 
differences in either total or active integrin β1 (Figure 3.10a; Figure 4.7). The 
surface levels of integrin β1 were also unaffected by expression of ADAMTS-15 
(Figure 4.7). Expression of integrin α5, as determined by qRT-PCR, was also 
approximately 2x higher in TS15 and E362A expressing cells (Figure 4.8). 
Since α5β1 binds fibronectin these data may provide mechanistic insight into 
the ADAMTS-15 associated matrix specific effects (Table 1.5). 
Integrin α6 can partner with either integrin β1 or β4, to form a laminin binding 
adhesion complex (Bass, Morgan and Humphries, 2007; Wang et al. 2010). 
Whilst there were no differences in α6 or β1 total protein, interestingly total 
integrin β4 protein is increased in MDA-MB-231 TS15 and E362A cells (Figure 
4.7). Earlier discussions have presented the context through which ADAMTS-15 
may function to maintain breast tissue integrity. This has clear synergies with 
what is already known about integrin β4 and its role in regulating cell adhesion 
and migration, however at this point a functional link between ADAMTS-15 and 
β4 is largely circumstantial. Nevertheless this will be of interest to future studies 
and therefore warrants some discussion.  
An increase in total integrin β4 may have a biological significance in breast 
tissues, since integrin α6β4 signalling regulates epithelial cell polarity (Litjens, 
de Pereda and Sonnenberg, 2006; Gilcrease et al. 2007; Natali et al. 1992). 
Integrin α6β4 is an essential component of the hemidesmosome adhesion 
complex, which functions to anchor cells, such as epithelial cells to laminin-5 
(332) in the basement membrane (Litjens, de Pereda and Sonnenberg, 2006; 
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van der Neut et al. 1996; Wang et al. 2010). In combination these integrin α6β4-
mediated processes act to establish and maintain the integrity of breast tissue 
architecture. The regulation of hemidesmosomes, particularly in a cancer 
context, is complex and involves extensive signalling crosstalk between α6β4, 
EGFR, syndecans and other cell surface receptors (Mariotti et al., 2001; Wang 
et al. 2010). Interactions between α6β4 and plectin are known to initiate the 
formation of type II hemidesosomes (Litjens, de Pereda and Sonnenberg, 
2006). The tetraspanin CD151 may also join during the early stages of 
hemidesomosme formation, followed by BP180 and BP230 (Litjens, de Pereda 
and Sonnenberg, 2006). Typically, integrin α3β1, syndecans and EGFR are 
recruited once the hemidesomosme reaches a mature state (Litjens, de Pereda 
and Sonnenberg, 2006). 
During the transition to invasive breast cancer, hemidesmosomes are 
disassembled and integrin α6β4 is re-distributed along the leading edge of the 
migrating cell (Mariotti et al. 2001; van der Neut et al. 1996; Wang et al. 2010). 
A re-distribution of α201 to the lamellipodia is associated with increased 
invasive potential and a poor clinical outcome for breast cancer patients 
(Gabarra et al. 2010; Gordon et al. 2003; Natali et al. 1992). Hemidesmosome 
disassembly is mediated either by activated EGFRs which can phosphorylate 
several tyrosine residues (Tyr- 1257, 1440, 1494 and 1526) and/or PKC-
mediated phosphorylation of several serine residues (Ser-1356, 1360, and 
1364) within the β4 signalling domain (Mariotti et al., 2001; Rabinovitz, Tsomo, 
and Mercurio, 2004; Wang et al. 2010). These signalling events alter the 
conformation of the β4 cytoplasmic domain, perturb β4-plectin interactions and 
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ultimately lead to the physical disassembly of the hemidesmosome complex 
(Mariotti et al., 2001; Wang et al. 2010).  
Interestingly, ADAMTS-15 and E362A expressing breast tumour cells are 
relatively insensitive to both EGF and PMA (PKC activator) (Figure 4.11, 4.12). 
Thus it is possible that ADAMTS-15 may inhibit signalling pathways which lead 
to the disassembly of hemidesmosomes. This hypothesis is also consistent with 
the phosphokinase array data. Several kinases, which lie downstream of 
integrin β4, such as Fyn, show reduced activation in TS15 and E362A 
expressing cells (Figure 4.14). It is already known that an inhibition of Fyn 
increases the stability of hemidesmosomes and that stable hemidesmosome 
complexes suppress cancer cell migration and invasion (Kashyap et al. 2011; 
Mariotti et al., 2001; Rabinovitz, Tsomo, and Mercurio, 2004). Therefore it is 
possible that ADAMTS-15 and α6β4 might act synergistically to anchor 
epithelial cells to the laminin-enriched basement membrane. In doing so, 
ADAMTS-15 may restrain epithelial cell migration and act to maintain breast 
tissue integrity. There is a distinct possibility that ADAMTS-15 might directly 
interact with hemidesmosomal integrin β4 or β1 via its disintegrin domain and 
thus act to stabilise hemidesmosomes directly. Although as of yet, there is no 
evidence of direct ADAMTS:integrin interactions. As an additional factor to 
consider, ADAMTS-15 expression did not alter the surface levels of integrin β4, 
as analysed by flow cytometry (Figure 4.7). Therefore the functional distribution 
and recycling of β4, rather than simply its total protein level may be more 
informative in terms of understanding how ADAMTS-15 inhibits cell migration on 
laminin. Future studies could utilise more sophisticated co-culture assays, such 
as the organoid models utilised by Holliday et al. 2009. These systems are 
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better equipped to examine any co-incidental link between hemidesmosome 
and basement membrane disassembly, the redistribution of α6β4 into 
lamellipodia and the loss of ADAMTS-15, which may all temporally coincide 
during the transition to invasive breast cancer.  
4.7.3	  ADAMTS-­‐15	  and	  syndecan-­‐4	  
ADAMTS-15 may influence other cell adhesion receptors, such as syndecans 
and this thesis contains data in support of this. As previously discussed the 
syndecans are a family of four heparan sulfate proteoglycans that sit within the 
cell membrane as type I transmembrane receptors (Choi et al. 2011). 
Syndecans are functionally diverse though they may primarily function to recruit 
and activate integrins or growth factor receptors at matrix adhesion sites 
(Couchman and Woods, 1999; Choi et al. 2011; Morgan et al., 2007; Wang et 
al., 2010). Thus, the syndecans participate in the regulation of cell adhesion and 
migration signalling (Choi et al. 2011; Morgan et al., 2007; Wang et al., 2010). 
More specifically syndecan-1, which is broadly expressed in epithelial cells (also 
see Figure 4.8) has been shown to directly activate αvβ3 and αvβ5 integrins 
during breast tumour cell invasion (Beauvais, Burbach and Rapraeger, 2004; 
Wang et al., 2010). Syndecan-4, on the other hand acts as a co-receptor for 
fibronectin in conjunction with integrin α5β1 (Bass, Morgan and Humphries, 
2007; Wang et al. 2010). In some contexts syndecan-4 competes with 
syndecan-1 for binding to the laminin receptor α6β4 (Bass, Morgan and 
Humphries, 2007; Wang et al. 2010). As a generalisation, when syndecan-1 is 
bound to α6β4 they become a part of a complex involving Src family kinases 
and ErbB2 (Wang et al. 2010). Syndecan-1 is not required for the formation of 
the complex, however the binding of syndecan-1 to the distal region of the α6β4 
Chapter 4 | Page 155 
 
cytoplasmic domain, enables Fyn to more efficiently phosphorylate and thus 
activate β4 (Wang et al. 2010). In concert the activated ErbB2, α6β4 and Fyn 
complexes promote a pro-migratory phenotype (Wang et al. 2010). In contrast 
to this, whilst syndecan-4 may also mediate a similar process, there is growing 
evidence that syndecan-4, is anti-migratory (Rodríguez-Manzaneque et al., 
2009). Some reports describe syndecan-4 as being able to sequester and 
recycle integrin α6β4 within intracellular vesicles (Wang et al. 2010). Thus 
syndecan-1 and -4 may compete with one another to regulate the localisation 
and activity of integrins towards sites of active matrix engagement (Wang et al. 
2010). As a result the levels of syndecans and integrins are a complex and 
highly regulated balance, with a net effect that is either pro or anti-migratory.  
Interestingly, ADAMTS-15 and E362A expression are associated with increased 
surface levels of syndecan-4 (Figure 4.9). Thus it is possible, that in this study, 
the MDA-MB-231 TS15 and E362A cells are compensating for increased 
syndecan-4 mediated recycling of integrin β4, through an up regulation of total 
β4 protein (Figure 4.7). Thus a balance would be established where surface β4 
would be largely maintained (Figure 4.7). Yet the up regulation of β4 protein in 
ADAMTS-15 expressing cells is not offsetting the pro-adhesive and anti-
migratory activity of syndecan-4 (Rodríguez-Manzaneque et al., 2009). So it is 
unclear why the tumour cells would compensate in this way and not through a 
more robust up regulation of the syndecan-4 sheddases ADAMTS-1 and -4 
(Figure 4.8). A profiling of all laminin and fibronectin integrins in future studies 
will be revealing. It could be that as suggested here, the increase in total β4 is a 
side effect of the main mechanism(s) through which ADAMTS-15 mediates the 
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anti-migratory phenotype, namely that ADAMTS-15 protects syndecan-4 from 
being shed from the cell surface (Figure 4.9; Figure 4.16). 
Figure 4.16: ADAMTS-15 may protect syndecan-4 from being shed from 
the cell surface. (left) Known ADAMTS-1 shedding activity is depicted (right) 
ADAMTS-15 directly or in-directly prevents ADAMTS-1 shedding of syndecan-4. 
 
Expression of TS15 and E362A in MDA-MB-231 cells were associated with 
increased surface levels of syndecan-4 in comparison to control EV cells 
(Figure 4.9). Yet expression of the syndecan-4 sheddases ADAMTS-1 and -4 
were approximately 2x higher in TS15 and E362A expressing cells (Figure 4.8). 
Thus it could be inferred that ADAMTS-15 may be protecting syndecan-4 from 
sheddase activity. In agreement with this hypothesis knockdown of syndecan-4 
in MDA-MB-231 TS15 and E362A expressing cells abrogated the anti-migratory 
phenotype (Figure 4.10). Directionality was also lost upon knockdown of 
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syndecan-4 in TS15 and E362A expressing cells, whilst syndecan-4 knockdown 
in control cells elicited no effect (Figure 4.10).  
Based on these data it is possible that syndecan-4 and ADAMTS-15 are 
functionally linked within the context of regulating breast tumour cell migration, 
such that ADAMTS-15 may protect syndecan-4 from sheddases, thus 
promoting the syndecan-4-associated anti-migratory phenotype. Whilst this 
thesis does not present any evidence of a direct association between ADAMTS-
15 and syndecan-4, experimental modulation of syndecan-4 or downstream 
PKC signalling indicates that there is a functional link. 
Stimulation with the PKC activator phorbol-12-myristate-13-acetate (PMA), 
increased the migration rate of EV cells, and it also overcame the inhibitory 
effects of TS15 and E362A, resulting in the cells displaying the same level of 
migration as control EV cells (Figure 4.11). The interpretation of these data is 
potentially complex (thesis section 4.5.2), however based upon what is known 
in the literature, it is possible that PMA stimulated an increase in the expression 
of the syndecan-4 sheddases. Thus PMA stimulation may have accelerated the 
shedding of syndecan-4 such that any protective effects elicited by ADAMTS-15 
were overcome (Rodríguez-Manzaneque et al. 2009). Alternatively, ADAMTS-
15 may influence the ability of syndecan-4 to activate downstream PKC 
signalling. In this case, PMA stimulation bypassed the ADAMTS-15 mediated 
inhibition of PKC activation and ultimately restored cell migration to that of 
control levels. In agreement with this perspective, treatment with the PKC 
inhibitor, bisindolylmaleimide (bis I) reduced the migration of EV control cells to 
the same level as that of TS15 and E362A expressing cells (Figure 4.11). 
Therefore as previously suggested it could be argued that PKC signalling in 
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TS15 and E362A cells is already reduced such that the addition of an inhibitor 
has no effect. However, until syndecan-4/PKC activity and localisation is 
examined in greater detail these data are supportive, but not conclusive of a 
functional link between ADAMTS-15 and syndecan-4. 
 
4.8	  Chapter	  summary	  
• ADAMTS-15 reduces 2D and 3D migration of human breast cancer cell 
lines in a metalloproteinase independent manner. 
o Expression of ADAMTS-15 or E362A inhibits 2D migration of 
human breast cancer cell lines on fibronectin and laminin but not 
collagen type I. 
o Expression of ADAMTS-15 or E362A inhibits 3D migration of 
human breast cancer cell lines through matrigel but not collagen 
type I. 
o Expression of ADAMTS-15 or E362A is associated with an altered 
integrin profile, including an increase in total integrin β4 protein. 
• ADAMTS-15 anti-migratory function is likely due to syndecan-4  
o ADAMTS-15 and E362A expression is associated with increased 
levels of syndecan-4 on the cell surface. 
o Knockdown of syndecan-4 or modulation of syndecan-4 signalling 
abrogates the ADAMTS-15 mediated anti-migratory phenotype. 
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Chapter	  Five:	  The	  Effects	  of	  ADAMTS-­‐15	  on	  Angiogenesis	  
and	  Metastasis	  
 
5.1	  Introduction	  
The aim of this chapter is to investigate the anti-angiogenic potential of 
ADAMTS-15 and to discern whether ADAMTS-15 influences the ability of 
human breast cancer cells to metastasise.  
5.2	  Angiogenesis	  assays	  
Whilst several hyalectanases including ADAMTS-1, -4, -5, -8 and -9 have been 
reported to have anti-angiogenic effects, the role of ADAMTS-15 in 
angiogenesis is unknown (Hsu et al. 2012; Koo et al. 2010; Kumar et al. 2012; 
Luque et al. 2003; Vázquez et al. 1999). The hyalectanases are not the only 
ADAMTSs shown to modulate angiogenesis, since ADAMTS-2 and ADAMTS-
12 have demonstrable anti-angiogenic effects (Dubail et al. 2010; El Hour et al. 
2010; Llamazares et al. 2007). Indeed the central TSR found in all ADAMTSs 
may confer an implicit anti-angiogenic potential since peptides derived from the 
central TSR domains of ADAMTS-4, -16, and -18, termed adamtsostatins, are 
being developed as anti-angiogenic therapeutic agents (Karagiannis and Popel, 
2007).  
ADAMTS-1, -4 and -5 require their central TSR to bind VEGF, resulting in 
diminished downstream pro-angiogenic signalling (Freitas et al. 2013; Hsu et al. 
2012; Kumar et al. 2012; Luque et al. 2003). However the anti-angiogenic 
activities of several ADAMTSs require proteolytic activity. ADAMTS-1 cleavage 
of thrombospondin (TSP)-1 and -2 releases anti-angiogenic fragments (Lee et 
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al. 2006). ADAMTS-1 is also capable of autolytic cleavage, which releases C- 
and N- terminal ADAMTS-1 fragments that are anti-angiogenic (Liu et al. 2006). 
And in the case of ADAMTS-9, only the active metalloproteinase was able to 
reduce HUVEC tube formation in an in vitro model of angiogenesis (Koo et al. 
2010).  
5.2.1	  HUVEC	  tube	  formation	  
Human umbilical vein endothelial cells (HUVECs) form tube-like structures 
when cultured in 3D matrix environments (Cooley et al. 2010). Tube formation is 
enhanced when HUVECs are stimulated with pro-angiogenic growth factors and 
conversely anti-angiogenic factors reduce tube formation (Cooley et al. 2010). 
Thus HUVEC tube formation assay is an established and informative model of 
angiogenesis. In the context of the ADAMTS family, tube formation assays have 
previously been utilised to determine the anti-angiogenic properties of 
ADAMTS-2, -9 and -12 (Dubail et al. 2010; Koo et al. 2010; Llamazares et al. 
2007). 
In this assay HUVECs were suspended into Collagen type I gels and treated 
with conditioned media from MDA-MB-231 EV, TS15 or E362A cells (Methods 
2.27). At 24 hours post-seeding, cells were fixed with 4% PFA, stained 
(Phalloidin and DAPI) and tube formation was quantified as described in 
materials and methods. ADAMTS-15 but not E362A (metalloproteinase inactive 
ADAMTS-15) reduced HUVEC tube formation in comparison to control (EV) 
(Figure 5.1). This data demonstrates for the first time that ADAMTS-15 is anti-
angiogenic and that it’s proteolytic activity is required. To further confirm these 
results an aortic ring assay was utilised.   
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Figure 5.1: ADAMTS-15 reduces HUVEC tube formation in a 
metalloproteinase dependent manner. HUVECs seeded into Collagen type I 
gels were treated with conditioned media from MDA-MB-231 EV, TS15 or 
E362A cells and cultured for 24 hours to allow tube-like structures to form. Cells 
were stained, images taken and analysed as described in materials and 
methods, data represent 4 wells per group, error bars represent s.e.m.; 
*p<0.05, ***p<0.001. Data in collaboration with Dr. Lin Cooley. 
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5.2.2	  Aortic	  ring	  assay	  
The murine aortic ring assay is an ex vivo model of angiogenesis. Since this 
model utilises multiple cell types, including endothelial cells, pericytes and 
fibroblasts the assay is physiologically analogous to in vivo angiogenesis (Baker 
et al. 2012). The assay has precedent within the context of the 
metalloproteinase field.  The aortic ring assay was utilised by El Hour et al. 
2010 to demonstrate that addition of exogenous ADAMTS-12 reduced sprouting 
back to wildtype levels in aortic rings excised from Adamts12 -/- mice.  
In these experiments aortic rings were excised from mice and embedded in 
collagen type I (Methods 2.27; Baker et al. 2012). Aortic rings were treated with 
MDA-MB-231 EV, TS15 or E362A conditioned media and VEGF (30 ng/ml). Six 
days later, rings were fixed and the number of sprouting micro vessels was 
quantified under phase contrast. ADAMTS-15 but not E362A (metalloproteinase 
inactive ADAMTS-15) reduced sprouting in comparison to control (EV) (Figure 
5.2). The data complements the HUVEC tube formation assay in confirming that 
wildtype ADAMTS-15 is anti-angiogenic. Interestingly wildtype ADAMTS-15 was 
able to reduce sprout formation even though aortic rings were also treated with 
pro-angiogenic VEGF (Figure 5.2). Thus the anti-angiogenic effect of ADAMTS-
15 is robust. Whilst like other ADAMTSs, ADAMTS-15 may be able to bind 
VEGF, E362A had no effect on sprouting. Therefore determining ADAMTS-15 
proteolytic substrates will be more productive in determining the anti-angiogenic 
mechanism. 
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Figure 5.2: ADAMTS-15 reduces aortic ring sprouting in a 
metalloproteinase dependent manner. Thoracic aortae were isolated from 6- 
to 8-week-old mice and prepared for embedding in collagen matrix as described 
in Baker et al. 2012. Aortic rings were treated with EV, TS15 or E362A 
conditioned media as described (Thesis chapter 2.27.1) and VEGF (30 ng/ml). 
Six days later, rings were fixed and the number of micro-vessels were quantified 
under phase contrast. Data represent 24 wells per cell group, error bars 
represent s.e.m. **p<0.01. Data in collaboration with Dr. Stephen Robinson. 
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5.3	  Experimental	  metastasis	  (tail	  vein	  assay)	  
MDA-MB-231 EV, TS15 and E362A cells were injected intravenously into the 
tail veins of immune-compromised CD1 nu/nu mice. Prior to injection cells were 
tagged by retroviral transduction with a β-galactosidase marker to enable the 
detection of disseminated tumour cells. At 35 days post injection mice were 
culled and several organs were removed for staining and analysis of micro-
metastasis as previously described (Methods 2.28; Elkin and Vlodavsky, 2001; 
Krüger et al. 1994). 
The overall number of micro-metastasis observed in the Liver was much lower 
than that of the lungs (Figure 5.3; 5.5). With only 25-50% of mice positive for 
micro-metastasis in the Liver, yet 80-100% of mice were positive micro-
metastasis in the Lungs (Figure 5.3; 5.5). In patients basal-like tumours 
preferentially metastasise to the lungs, brain and bone, yet comparatively 
speaking exhibit a lower rate of liver metastasis (Kennecke et al. 2010) These 
global patterns may therefore be indicative of the general metastatic potential of 
MDA-MB-231 cells, which are a basal-like human breast cancer cell line (Table 
3.1).  
ADAMTS-15 reduced metastatic spread to Liver in a metalloproteinase 
independent manner (Figure 5.3), yet ADAMTS-15 enhanced metastatic spread 
to the lungs in a metalloproteinase dependent manner (Figure 5.5). ADAMTS-
15 did not affect metastatic spread to the bone marrow (Figure 5.4). 
These data reveal that ADAMTS-15 has organ specific effects on the ability of 
mammary cancer cells to colonize and grow that can be either dependent or 
independent of its catalytic activity.        
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Figure 5.3: ADAMTS-15 reduces metastatic spread to Liver in a 
metalloproteinase independent manner. ADAMTS-15 reduces metastatic 
spread to Liver in vivo. LacZ tagged MDA-MB-231 EV, TS15, and E362A cells 
were intravenously injected into the tail veins of CD1 nu/nu mice. At 35 days 
post injection mice were culled. (a) Livers were excised and stained to enable 
visualisation of micro-metastatic foci. (b) The percentage of mice with visible 
metastatic foci present in the Liver. Data represent 10-11 mice per group, error 
bars represent s.e.m. *p<0.05. In vivo experiments were designed according to 
three R principles. 
 
 
 
Figure 5.4: ADAMTS-15 does not affect metastatic spread to the bone 
marrow. LacZ tagged MDA-MB-231 EV, TS15, and E362A cells were 
intravenously injected into the tail veins of CD1 nu/nu mice. At 35 days post 
injection mice were culled. qRT-PCR analysis of LacZ was used to determine if 
MDA-MB-231 EV, TS15 or E362A cells had metastasised to bone marrow. Data 
represent 3-6 tissue samples per group, error bars represent s.e.m, *p<0.05.  
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Figure 5.5: ADAMTS-15 enhances metastatic spread to the Lungs in a 
metalloproteinase dependent manner. LacZ tagged MDA-MB-231 EV, TS15, 
and E362A cells were intravenously injected into the tail veins of CD1 nu/nu 
mice. At 35 days post injection mice were culled. (a) Lungs were excised and 
stained to enable visualisation of micro-metastatic foci. Data represent 10-11 
mice per group, error bars represent s.e.m. **p<0.01(b) qRT-PCR analysis of 
LacZ was used to determine if MDA-MB-231 EV, TS15 or E362A cells had 
metastasised to the lungs, Data represent 3-6 tissue samples per group, error 
bars represent s.e.m, *p<0.05. (c) The percentage of mice with visible 
metastatic foci present in the Lung. Data represent 10-11 mice per group (d) 
Images show representative lungs. In vivo experiments were designed 
according to three R principles. 
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5.4 	  Discussion	  
5.4.1	  Angiogenesis	  
The initial interest in understanding the angiogenic potential of the ADAMTSs 
began in 1999 when ADAMTS-1 and -8 were found to have a high level of anti-
angiogenic activity in in vivo angiogenesis models (Vázquez et al. 1999). 
Subsequent studies have identified several ADAMTSs with anti-angiogenic 
potential including ADAMTS-1, -2, -4, -5, -8, -9 and -12 (Dubail et al. 2010; Hsu 
et al. 2012; Koo et al. 2010; Kumar et al. 2012; Llamazares et al. 2007; Luque 
et al. 2003; Vázquez et al. 1999). The hyalectans feature predominantly in the 
list of known anti-angiogenic ADAMTSs, although it should be noted that the 
ADAMTSs may have an intrinsic anti-angiogenic potential that is mediated by 
the central TSR, a structural feature present in all family members. ADAMTS-1, 
-4 and -5 are all capable of binding the pro-angiogenic signalling molecule 
VEGF via their central TSR, thus diminishing downstream pro-angiogenic 
signalling (Freitas et al. 2013; Hsu et al. 2012; Kumar et al. 2012). This intrinsic 
potential is being commercially exploited. Peptides derived from the central TSR 
domains of ADAMTS-4, -16, and -18, termed adamtsostatins, are being 
developed as anti-angiogenic therapeutic agents (Karagiannis and Popel, 
2007). 
However not all ADAMTSs, including ADAMTS-9 are able to bind VEGF (Koo et 
al. 2010). Instead ADAMTS-9 requires its proteolytic activity to mediate its anti-
angiogenic effect (Koo et al. 2010). ADAMTS-1 is also capable of modulating 
angiogenesis through several mechanisms that require its proteolytic activity 
and is perhaps the most insightful comparator to assess the angiogenic 
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potential of ADAMTS-15 since ADAMTS-1 is the most well studied family 
member. 
ADAMTS-1 is involved in array of mechanisms that can have both pro and anti-
tumorigenic consequences in cancer (Esselens et al. 2010; Liu et al. 2006; 
Vázquez et al. 1999). The catalytic activities of ADAMTS-1 seem to lie at the 
heart of these seemingly conflicting reports. Full length ADAMTS-1 is able to 
cleave and/or act as a sheddase for an array of substrates that ultimately have 
pro-tumorigenic and pro-angiogenic consequences.  Liu et al. 2006 reported 
that full length ADAMTS-1 was involved in the shedding of the transmembrane 
precursors of heparan-binding epidermal growth factor (HB-EGF) and 
amphiregulin (AR). ADAMTS-1 was also found to be associated with the 
activation of ErbB-2 and EGF receptors (Liu et al. 2006) In combination these 
proteolytically mediated activities contribute to an inhibition of apoptosis and 
enhanced tumour angiogenesis (Liu et al. 2006).  
Conversely the autolytic cleavage of ADAMTS-1 leads to the generation of two 
fragments, an N-terminal fragment and a C-terminal fragment both of which are 
capable of inhibiting metastasis and tumour angiogenesis (Liu et al. 2006). 
ADAMTS-1 can also cleave thrombospondin (TSP)-1 and -2 the result of which 
is the release of anti-angiogenic fragments (Lee et al. 2006). Thus ADAMTS-1 
requires its proteolytic activity to be both pro and anti-angiogenic, depending on 
whether itself or another substrate is targeted for proteolytic activity. 
To explore the angiogenic potential of ADAMTS-15 an in vitro model of 
angiogenesis was adapted from the one described by Cooley et al. 2010. 
HUVECs embedded in collagen type I gels were treated with conditioned media 
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from MDA-MB-231 EV, TS15 and E362A cells. Primary HUVECs were utilised 
which can be highly sensitive and difficult to culture in comparison to 
immortalised cell lines. So to ensure optimal assay conditions, conditioned 
media was generated with HUVEC media and 2% fetal calf serum, rather than 
the DMEM media that MDA-MB-231 cells were routinely cultured in. This 
precaution was taken since the HUVECs did not tolerate being cultured in 
DMEM conditioned media, whereas MDA-MB-231 cells were fine in HUVEC 
media throughout the 48h media-conditioning period. 
The anti-angiogenic activity of ADAMTS-15 was assayed again in the murine 
aortic ring assay. The aortic ring assay is an ex vivo model of angiogenesis and 
since this model utilises multiple cell types, including endothelial cells, pericytes 
and fibroblasts the assay is physiologically analogous to in vivo angiogenesis 
(Baker et al. 2012). As in the case of the tubulogenesis assays aortic rings were 
treated with MDA-MB-231 EV, TS15 or E362A conditioned media. Based on 
experiences of generating conditioned media for the tubulogenesis assays 
HUVEC media was also used to generate the conditioned media. However, 
assay conditions could be further optimised, since sprouting was three fold 
higher in the no treatment control, in which neat media was used (data not 
shown). In future assays recombinant ADAMTS-15 could be utilised to 
overcome any general MDA-MB-231 conditioned media effects. Another 
advantage to using recombinant proteins over conditioned media is that the 
absolute levels of ADAMTS-15 or E362A protein were not known. The levels of 
pro- and anti-angiogenic factors in the conditioned media, such as VEGF were 
also not examined.  
Chapter 5 | Page 170 
 
However in defence of these assays the MDA-MB-231 EV, TS15 and E362A 
cells used to generate conditioned media were extensively characterised to 
ensure that the levels of expression of ADAMTS-15 and E362A were 
comparable. The anti-angiogenic activities of the other hyalectanases can also 
be excluded since all the stables cell lines expressed comparable levels of 
ADAMTS-1, -4, -5, -8, -9 and -20. 
Both wildtype ADAMTS-15 and E362A contain the same central TSR and 
spacer domains both of which are required for VEGF binding (Freitas et al. 
2013; Hsu et al. 2012; Kumar et al. 2012). Since E362A did not have any 
observable anti-angiogenic effect it is unlikely that ADAMTS-15 sequestered 
VEGF signalling in these assays. Therefore from these data it can be concluded 
that the anti-angiogenic activity of ADAMTS-15 requires its proteolytic activity.   
Also unlike ADAMTS-1, -2, -4, and -5, no evidence has been found to suggest 
that ADAMTS-15 undergoes autolytic cleavage at least not in the cell lines 
examined in this project (Colige et al. 2005; Flannery et al. 2002; Kashiwagi et 
al. 2004; Liu et al. 2006; Zeng et al. 2006). Therefore ADAMTS-15 does not 
seem to be producing autolytic fragments with anti-angiogenic potential.  
It could be speculated that like ADAMTS-1, ADAMTS-15 might release anti-
angiogenic fragments through the cleavage of thrombospondin (TSP)-1 or -2 
(Lee et al. 2006). Though this may not be a reliable assumption since ADAMTS-
9 mediates its anti-angiogenic effects via proteolytic activity, yet ADAMTS-9 
does not cleave either TSP-1 or TSP-2 (Koo et al. 2010). Indeed the relevant 
anti-angiogenic substrates for both ADAMTS-9 and -15 are currently unknown 
and will be of interest for future studies.   
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5.4.2	  Metastasis	  
In vivo data from FVB-PyMT mice, a transgenic model of highly metastatic 
mammary carcinoma has provided some insight into the protective nature of 
ADAMTS-15 in breast cancer. In a time course experiment ADAMTS-15 
expression levels were reduced in FVB-PyMT mice compared to age-matched 
wildtype FVB mice (Porter et al. 2006). In particular ADAMTS-15 expression 
was significantly reduced in FVB-PyMT mice beyond week 7. Essentially 
ADAMTS-15 expression was lost as the tumours in these mice became poorly 
differentiated and more metastatic (Porter et al. 2006). The loss of ADAMTS-15 
expression in vivo matches histological data from breast cancer patients in 
which ADAMTS-15 expression inversely correlate with tumour grade (Porter et 
al. 2004; Porter et al. 2006).  
A similar pattern has also been observed in colorectal cancer, knockdown of 
ADAMTS-15 in SW-620 colorectal cancer cells resulted in an invasive 
phenotype in vitro and the invasive phenotype acquired by these cells 
enhanced their tumourigenic potential in vivo (Viloria et al. 2009). Subcutaneous 
injection of SW-620 cells into severe combined immunodeficient mice (SCID) 
resulted in the formation of tumours (Viloria et al. 2009). Knockdown of 
ADAMTS-15 in these cells enhanced the number and size (volume) of the 
tumours which formed (Viloria et al. 2009). In agreement with histological 
analysis of human samples, SW-620 tumours with low ADAMTS-15 expression 
were poorly differentiated (Porter 2006; Viloria et al. 2009).  
These in vivo studies have demonstrated concordance between the protective 
mechanisms of ADAMTS-15 in vitro and histological analysis of patient 
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samples. However the role of ADAMTS-15 catalytic activity in determining 
metastatic potential is unknown. To this end an experimental metastasis assay 
was conducted in which MDA-MB-231 EV, TS15 and E362A cells were injected 
into the tail veins of CD1nu/nu mice (Elkin and Vlodavsky; 2001; Krüger et al. 
1994). Since injected cells were able to freely circulate to the lungs, liver and 
other organs, differences in the metastatic potential of these human mammary 
cancer cell lines could be observed. 
ADAMTS-15 reduced the metastatic spread of MDA-MB-231 cells to the Liver in 
a metalloproteinase independent manner. In combination with the anti-migratory 
effects of ADAMTS-15 these data suggest that ADAMTS-15 might elicit its 
protective effects through an inhibition of the metastatic potential of breast 
tumour cells. However, the protective effects of ADAMTS-15 in vivo may be 
complex since these data indicate that expression of ADAMTS-15 influences 
the metastatic potential of human breast cancer cells differently depending upon 
the tissue context (Figures 5.3-5.5) and interestingly, some of these effects 
require its proteolytic activity. For instance, in contrast to the Liver, ADAMTS-15 
enhanced the metastatic spread of MDA-MB-231 cells to the lungs in a 
metalloproteinase dependent manner. Additionally, the anti-angiogenic activity 
of ADAMTS-15 also requires its proteolytic activity.  
Therefore these data indicate that ADAMTS-15 modulates the metastatic ability 
of breast cancer cells via metalloproteinase dependent and independent 
processes. Through these processes ADAMTS-15 influences the ability of 
breast tumour cells to metastasise and colonise different tissues.  
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5.5 Chapter	  summary	  
• The anti-angiogenic activity of ADAMTS-15 requires its proteolytic 
activity. 
o ADAMTS-15 reduced HUVEC tube formation in a 
metalloproteinase dependent manner.  
o ADAMTS-15 reduced aortic ring sprouting in a metalloproteinase 
dependent manner.  
• ADAMTS-15 has organ specific effects on the ability of mammary cancer 
cells to metastasise that can be either dependent or independent of its 
catalytic activity. 
o ADAMTS-15 reduces metastatic spread to Liver in a 
metalloproteinase independent manner. 
o ADAMTS-15 enhances metastatic spread to the Lungs in a 
metalloproteinase dependent manner.
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Chapter	  Six:	  Final	  discussion	  and	  Future	  Perspectives	  
 
The human ADAMTSs (a disintegrin and metalloproteinase with 
thrombospondin motifs) are a family of 19 secreted, matrix-associated zinc 
metallo-endopeptidases that have diverse roles in the regulation of tissue 
morphogenesis, cell migration, inflammation, and angiogenesis (Esselens et al. 
2010; Kelwick and Edwards, 2014; Porter et al. 2005; Rodríguez-Manzaneque 
et al. 2009; Wagstaff et al. 2011). Whilst the loss of individual ADAMTSs may in 
some cases be phenotypically mild, broad changes in ADAMTS expression, 
function or localisation are associated with an array of arthritis and cancer 
patho-physiological processes (Kelwick and Edwards, 2014; Kevorkian et al. 
2004; Lin and Liu, 2010; Porter et al. 2004; Wagstaff et al. 2011). In the case of 
ADAMTS-15, expression of this metalloproteinase inversely correlates with 
tumour grade in both breast and colorectal cancer, such that ADAMTS-15 
expression is significantly reduced in grade III tumours compared to grade I or II 
(Porter et al. 2004; Viloria et al., 2009). In colorectal cancer, ADAMTS-15 is 
genetically inactivated through the emergence of somatic mutations, which 
impair the ability of the protein to suppress the invasive potential of colorectal 
cancer cell lines (Viloria et al. 2009). ADAMTS-15 is also protective in breast 
cancer, where ADAMTS-15 expression is associated with increased overall 
survival (Porter et al. 2006). However, in breast cancer the functional basis of 
ADAMTS-15 tumour suppression is unknown and therefore merits further 
investigation. To this end, this thesis set out to explore the effects of ADAMTS-
15 on human mammary cell behaviour. 
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MDA-MB-231 and MCF-7 cells were engineered for stable, constitutive 
expression of either wildtype (TS15) or metalloproteinase inactive (E362A) 
ADAMTS-15. These expression systems were initially characterised to explore 
ADAMTS-15 localisation and proteolytic activity before moving onto functional 
assays. To summarise these data, ADAMTS-15 associated with the ECM via its 
ancillary domain, however the proportion of ECM bound ADAMTS-15 varied 
between different cell lines. In terms of proteolytic activity, ADAMTS-15 is a 
reported versicanase (Stupka et al. 2013) and in this study, these data confirm 
ADAMTS-15 as an active, though weak, aggrecanase. However, more detailed 
kinetic analyses are required in order to quantifiably compare ADAMTS-15 
aggrecanase activity against other aggrecanase, such as ADAMTS-5.  Addition 
of N-TIMP-3 was sufficient to inhibit aggrecanolytic activity and as expected 
E362A was incapable of aggrecan cleavage. Thus ADAMTS-15 is now 
sufficiently characterised amongst the hyalectanases.  
In functional assays, expression of ADAMTS-15 did not affect breast cancer cell 
viability or growth, as determined via MTT, growth curves and a cell cycle 
analysis. Instead the major functional consequences of ADAMTS-15 expression 
centre upon breast tumour cell migration, angiogenesis and metastasis (Figure 
6.1). Breast tumour cells expressing either wildtype (TS15) or metalloproteinase 
inactive (E362A) ADAMTS-15 displayed reduced cell migration and upon 
knockdown of ADAMTS-15, cell migration was restored to the level of control 
cells. Therefore it can be concluded that ADAMTS-15 inhibits breast cancer cell 
migration in a metalloproteinase independent manner. More specifically, in 2D 
migration assays, ADAMTS-15 inhibited cell migration on fibronectin and 
laminin but not collagen type I. Interestingly, these matrix specific effects were 
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also consistent across 3D migration assays, where ADAMTS-15 inhibited cell 
migration through matrigel but not collagen type I gels. The mechanistic basis 
for this inhibition of cell migration can be explained, in part, through the 
observation that ADAMTS-15 expressing cells adhere more strongly to 
fibronectin and laminin. Thus on these matrices, cell adhesion was strong 
enough to inhibit cell migration. Additionally, the integrin profiles of ADAMTS-15 
expressing cells differ in comparison to control cells. Integrin α5 and β1 
subunits, which form a major fibronectin-binding integrin, were found to be up-
regulated two fold in ADAMTS-15 expressing cells. However ADAMTS-15 
expression did not alter the activity or surface level of integrin β1. From 
amongst the laminin binding integrins, α6 and β4 were examined. 
Unexpectedly, ADAMTS-15 expression was associated with an increase in total 
β4 protein. However this association is complex, since ADAMTS-15 expression 
did not alter the level of integrin β4 on the cell surface. Also, there were no 
differences in total α6 protein. Nevertheless, an examination of integrin β4 will 
be of interest in future studies, particularly in terms of the role integrin β4 plays 
in regulating hemidesmosome adhesion complexes, which function to anchor 
epithelial cells to laminin-5 (332) in the basement membrane (Litjens, de Pereda 
and Sonnenberg, 2006; van der Neut et al. 1996; Wang et al. 2010). A potential 
function of myoepithelial derived ADAMTS-15 may be to induce integrin β4 
expression, which in turn will act to restrain epithelial cells within the ductal 
structures of the breast. In this case, the functional distribution of β4, within 
hemidesmosomal structures rather than simply its total protein level will be 
more informative. Therefore in future studies, more sophisticated co-culture 
assays could be utilised, such as the organoid model described in Holliday et 
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al., (2009). These systems are better equipped to examine any co-incidental 
link between hemidesmosome and basement membrane disassembly, the 
redistribution of pro-migratory α6β4 into lamellipodia and the loss of ADAMTS-
15, which may all temporally coincide during the transition to invasive breast 
cancer. 
In order to reconcile the ADAMTS-15 anti-migratory phenotype, syndecans-1 
and -4 were examined. These proteoglycans are broadly expressed in epithelial 
cells, are known to regulate the activity of several fibronectin and laminin-
binding integrins and have functional consequences on cell adhesion and 
migration (Bass, Morgan and Humphries, 2007; Beauvais, Burbach and 
Rapraeger, 2004; Couchman and Woods, 1999; Rodríguez-Manzaneque et al. 
2009; Wang et al. 2010). Within the context of breast cancer, ADAMTS-1 or -4 
shedding of syndecan-4 results in a functional loss of cell adhesion and 
promotes a pro-migratory phenotype with a concomitant loss of directionality 
(Bass et al. 2007; Choi et al. 2011; Rodríguez-Manzaneque et al. 2009). In this 
study these data reveal that expression of wildtype or inactive E362A mutant 
ADAMTS-15 by breast cancer cells is associated with an increase in the surface 
level of syndecan-4. It is possible therefore that ADAMTS-15 may be protecting 
syndecan-4 from sheddases, thus promoting its accumulation on the cell 
surface. Since wildtype ADAMTS-15 elicits the same protective capacity as the 
inactive E362A form, it is conceivable that ADAMTS-15 may be an inefficient 
syndecan-4 sheddase (in contrast to ADAMTS-1 and -4) and therefore 
protection could be a result of ADAMTS-15 blocking access of the more efficient 
hyalectanases to their substrate. An examination of syndecan-4 shedding in the 
presence or absence of ADAMTS-15 and other hyalectanses will provide the 
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experimental evidence required to ratify this hypothesis. An inducible ADAMTS-
15 expression system where ADAMTS-15 expression is induced upon the 
removal of doxorubicin (TET-OFF) has been established and could be utilised 
to test this hypothesis. 
Whilst this thesis does not present any evidence of a direct association between 
ADAMTS-15 and syndecan-4, experimental modulation of syndecan-4 or 
downstream signalling indicates that there is a functional link. In particular, 
knockdown of syndecan-4 restored the migration of ADAMTS-15 expressing 
cells to control levels. PMA stimulation of PKC signalling also abrogated the 
anti-migratory phenotype; this likely involves changes in actin dynamics but also 
may lead to increased expression of potent syndecan-4 sheddases such as 
ADAMTS-1, and -4 (Rodríguez-Manzaneque et al. 2009). Conversely treatment 
with the PKC inhibitor, bisindolylmaleimide I suppressed migration in control 
cells, yet had no effect on ADAMTS-15 expressing cells. In combination these 
data suggest that ADAMTS-15 influences cell migration in a metalloproteinase-
independent manner by altering cell surface syndecan-4 function or turnover via 
a mechanism that is upstream of Protein Kinase-C (PKC)-regulated events. 
Nevertheless in future studies it will still be worthwhile to fully characterize the 
ADAMTS-15 anti-migratory phenotype, including those signaling events that lie 
downstream of PKC. The activity of the core migration signaling machinery 
(RhoA/Rac1/Cdc42) could be examined through several commercially available 
activity assays, which primarily utilize antibodies to recognize their active forms. 
Additionally actin dynamics, which are altered in syndecan-4 shed cells, could 
be examined in real time through live cell imaging, in which ADAMTS-15 
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expressing cells could be transfected with a GFP tagged actin expression 
system. 
Several hyalectanases including ADAMTS-1, -4, -5, -8 and -9 have been 
reported to have anti-angiogenic effects, yet the anti-angiogenic potential of 
ADAMTS-15 is unknown (Hsu et al. 2012; Koo et al. 2010; Kumar et al. 2012; 
Luque et al. 2003; Vázquez et al. 1999). To assess the angiogenic potential of 
ADAMTS-15, growth media were conditioned by MDA-MB-231 ADAMTS-15 
expressing cells and then incorporated into HUVEC tube formation assays. 
Wildtype but not the metalloproteinase-inactive (E362A) ADAMTS-15 
conditioned media reduced HUVEC tubulogenesis compared to control. These 
conditioned media were also utilised in an ex vivo angiogenesis model, the 
murine aortic ring assay. In these assays wildtype ADAMTS-15, but not E362A 
conditioned media inhibited angiogenic sprouting. Taken together these data 
demonstrate that ADAMTS-15, like several other ADAMTSs, displays anti-
angiogenic activity, but in contrast to its effects on cell migration, its effects on 
endothelial sprouting and tube formation require its metalloproteinase activity. 
Based upon what is known from other ADAMTSs, likely anti-angiogenic 
substrates include thrombospondin (TSP)-1 and -2, which upon cleavage 
release anti-angiogenic fragments (Lee et al. 2006). However this may not be a 
reliable assumption since ADAMTS-9 mediates its anti-angiogenic effects via 
proteolytic activity, yet ADAMTS-9 does not cleave either TSP-1 or TSP-2 (Koo 
et al. 2010). Instead the relevant anti-angiogenic substrates for both ADAMTS-9 
and -15 are currently unknown and will be of interest for future studies. 
Additionally, proteomics based approaches are identifying novel ADAMTS 
substrates that lie beyond the current ADAMTS sub-group descriptors, and by 
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inference allude to novel biological functions (Esselens et al. 2010; Lopez-Otin 
and Overall, 2002; Rodríguez-Manzaneque et al. 2009). 
The identification of novel ADAMTS-15 substrates will ultimately help to unravel 
the complex influence this metalloproteinase has on the metastatic potential of 
breast tumour cells. In experimental metastasis assays, ADAMTS-15 
expression in MDA-MB-231 cells inhibited metastatic spread to the liver in a 
metalloproteinase-independent manner. Yet in contrast to this, wildtype but not 
metalloproteinase inactive (E362A) ADAMTS-15 enhanced metastatic spread to 
the lungs. The availability of hyalectanase substrates within the tissue 
microenvironment will likely influence the metastatic propensity of ADAMTS-15 
expressing cells. Additionally, since ADAMTS-15 has matrix specific effects on 
cell adhesion and migration it is possible that some tissue environments may be 
more favourable to the establishment and development of a metastatic niche 
(Freitas et al. 2013; Kaplan et al. 2005; Kopitz et al. 2007; Hanahan and 
Weinberg, 2011; Liu et al. 2006) 
These seemingly contradictory outcomes are not uncommon in the ADAMTS 
family. For example, expression of catalytically active ADAMTS-1 enhances the 
metastatic propensity of TA3 mammary carcinoma and Lewis Lung Carcinoma 
cells in vivo (Liu et al. 2006). In other contexts, including breast cancer, 
ADAMTS-1 shedding of syndecan 4 or semaphorin 3C enhances the migratory 
behaviour of cancer cell lines (Esselens et al. 2010; Rodríguez-Manzaneque et 
al. 2009). Conversely ADAMTS-1 proteolytic activity can also be anti-metastatic. 
ADAMTS-1 proteolytic cleavage of thrombospondins -1 and -2 releases anti-
angiogenic fragments (Lee et al. 2006). ADAMTS-1 also displays auto-catalytic 
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behaviour, at a cleavage site within its own spacer region (Liu et al. 2006). This 
autocatalytic event releases N- terminal and C-terminal anti-metastatic 
fragments that act both as anti-angiogenic and metastasis-inhibitory factors 
(Liu et al. 2006). ADAMTS-1 can also elicit anti-tumorigenic effects in a 
metalloproteinase independent manner, through the binding of VEGF. The 
binding of VEGF sequesters both pro-angiogenic and pro-migratory signalling 
(Freitas et al. 2013; Luque et al. 2003).  An Adamts15-knockout mouse has 
been established (UC Davis knock out mouse project 
https://www.komp.org/geneinfo.php?project=VG10097), which may provide 
additional insight. One approach would be to intercross such animals with the 
mouse mammary cancer model MMTV-PyMT mice, to determine the effect on 
disease progression. Using these models an examination of spontaneous 
mammary tumour formation, progression and tumour angiogenesis could be 
carried out that may shed additional light into the protective role of ADAMTS-15 
in breast cancer.   
In conclusion this work has contributed to our understanding of the fundamental 
characteristics of ADAMTS-15; namely its association with the ECM and 
aggrecanase activity. This work has also provided mechanistic insight into the 
anti-tumourigenic roles of ADAMTS-15 in modulating breast tumour cell 
migration, metastasis and angiogenesis. However in continuation of this study, 
more research is needed to unravel the complexities of the metalloproteinase 
dependent and independent functions of ADAMTS-15 in breast cancer. 
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Figure 6.1: Summary of ADAMTS-15 protective effects in breast cancer 
that have been experimentally verified in this thesis. 
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Appendix	  1:	  ADAMTS	  evolutionary	  history	  	  
 
Figure A1: ADAMTS evolutionary history and genomic locations. (Top) 
The figure shows a representation of the likely gene duplications and a 
retrotransposition event that gave rise to the expansion of the ADAMTS family. 
The figure is not drawn to scale, in terms of evolutionary distance. Adapted from 
Nicholson et al. 2005; Huxley-Jones et al. 2005; Angerer et al. 2006; Brocker et 
al. 2009; Kelwick and Edwards, 2014. (Bottom) The genomic locations of the 
19 human ADAMTS genes. 
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Organism Number of ADAMTS Genes 
Mus musculus 
(Mouse) 
19 
ADAMTS-1,-2,-3,-4,-5,-6,-7,-8,-9,-10,-12,-13,-14,-
15,-16,-17,-18,-19 and -20 
Rattus norvegicus 
(Rat) 
19 
ADAMTS-1,-2,-3,-4,-5,-6,-7,-8,-9,-10,-12,-13,-14,-
15,-16,-17,-18,-19 and -20 
Danio rerio 
(Zebrafish) 
15  
ADAMTS-1,-2,-3, -6,-8a-d,-9,-10,-12,-13,-14,-15a-
c,-16,-17,-18 and -20 
Takifugu rubripes  
(Puffer Fish) 
16 
ADAMTS-1,-2,-3,-4,-5,-6,-7,-8,-9,-10,-12,-14,-15,-
16,-18, and -20 
Ciona intestinalis 
(Sea Squirt) 
6 
ADAMTS-a [2,3,14], -b [16,18], -c [7,12], -d [9,20],  
-e [6,10] and –f [1,4,5] 
[human orthologues]  
Drosophila 
melanogaster 
(Fruit Fly) 
3 
CG4096 [7,12], CG6107 [9,20], CG14869 [none] 
[human orthologues] 
Table A1: ADAMTS orthologues. Data adapted from Ensemble genome 
browser (last accessed 1/1/13); Huxley-Jones et al. 2005; Huxley-Jones et al. 
2007; Nicholson et al. 2005 
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Figure A1.2: ADAMTS metalloproteinase sequence identity. ClustalW 
analysis of the sequence identities between human ADAMTS metalloproteinase 
domains. Domains that show the greatest similarities (≥50% identity) are 
shaded in grey. Adapted from Kelwick and Edwards, 2014 
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Appendix	  2:	  miRNA	  regulation	  of	  ADAMTSs	  	  
Gene Predicted miRNA 
ADAMTS-1 miR-142-5p  miR-628-3p  miR-340  miR-15a  miR-98  
miR-10b  miR-34a  miR-155  miR-380  miR-338-3p 
ADAMTS-2 miR-27a  miR-95  miR-7  miR-10a  miR-10b  miR-217  
miR-223  miR-200b  miR-27b  miR-141 
ADAMTS-3 miR-199a-3p  miR-501-3p  miR-16  miR-95  miR-101  
miR-144  miR-9  miR-30e  miR-429  miR-202 
ADAMTS-4 miR-125b  miR-182  miR-342-3p  miR-339-5p  miR-345  
miR-384  miR-329  miR-485-3p  miR-202  miR-495 
ADAMTS-5 miR-16  miR-105  miR-181a  miR-203  miR-211  miR-
224  miR-140-5p  miR-145  miR-134  miR-382 
ADAMTS-6 miR-29b  miR-221  miR-203  miR-140-5p  miR-9  miR-
369-3p  miR-515-5p  miR-587  miR-605  miR-330-5p 
ADAMTS-7 miR-29b  miR-767-5p  miR-541  miR-370  miR-596  
miR-920  miR-921  miR-29a  miR-129-5p  miR-29c 
ADAMTS-8 let-7f  miR-203  miR-153  miR-346  miR-448  miR-519a  
miR-450b-5p  let-7a  let-7b  let-7c 
ADAMTS-9 miR-205  miR-338-5p  miR-548a-5p  miR-216b  miR-
29a  miR-30a  miR-32  miR-29b  miR-103  miR-182 
ADAMTS-10 miR-27a  miR-29a  miR-101  miR-149  miR-296-5p  
miR-331-3p  miR-512-3p  miR-637  miR-767-5p  miR-
361-3p 
ADAMTS-12 let-7a  let-7b  let-7c  let-7d  let-7e  let-7f  miR-98  miR-
198  miR-214  let-7g 
ADAMTS-13 miR-525-5p  miR-520a-5p  miR-509-3p  miR-596  miR-
769-5p  miR-766  miR-197  miR-34a  miR-149  miR-
302a 
ADAMTS-14 miR-218  miR-636  miR-615-5p  let-7d  miR-24  miR-
30b  miR-328  miR-202  miR-516b  miR-766 
ADAMTS-15 miR-29a  miR-29b  miR-10a  miR-217  miR-223  miR-
137  miR-153  miR-150  miR-29c  miR-362-5p 
ADAMTS-16 miR-142-5p  miR-545  miR-124  miR-524-5p  miR-567  
miR-587  miR-595  miR-612  miR-340  miR-892a 
ADAMTS-17 miR-758  miR-19a  miR-101  miR-29b  miR-144  miR-
134  miR-362-5p  miR-324-3p  miR-346  miR-486-5p 
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ADAMTS-18 miR-181a  miR-302a  miR-16  miR-19a  miR-29b  miR-
148a  miR-205  miR-130a  miR-302c  miR-382 
ADAMTS-19 miR-369-3p  miR-380  miR-26b  miR-148a  miR-214  
miR-219-5p  miR-133a  miR-154  miR-301a  miR-374a 
ADAMTS-20 miR-19b  miR-27a  miR-29b  miR-200b  miR-27b  miR-
141  miR-186  miR-200a  miR-379  miR-429 
Table A2: miRNA regulators of the ADAMTSs. Data in table adapted 
from: http://www.mirnabodymap.org/index.php and Kelwick and 
Edwards, 2014. 
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Appendix	  3:	  ADAMTS	  domain	  sizes	  
 
Figure A3: ADAMTS domain sizes. The size (numbers of amino acid 
residues) of every domain in the human ADAMTS family is shown. The grey 
bars are a visual representation of the data. Data adapted from Kelwick and 
Edwards, 2014 
Appendix	  4:	  ADAMTS-­‐15	  sequences	  
>ADAMTS-15_protein 
MLLLGILTLAFAGRTAGGSEPEREVVVPIRLDPDINGRRYYWRGPEDSGDQGLIFQITAFQEDFYLHLTP
DAQFLAPAFSTEHLGVPLQGLTGGSSDLRRCFYSGDVNAEPDSFAAVSLCGGLRGAFGYRGAEYVISPLP
NASAPAAQRNSQGAHLLQRRGVPGGPSGDPTSRCGVASGWNPAILRALDPYKPRRAGFGESRSRR RSG 
RAKRFVSIPRYVETLVVADESMVKFHGADLEHYLLTLLATAARLYRHPSILNPINIVVVKVLLLRDRDSG
PKVTGNAALTLRNFCAWQKKLNKVSDKHPEYWDTAILFTRQDLCGATTCDTLGMADVGTMCDPKRSCSVI
EDDGLPSAFTTAHELGHVFNMPHDNVKVCEEVFGKLRANHMMSPTLIQIDRANPWSACSAAIITDFLDSG
HGDCLLDQPSKPISLPEDLPGASYTLSQQCELAFGVGSKPCPYMQYCTKLWCTGKAKGQMVCQTRHFPWA
DGTSCGEGKLCLKGACVERHNLNKHRVDGSWAKWDPYGPCSRTCGGGVQLARRQCTNPTPANGGKYCEGV
RVKYRSCNLEPCPSSASGKSFREEQCEAFNGYNHSTNRLTLAVAWVPKYSGVSPRDKCKLICRANGTGYF
YVLAPKVVDGTLCSPDSTSVCVQGKCIKAGCDGNLGSKKRFDKCGVCGGDNKSCKKVTGLFTKPMHGYNF
VVAIPAGASSIDIRQRGYKGLIGDDNYLALKNSQGKYLLNGHFVVSAVERDLVVKGSLLRYSGTGTAVES
LQASRPILEPLTVEVLSVGKMTPPRVRYSFYLPKEPREDKSSHPKDPRGPSVLHNSVLSLSNQVEQPDDR
PPARWVAGSWGPCSASCGSGLQKRAVDCRGSAGQRTVPACDAAHRPVETQACGEPCPTWELSAWSPCSKS
CGRGFQRRSLKCVGHGGRLLARDQCNLHRKPQELDFCVLRPC 
 
 
Legend: Signal/Pro-domain Furin cleavage site RAKR Metalloproteinase domain E362A 
mutation position Disintegrin domain TSR1  Cysteine rich domain Spacer domain TSR2 
TSR3   
 
Figure A4: ADAMTS-15 Sequence. The figure highlights the key ADAMTS-15 
protein domains and the location of the E362A mutation in the 
metalloproteinase inactive construct used in this study. 
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Appendix	  5:	  Validation	  of	  ADAMTS-­‐15	  antibodies	  
 
Figure A5: Commercial ADAMTS-15 antibodies do not reliably detect 
endogenous ADAMTS-15. Several commercially available ADAMTS-15 
antibodies were tested and none were able to reliably detect ADAMTS-15 
(predicted size ~103kDa) from cell lysate samples of human breast cancer 
cells. Santa Cruz antibody H-135 is reported to detect ADAMTS-15 (Viloria et 
al. 2009) however in our hands ADAMTS-15 could not be detected in either 
MCF-7 (lanes 1-2) or MDA-MB-231 ADAMTS-15 expressing cells (lanes 3-4). 
For Abcam antibodies, cell lysates from MDA-MB-231 EV (C, control), TS15 
and E362A constitutive cells were used. Some antibodies were generated using 
ADAMTS-15 peptides that correspond to the indicated residues.  
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Appendix	  6:	  Phosphokinase	  array	  data	  
 
Figure A6: Human phosphokinase array data. Cell lysates from MDA-MB-
231 EV, TS15 and E362A were incubated with membranes that were pre-
treated with anti-phosphokinase antibodies as part of the R&D Human 
phosphokinase array kit. An analysis of HRP signal pixel density was utilised to 
determine the levels of kinase activation compared to control spots on the 
membrane. Colour coding is assigned according to pixel density values, where 
red denotes high values and green denotes low values. The diagrams in the 
right hand column in combination with the coloured categories (see figure 
legend) are intended to highlight phosphokinase patterns associated with 
ADAMTS and/or E362A expression compared to control EV cells. 
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Appendix	  7:	  qRT-­‐PCR	  data	  
 
Figure A7: Expression profile of MDA-MB-231 and MCF-7 cells. qRT-PCR 
analysis of gene expression in MDA-MB-231 and MCF-7 cells. Relative 
expression levels are shown as a Ct value heat-map. The displayed Ct values, 
±standard deviation, are averaged from three independently collected RNA 
samples. These data are the same as that shown in figure 3.3, except in this 
figure the standard deviation of three independently collected RNA samples are 
also shown. 
 
 
Figure A8: Expression profile of MDA-MB-231 EV, TS15 and E362A cells. 
qRT-PCR analysis of gene expression in MDA-MB-231 EV, TS15 and E362A 
cells. Relative expression levels are shown as a Ct value heat-map. The 
displayed Ct values, ±standard deviation, are averaged from three 
independently collected RNA samples. These data are the same as that shown 
in figures 3.8 and 4.8, except in this figure the standard deviation of three 
independently collected RNA samples are also shown. 
MDA-­‐MB-­‐231 MCF7	  
ADAMTS1 26 ±0.40 34 ±0.40 Ct 15-25 Very high expression
ADAMTS4 21 ±0 40 ±0 Ct 26-30 High expression
ADAMTS5 36 ±0 40 ±0 Ct 31-35 Moderate expression
ADAMTS8 40 ±0 40 ±0 Ct 36-39 Low expression
ADAMTS9 26 ±0.04 40 ±0 Ct <40 Very low / undetectable expression
ADAMTS15 29 ±0.03 30 ±0.41
ADAMTS20 37 ±0.20 36 ±0.47
TIMP3 26 ±0.14 29 ±0.27
Syndecan 1 28 ±0.06 26 ±0.04
Syndecan 4 25 ±0.18 26 ±0.04
Integrin β1 25 ±0.19 27 ±0.01
Integrin α5 24 ±0.07 27 ±0.07
MDA-­‐MB-­‐231
EV TS15 E362A
ADAMTS1 25 ±0.16 24 ±0.15 24 ±0.23 Ct 15-25 Very high expression
ADAMTS4 21 ±0.36 20 ±1.26 20 ±0.01 Ct 26-30 High expression
ADAMTS5 35 ±1.20 34 ±0.56 34 ±0.82 Ct 31-35 Moderate expression
ADAMTS8 40 ±0.00 40 ±0.00 40 ±0.00 MCF-­‐7 Ct 36-39 Low expression
ADAMTS9 30 ±1.16 31 ±0.41 30 ±0.75 EV TS15 E362A Ct <40 Very low / undetectable expression
ADAMTS15 26 ±0.81 23 ±0.42 23 ±0.53 31 ±1.48 20 ±0.21 25 ±0.13
ADAMTS20 37 ±0.74 36 ±0.65 37 ±0.71
TIMP3 24 ±1.33 24 ±0.57 23 ±0.47
Syndecan 1 26 ±0.89 26 ±0.65 25 ±0.00
Syndecan 4 24 ±0.01 24 ±0.12 25 ±0.38
Integrin β1 27 ±1.37 26 ±1.12 26 ±0.09
Integrin α5 25 ±0.93 24 ±0.81 24 ±0.56
